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error can be reduced by using the average scores from two different readers who inde-
pendently read the radiographs.12 There is no consensus on whether radiographs should 
be scored in random or in known time sequence. The method should be taken into 
account when interpreting radiological outcomes because scoring with known time 
sequence might overestimate joint damage while scoring in random order might result 
in a more conservative scoring approach leading to a decrease in signal-to-noise ratio.13,14 
Joint damage progression has a skewed distribution: a minority of patients shows 
marked progression, whereas the majority shows little or no progression. Therefore by 
only showing means with standard deviations or medians with interquartile ranges, 
information might be missed. With cumulative probability plots joint damage progres-
sion in every individual patient can be shown by depicting a single dot per patient.14 The 
Smallest Detectable Change can be used as a cut-off for distinguishing measurement 
error form ‘real’ progression.15
A structured regular assessment of joint damage progression is not a routine part of clinical 
care. Regular performance of x-rays is however recommended. More structured assess-
ments would help identifying patients showing progression of joint damage which is not 
always accompanied by clear clinical synovitis. Treatment change may inhibit this process 
which would be missed with clinical assessments alone. Drawbacks for the introduction of 
structured damage assessments in daily practice with e.g. the Sharp-van der Heijde method 
are that the method is comprehensive, time-consuming and requires training. Further-
more, rheumatologists might not be aware of the gain of structured damage assessments. 
An alternative might be the simplified erosion and narrowing score (SENS), a simplified 
version of the Sharp-van der Heijde score in which the number of joints with erosions 
or joint space narrowing are simply counted, without taking into account the grading of 
damage per joint, making it more feasible for clinical practice.16 The total score ranges from 
0-86, with a maximum score of 44 for erosions and 42 for joint space narrowing.
Functional ability
A second important outcome in rheumatoid arthritis research and treatment is func-
tional capacity, which can be measured using the validated health assessment question-
naire (HAQ) developed in 1980.17 Later, Siegert, et al validated the Dutch version of the 
HAQ.18 With the HAQ patients are asked whether they are able to perform different daily 
activities on 8 domains: dressing and grooming, arising, eating, walking, hygiene, reach, 
grip and activities with four possible answers: 0, without any difficulty; 1, with some diffi-
culty; 2, with much difficulty and 3, unable to do. The use of aids or devices and help from 
another person is taken along. The total score ranges from 0 to 3 (0=best; 3=worst).19 A 
difference of 0.22 is described as a minimally clinical important difference. 
Extra-articular features
Besides the articular features, extra-articular manifestations may be present, such as lung 
fibrosis, pleuritis, scleritis, pericarditis, lymphadenopathy, amyloidosis, peripheral neu-
ropathy, vasculitis and splenomegaly.20 Furthermore, rheumatoid arthritis is associated 
G en er Al  i nt rO d uC t i O n
This thesis is based on data of the BeSt study (Dutch acronym for Behandel Strategieën; 
treatment strategies), a large randomised controlled trial comparing four different treat-
ment strategies in patients with recent-onset rheumatoid arthritis.1-3 After a brief over-
view of the clinical picture and pathophysiology of rheumatoid arthritis, an overview of 
the available treatment options is given, followed by an introduction of the concepts of 
early treatment, tight control and combination therapy. These three concepts form the 
basis of the four treatment strategies of the BeSt study. 
rheumatoid arthritis
Clinical picture
Rheumatoid arthritis is a systemic inflammatory auto-immune disease characterised 
by the presence of poly-articular inflammation of synovial tissue in di-arthrodial joints, 
resulting in pain, swelling and stiffness. The metacarpophalangeal (MCP) joints, proximal 
interphalangeal (PIP) joints of the hands, the wrists and the metatarsophalangeal (MTP) 
joints of the feet are most commonly affected. Less frequently, larger joints are involved 
in the disease process. The disease course is heterogeneous, varying from a mild pattern, 
to a severe course with significant functional limitations, severe joint destruction, loss 
of quality of life and even death4 if not treated properly. In the short-term functional 
limitations are mainly determined by the presence of active synovitis, whereas in the 
long-term joint damage contributes significantly to functional limitations.5 
Joint damage
Radiological damage progression assessed on plain x-rays is one of the main outcomes 
in rheumatoid arthritis (RA) treatment.6 The amount of joint damage is highly variable 
among patients with rheumatoid arthritis. Some patients have already damage at base-
line and will show rapid destruction if not treated properly, whereas others do not have 
any damage. Joint damage progression assessed on plain radiographs is related to dis-
ease activity and functional status5,7,8 and is a measure for disease severity and treatment 
response, with the advantage of easy access and limited costs. 
Several methods to quantify joint damage have been developed, of which the methods of 
Sharp9 and Larsen10 and its modifications are most often used. The Sharp-method, mod-
ified by Van der Heijde11 is well-validated and commonly used in clinical trials. In total, 32 
and 12 joints of hands and feet are assessed for erosions respectively (range per joint 0-5 in 
hands, 0-10 in feet) and 30 and 12 joints of hands and feet for joint space narrowing respec-
tively (range per joint 0-4). The maximum erosion score is 280 and the maximum score for 
joint space narrowing is 168 points, with a total score ranging from 0-448.
To assess the effectiveness of treatment, joint damage progression scores rather than 
absolute joint damage scores are used. Therefore sets of radiographs of hands and feet 





The term ‘Rheumatoid Arthritis’ was first used in 1859, by the British Rheumatologist 
Alfred Baring Garrod.39 Since then, different classification criteria have been proposed 
to distinguish rheumatoid arthritis from other inflammatory disease entities and to 
encourage the use of a uniform definition in clinical trials. Until the mid-1980s, the 1958 
criteria were used, in which patients could be classified as having ‘probable’ or ‘definite 
RA’.40 Until May 2010, the classification criteria formulated by the American College 
of Rheumatology (ACR) in 1987 for rheumatoid arthritis41 were used. They included 
the following 7 items: 1. morning stiffness for at least 1 hour, 2. swelling (soft tissue or 
fluid) in at least 3 joints, 3. swelling (soft tissue or fluid) in hands (MCP, PIP) or wrists, 4. 
symmetrical distribution, 5. subcutaneous nodules, 6. positive rheumatoid factor and 
7. radiographic changes on hands/wrist radiographs (erosions or juxta-articular oste-
oporosis). Criteria 1, 2, 3 and 4 had to be present for at least 6 weeks. Patients were 
classified as having rheumatoid arthritis if at least 4 out of 7 criteria were met. The 1987 
RA criteria have shown value as classification criteria, but were not developed for diag-
nostic purposes. In early disease the criteria have poor sensitivity to diagnose RA, in 
particular the earliest manifestations of the disease.42 Features that might be prevented 
with accurate treatment, such as radiographic changes and subcutaneous nodules, are 
included in the 1987 criteria. It has been recognised that early treatment with antirheu-
matic therapy (disease-modifying antirheumatic drugs, or DMARDs) results in better 
prevention of  radiological joint damage and better maintenance of functional abil-
ity than delayed treatment.43 It is hypothesised that the development of rheumatoid 
arthritis progresses on a continuous timeline, starting in the general population where 
in individuals with a combination of genetic and environmental risk factors alterations 
in the immune response occur, leading to autoreactivity. Subclinical synovitis progresses 
to clinical undifferentiated arthritis, and finally rheumatoid arthritis that meets the clas-
sification criteria. In order to start treatment early the diagnosis has to be made earlier. 
To facilitate this, in 2010 new ACR/EULAR classification criteria for rheumatoid arthritis 
have been developed. The new criteria consist of a scoring system including early clini-
cal, serological and radiological findings in patients with one or more inflamed joints to 
estimate the chance that these are manifestations of early rheumatoid arthritis.44
Shift in traditional treatment paradigms 
The past decades great improvements in the treatment of rheumatoid arthritis have 
been made. Until the 1980s RA treatment was based on a pyramid strategy with the 
adagium ‘do no harm’ and ‘go low, go slow’. Treatment started with drugs that were 
considered to be the least toxic, like aspirin and NSAIDs. The next step was treatment 
with DMARDs in monotherapy. Because of concerns on toxicity, combination therapy 
was saved for a minority of patients with a severe disease course. New insights, i.e. the 
benefit of early introduction of DMARDs, tight control and the early use of combina-
tion treatment including corticosteroids or biologicals have led to the abandonment of 
the classic pyramid approach.45,46 How to use the available drugs in the best timing and 
with a higher prevalence of cardiovascular morbidity and mortality than in the general 
population.21-25 Inflammation, a shared feature in the pathophysiology of rheumatoid 
arthritis and atherosclerosis, seems to be the major contributor to the increased cardio-
vascular risk in RA patients, and adequate suppression of disease activity is necessary to 
lower cardiovascular risk.26 
Epidemiology
Rheumatoid arthritis is a common disease with a prevalence of about 0.5% to 1% and 
a mean annual incidence in north European countries of approximately 0.029% (range 
0.024%-0.036%).27 The disease is more prevalent in women than in men (ratio 3:1) and 
the onset of symptoms is most often between 40 and 60 years of age.28 
Pathophysiology 
The exact pathogenic mechanism of RA is unknown. In summary, it is thought that a 
combination of genetic (e.g. presence of shared epitope) and environmental factors 
(e.g. smoking) results in T-cell activation by the presentation of an unknown antigen by 
an antigen-presenting-cell.29 In the presence of costimuli, the T-cells become activated, 
migrate to the synovium and triggers activation of macrophages, B-cells, fibroblasts and 
osteoclasts and the production of proinflammatory cytokines, such as TNF, IL-1 and IL-6 
within the synovial tissue.30 Activated B-lymphocytes can present antigens to T-cells 
continuing the immune response. Furthermore, B-lymphocytes can differentiate into 
plasma cells, producing (auto) antibodies. The total immune cascade, probably initiated 
by T-cell activation, results in hyperplasia of the synovium (pannus), neovascularisation 
and the accumulation of inflammatory cells, subsequently leading to clinical synovitis 
and joint destruction.31 
Autoantibodies
The discovery of the presence of autoantibodies contributed to the concept of RA 
being an autoimmune disorder. Two classes of auto-antibodies, rheumatoid factor and 
anti-citrullinated protein antibodies (ACPA), are present in approximately two-thirds of 
RA patients. Rheumatoid factors are antibodies directed against the Fc region of immu-
noglobulin G, first described in 1939.32 Rheumatoid factor is not specific for RA and can 
be found in other inflammatory diseases and in healthy individuals as well. ACPA are 
antibodies against citrullinated proteins. Citrullination is a posttranslational modifica-
tion of arginine into citrulline catalysed by the enzyme peptidyl arginine deaminase. 
The presence of ACPA, as detected with a commercially available anti-CCP test, is highly 
specific for RA,33 and is predictive for a more severe disease course.34 ACPA positive 
patients seem to have a different genetic background than ACPA negative RA patients. 
Therefore, the hypothesis that ACPA positive and ACPA negative disease are two dis-
tinct disease entities has been proposed.35 There is increasing evidence that ACPA play a 
pathogenic role in rheumatoid arthritis,36,37 although the exact mechanism is unknown. 




early in the disease course has shown to induce rapid reduction of inflammation, reduc-
tion of clinical symptoms and prevention of radiological damage,86 the base of one of 
the four treatment strategies of the BeSt study. 
Toxicity associated with glucocorticoids is a concern, although the risk profile in low-
dose regimens is probably less harmful than what was expected earlier.87 With higher 
dosages, glucocorticoids toxicity may increase. Therefore, moderate to high dose pred-
nisolone are preferably given only during a short course. In 2007, a EULAR taskforce 
published evidence-based recommendations for the use of glucocorticoids in RA.88
Biologicals
With the increasing understanding of the immunological background of rheumatoid 
arthritis, several new therapies have been developed specifically targeting cytokines and 
cells of the immune system which are thought to play a role in the disease process of 
RA. These new treatments are referred to as ‘biologicals’. 
Anti-TNF
With the introduction of tumour necrosis factor alpha (TNF-a) inhibitors rheuma-
toid arthritis treatment changed considerably. Patients who were refractory to con-
ventional DMARDs improved substantially under anti-TNF treatment on both clini-
cal and radiological outcomes, a revolutionary step forward. Five TNF blocking agents 
are currently licensed for the treatment of RA: infliximab (a chimeric mouse-human 
monoclonal antibody), etanercept (TNF-a type II receptor/IgG1 fusion protein), adali-
mumab (humanized monoclonal antibody against TNF-a), certolizumab (polyethylene 
glycol (PEG)-olated humanized Fab fragment of a TNF antibody) and golimumab (a 
fully human monoclonal antibody). The combination of methotrexate and a TNF inhib-
itor has shown to be superior in reducing clinical symptoms of arthritis and inhibiting 
joint damage progression compared to either drug alone, both in established57,89-93 and 
in early RA.55,94-96 There have been no direct comparisons the efficacy of the different 
anti-TNFs in a randomised controlled trial. Indirect comparisons of clinical trial data 
suggested a comparable clinical efficacy.97,98 Due to high costs of anti-TNF therapy99 
in many countries, including the Netherlands, treatment with TNF inhibitors is only 
refunded by health insurance companies if patients have failed on two or more con-
ventional DMARDs including methotrexate and therefore the use of TNF inhibitors as 
initial treatment is restricted. 
An increased incidence of tuberculosis infections was seen in patients treated with anti-
TNF, mainly due to reactivation of latent tuberculosis infections.100 Therefore, screening 
is recommended prior to anti-TNF treatment, including the assessment of medical his-
tory, clinical examination, a purified protein derivate (PPD) skin test and a chest x-ray. In 
case of a latent infection, pretreatment with tuberculostatica is advised.101
Controversies exist on whether anti-TNF increase the risk for serious infections.102-105 
Data from randomised clinical trials and follow up studies suggest that upper respira-
tory tract infections are the most common infections. Opportunistic infections have 
order has been the question behind the BeSt study which is the basis of this thesis. The 
next section starts with a brief overview of the available antirheumatic drugs, followed 
by explaining the changes and new insights from the past decades on how and when 
antirheumatic treatment should be directed.
treatment options
Conventional DMARDs
A wide variety of DMARDs are registered for the treatment of rheumatoid arthritis. 
Methotrexate is considered to be the first DMARD of choice in the treatment of rheu-
matoid arthritis47 due to its clinical and radiological efficacy,48-52 acceptable long-term 
toxicity profile53, high retention rates54 and limited costs. Besides the efficacy as mono-
therapy, there is widespread experience of methotrexate in combination with other 
DMARDs and corticosteroids, and in combination therapy methotrexate is able to 
increase the efficacy of biologicals.55-57 The most common side effects are reversible liver 
toxicity and gastro-intestinal complaints, which can be reduced by dose reduction and/
or subcutaneous use, and by concomitant use of folic acid, recommended in a dose of 
at least 5 mg per week.58 Less common side effects are myelosuppression (particularly 
associated with overdosing), lung fibrosis and pneumonitis. 
Sulfasalazine is a conjugate of mesalazine (5-aminosalicylic acid) and sulfapyridine, with 
clinical and radiological efficacy in RA as well as efficacy in inflammatory bowel dis-
eases. Sulfasalazine can be prescribed as monotherapy,59 or in combination with other 
DMARDs,60-63 although the additional value remains controversial.63-65 Side effects may 
include gastrointestinal complaints and transient elevations of liver enzymes. Acute 
myelosuppression and hemolytic anemia are rare but serious side effects. 
Leflunomide is a pyrimidine synthesis inhibitor that has comparable clinical and radio-
logical efficacy as methotrexate and sulfasalazine.52,66,67 Leflunomide has been used as 
part of a combination therapy, but there may be toxicity concerns when it was com-
bined with methotrexate. Common side effects are gastrointestinal complaints, hyper-
tension, asymptomatic transaminase elevations, skin rash and myelotoxicity.52 
Other, less commonly used DMARDs are the antimalarials hydroxychloroquine and 
chloroquine (favourable safety profile, but limited efficacy as monotherapy),68-70 cic-
losporin A (positive effect on clinical and radiological outcomes, unfavourable toxicity 
profile with renal toxicity and hypertension),71-75 intramuscular gold (good efficacy, slow 
mode of action, probably more toxicity)76,77 and azathioprine (moderate clinical effi-
cacy, radiological efficacy inconclusive, unfavourable toxicity profile).78-80
Corticosteroids
In 1949, Hench, et al. described the beneficial effect of glucocorticoids on the symptoms 
of RA.81 Since then, several randomised trials showed the efficacy of low-dose glucocor-
ticoids (<10 mg) on clinical outcomes and on inhibiting joint destruction, alone,82 and 





The concept of tight control was introduced in the Tight Control for Rheumatoid 
Arthritis (TICORA) trial by Grigor, et al., a randomised clinical trial comparing an inten-
sively treated group versus a routinely treated group. The intensive group had signifi-
cantly more improvement in disease activity and function, more clinical remission and 
less radiographic progression.125 Comparable results were seen in the Computer Assisted 
Management in Early Rheumatoid Arthritis (CAMERA) trial, in which a routine group 
was compared to an intensively treated group with treatment adjustments based on a 
computerised decision program.126 
Tight control involves frequent visits to the outpatient clinics with frequent measure-
ments of disease activity, setting a goal e.g. low disease activity or remission and frequently 
adjust treatment until the goal is achieved.127 The benefit of tight control has led to the 
international adoption of goal-steered treatment (treat to target). The combination of 
both concepts results in frequent evaluations of disease activity with treatment adjust-
ments as long as a predefined target of disease activity (ideally remission, possibly low 
disease activity) is not yet reached. Recommendations on whether or how to adjust treat-
ment when the target of low disease activity or remission is achieved are lacking. Tapering 
high dosages or combination therapies under strict control of disease activity may be the 
next step, with the possible benefits of limiting adverse events and costs but the possible 
disadvantage of a flare of disease. Evidence from systematic randomised controlled trials 
on if and how treatment should be tapered and discontinued is scarce.128-135 
The BeSt study has incorporated tapering and discontinuation of medication in patients 
with persistent low disease activity and discontinuation of all DMARDs in patients with 
persistent clinical remission in the protocol. Recently, an international taskforce pub-
lished 10 recommendations on targeted treatment in rheumatoid arthritis based on a 
systematic literature search and expert opinion.136
disease activity and clinical remission
Disease activity
The disease activity of rheumatoid arthritis cannot entirely be expressed in one clinical 
measure. Therefore, composite indices for disease activity have been developed. The Dis-
ease Activity Score, shortly DAS, is a statistically derived composite index, developed by van 
der Heijde, et al.137,138, based on the judgment of rheumatologists on treatment adjustments 
in clinical practice. The DAS consists of 4 variables: 1. a 44 swollen joint count (SJC44); 2. 
the Ritchie Articular Index for assessing tenderness in 53 joints (RAI)139; 3. the erythrocyte 
sedimentation rate (ESR); and 4. patients assessment of general health, assessed on a 100 
mm Visual Analogue Scale (VAS). With the following formula the DAS can be calculated: 
0.5398√(RAI) + 0.06465(SJC44) + 0.330ln(ESR) + 0.00722(VAS). 
Cut-off values have been identified in accordance with patients’ and rheumatologists’ 
evaluations, representing high disease activity, moderate disease activity, low disease 
activity or clinical remission. In general, a DAS >2.4 is considered to represent too high 
been reported. Also the question whether anti-TNF treatment is associated with an 
increased risk for malignancies is still subject of debate. Rheumatoid arthritis itself is 
associated with such a risk. So far, there is no convincing evidence that the overall risk 
for malignancies is higher among anti-TNF treated patients.102,105,106 
Some studies suggest an inhibiting effect of TNF inhibitors on joint damage progression, 
irrespective of the clinical response. This disconnect has been shown on patient level. It 
is unknown whether such a disconnect is present at the individual joint level.107 
Other biologicals
After the success of the introduction of anti-TNF in the treatment of RA several other 
biologicals have been developed. Biologicals currently registered for RA treatment, 
other than targeting TNF, are: anakinra (IL-1 receptor antagonist),108 rituximab (B-cell 
depleter, anti-CD20),109,110 abatacept (blocks CD80/CD86:CD28 costimulatory signal 
required for full T-cell activation),111,112 and tociluzimab (anti-IL6).113-116 A variety of other 
targets are currently under investigation: e.g. the inhibition of various kinases.117 Anti-
TNF is currently the first-choice biological for RA, due to its efficacy and longer expe-
rience.118 Despite the remarkable response on anti-TNF treatment, approximately 1/3 of 
patients fail to respond on anti-TNF.119  Subsequently, a second anti-TNF or a biological 
with another target can be chosen. With the expanding armamentarium of biologicals 
the options grow exponentially, but there is insufficient evidence what would be the 
best choice of treatment if patients fail a first anti-TNF.      
treatment concepts
Combination therapy
Abundant evidence showed that combination therapy is more effective than mono-
therapy, especially combination therapy including corticosteroids or a biological57,63,89-93 
with limited toxicity. Unfortunately, many of these studies have a static design which 
might overestimate the advantage that combination therapy would have in daily prac-
tice, in which a more dynamic treatment approach is used.  
Early treatment and the ‘window-of-opportunity’ 
Numerous studies demonstrated the importance of early introduction of DMARDs in 
order to improve clinical outcome120,121 and prevent joint damage progression.43,122 It has 
been proposed that by early introduction not only the joint damage progression that 
would have happened during the delay could be prevented, but that in addition the 
slope of the progression curve could be decreased.43 These findings support the intrigu-
ing window-of opportunity hypothesis, which was first formulated during the 1990s.123,124 
The idea is that there exists a critical period, early in the disease course, in which the 
disease is more responsive to treatment, and the disease course can be altered resulting 





working in 20 hospitals in the southwestern part of the Netherlands. The main question 
addressed in the BeSt study was: how to treat RA? Is it necessary to start with combina-
tion therapy in all patients or should these intensive therapies be reserved for patients 
failing on DMARD monotherapy? Between 2000 and 2002, 508 patients with active, 
recent-onset RA according to the 1987 classification criteria were randomly assigned into 
four treatment strategies. Group 1, sequential monotherapy (n=126) and group 2 (step 
up combination therapy, n=121) started both with methotrexate monotherapy and in 
case of insufficient response treatment was switched to another DMARD in monother-
apy (group 1) or DMARDs were added one by one (group 2). Treatment groups 3 and 
4 started both with combination therapy, group 3 with initial combination of metho-
trexate, sulfasalazine and prednisone (n=133) and group 4 with initial combination of 
methotrexate and the TNF inhibitor infliximab (n=128). In the treatment groups 1, 2 and 
3 patients could also receive the combination of methotrexate and infliximab after fail-
ing on at least 3 conventional DMARDs. 
For all four treatment groups a stepwise protocol was defined, aiming at a DAS of 2.4 
or lower (i.e. low disease activity, figure 1, page 64). For this purpose, every three months 
the DAS was calculated by trained nurses, blinded for treatment allocation to prevent 
bias. If the DAS was >2.4, the next step of the treatment protocol was taken. If the DAS 
was ≤2.4 for at least 6 months medication was tapered to a maintenance dose. Due to 
higher remission percentages than expected beforehand, from the third year onwards 
the possibility to discontinue DMARDs was incorporated in the protocol. If patients 
had a DAS <1.6 (clinical remission) for at least 6 months on a maintenance dose, the last 
DMARD could be tapered to 0. When a DAS ≥1.6 was measured, the last DMARD was 
immediately restarted. The discontinuation of DMARDs in prolonged clinical remission 
has not been studied before in a randomised trial early in the disease course.
Primary outcomes were 3-monthly assessed functional ability (HAQ) and joint damage 
progression assessed on annual x-rays of hands and feet. Secondary outcomes were remis-
sion percentages (defined as DAS <1.6) with and without DMARDs and quality of life.  
In the first year of the trial, the initial combination therapy groups showed an earlier 
clinical improvement than the initial monotherapy groups.1 From 1 year onwards the 
clinical outcomes in the four groups were comparable as a result of continuously aiming 
at low disease activity with treatment adjustments if necessary.2 The initial combination 
therapy showed significantly less joint damage progression than the initial monother-
apy groups during 4 years of follow-up. Furthermore, after 4 years, 43% of patients were 
in clinical remission and 13% of patients had successfully discontinued their DMARDs 
while retaining remission, with a median duration of 11 months.3 
The prolongation of three-monthly follow-up visits until 5 and eventually until 10 years 
of follow-up in the BeSt study provides a unique dataset from 508 tightly followed, 
intensively treated RA patients, of whom a wealth of information has been gathered. 
Important questions needing to be answered with longer follow-up duration are 
whether the initial clinical improvements including functional capacity, quality of life 
and high remission percentages in all treatment groups can be maintained with the 
disease activity, whereas a DAS<1.6 is equivalent to clinical remission.140,141 The DAS gives 
a general impression of the activity of the disease, can be used as a practical instrument 
to guide treatment decisions and can be used to introduce tight-controlled treatment 
into daily practice.  Evidence on whether the treatment target should be low disease 
activity or remission is limited. New composite indices have been developed, adapted 
and simplified versions of the original DAS, like the disease activity score in 28 joints 
(DAS28; ignoring the joints of the feet),142 the clinical disease activity index (CDAI)143 
and the simplified disease activity index (SDAI).144 As with the original DAS, for all these 
composite indices cut-offs for remission, low disease activity, moderate disease activity 
and high disease activity have been published. There is no consensus on which disease 
activity measure should be preferred. All indices has shown to be related to functional 
ability and joint damage progression, two main outcomes in RA research and treat-
ment.143-146 Comparing the association between the different disease activity measures, 
functionality and joint damage progression is difficult since they had not all been com-
pared in one study.  
Defining clinical remission
Remission can be seen as a state of disease in which both physician and patient agree 
that the disease is completely suppressed and evidence of active disease can no longer 
be detected. Remission has become a realistic treatment goal in rheumatoid arthritis. 
That sounds easy; however finding a proper definition for remission in RA is a challenge.
There exists a wide variety of clinical remission definitions, based on single measures, 
cut-off values of composite indices and Boolean criteria. ACR remission criteria,147 remis-
sion based on the clinical disease activity index (CDAI) and simplified disease activity 
index (SDAI) are generally considered to be strict. Remission based on DAS, DAS28 and 
single measures classify a higher percentage of patients in remission. An international 
taskforce developed ACR/EULAR remission criteria, a challenging job, while no gold 
standard exists. The general feeling was that existing criteria allowed residual disease 
activity. According to these criteria with the ‘one’-rule, remission is defined as no more 
than one swollen and/or one tender joint, a CRP level lower than 1 mg/dl and a patient 
global assessment of disease activity lower or equal to one on a 0-10 cm visual analogue 
scale. A distinct set of criteria for the use in clinical practice (without CRP level) and 
research (including CRP level) has been proposed.148
the Best study
The new insights of early intensive tight-controlled treatment and the use of combina-
tion therapy have all been incorporated in the BeSt study (Dutch Acronym for Behan-
del Strategieën; treatment strategies), a unique randomised trial that compares four 
dynamic treatment strategies instead of individual therapies, using antirheumatic drugs 
and combinations of drugs in various orders. Designed in the late 1990s, it is ambitious 
in aiming at low disease activity for all patients. The study was conducted by the Foun-
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continuation of DAS-steered therapy, aiming at low disease activity. Is aiming for low 
disease activity strict enough? Can the amount of joint damage be limited over time, 
preserving the association between the presence of synovitis and functional limitations 
and providing a rationale for continuing treating to target on the long term?
In addition, longer follow-up duration will elucidate how many patients can maintain 
drug-free remission over time, coming close to cure. Are the differences in joint damage 
progression rates between the initial monotherapy groups and combination therapy 
groups seen after 4 years based on differences in clinical response in the first year or did 
initial combination therapies induce durable lower progression rates fitting in the win-
dow of opportunity hypothesis? Is starting DMARDs after fulfilling the 1987 classifica-
tion criteria for RA early enough? How has RA changed in manifestations and outcomes 
when modern drugs and concepts of treatment are applied? 
Outline of the thesis
In chapter 2 an overview of clinical aspects and treatment of RA for generalists is given. 
Chapter 3 reviews strategy trials in the treatment of RA as an introduction to the BeSt 
study. In chapter 4 the clinical and radiological results of the four treatment strate-
gies of the BeSt study are described after 5 years of DAS-guided, tight-controlled treat-
ment. A detailed analysis of the longitudinal relationship between changes in disease 
activity and functional capacity in the BeSt study is performed in chapter 5. In chap-
ter 6 three simplified versions of the original DAS with adjusted easier tender joint 
counts were validated. Chapter 7 describes the results of a comparison between 9 dis-
ease activity measures and their relationship to functional ability and joint damage, 
including the three versions of the original DAS that were validated in chapter 6. Fur-
thermore, an extensive comparison of remission definitions based on disease activity 
measures and the 2011 ACR/EULAR remission is described in this chapter. Chapter 8 
and 9 focus on the question what to do if a preset treatment goal is reached. Can med-
ication be tapered safely in all patients? Chapter 8 describes the cessation of infliximab 
after achieving low disease activity, predictors of persistent low disease activity and 
the effect of the reintroduction of infliximab for those who lost low disease activity. 
Chapter 9 gives an overview of the patients who discontinued all DMARDs because of 
longstanding clinical remission (drug-free remission), predictors of persistent drug-free 
remission and describes the effect of reintroduction of medication for those who lost 
drug-free remission. The relationship between clinical signs of synovitis and progression 
of erosions and joint space narrowing at the joint level is described in chapter 10. The 
associations are separately assessed for the different treatment groups and for hands 
versus feet. Chapter 11 compares 2 scoring methods to assess joint damage on x-rays: 
the comprehensive and well-validated Sharp-Van der Heijde score and the quicker and 
easier simplified erosion and narrowing score. Chapter 12 describes the relationship 
between the level of disease activity and blood pressure and compares blood pressure 
changes among the four treatment arms. Finally, in chapter 13 the results of the thesis 
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sources and selection criteria
We used recently published recommendations on the treatment of rheumatoid arthri-
tis. We also searched the Cochrane Database of Systematic Reviews (without time lim-
its) and performed PubMed and Embase searches (October 2008 to July 2010) using 
the keywords “rheumatoid arthritis” and “disease modifying anti-rheumatic drugs” or 
“biologicals” and the names and the synonyms of the most commonly used disease 
modifying anti-rheumatic drugs separately. We selected well conducted systematic 
reviews, meta-analyses, and large randomised controlled trials. When no such studies 
were available, we considered small randomised control trials, cohort studies, and obser-
vational studies.
What is rheumatoid arthritis and who gets it?
Rheumatoid arthritis is a systemic inflammatory autoimmune disease with localised and 
general manifestations. It is characterised by polyarticular inflammation of synovial tis-
sue, which causes pain, swelling, and stiffness of the joints of the hands, wrists, and feet 
in particular.2 It also results in functional limitations and may progress to joint destruc-
tion and extra-articular disease (box 1). Observational studies have shown that mortality 
rates in patients with rheumatoid arthritis are higher than in the general population.3
Rheumatoid arthritis has an estimated prevalence of 0.5-1.1% and an incidence of 20-50 
per 100 000 person years in northern Europe and North America. Lower prevalences 
(0.1-0.7%) have been reported in southern Europe, South America, Asia, and the Mid-
dle East, with very low prevalences in some parts of Africa. Prevalence is high in Native 
Americans.4 The disease is more prevalent in women than in men (3:1 to 2:1). Cohort 
studies suggest that prevalence rises with age and peaks at 65-74 years.












ABs t r AC t
Until the 1990s patients with rheumatoid arthritis were initially treated with aspirin or 
other non-steroidal anti-inflammatory drugs; disease modifying anti-rheumatic drugs 
(DMARDs), such as methotrexate, were introduced only as the disease progressed. 
Combined treatment with more than one DMARD was reserved for patients with 
the most severe disease. The outcome for most patients was functional deterioration 
with progressive damage. However, innovations in drugs, better tools for monitoring 
treatment, and tight control strategies have improved the outlook for patients with 
rheumatoid arthritis. Remission with limited radiological damage and no functional 
deterioration is now a realistic treatment goal. Several randomised controlled trials 
have shown that treatment with DMARDs, corticosteroids, and biological agents early 
in the course of disease can retard progression of disease, reduce joint destruction, 
and improve functional ability and health related quality of life. This, along with 
the introduction of new tools to monitor response to treatment, has led to a new 
treatment approach and improved outcomes.1 We review evidence from randomised 
trials, systematic reviews, and recently published guidelines and outline the new 
approach to treatment, emphasising the importance of early diagnosis, referral, and 
treatment. 
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Investigations by general practitioner
Patients with clinical signs and symptoms of arthritis should be referred to a rheuma-
tologist as early as possible.6 More than a 12 week delay in referral is associated with a 
reduced chance of drug-free remission and increased risk for progressive joint dam-
age.8 Radiographs and laboratory assessments are not necessary before referral and may 
delay treatment. Once the presence of arthritis is established, these tests may help iden-
tify monoarthritis or oligoarthritis in the early phases of disease.
Investigations by a specialist
Investigations in newly diagnosed patients include measurement of acute phase reac-
tants (to calculate disease activity), a full blood count, and autoantibody tests. When 
an infectious cause or crystal induced (poly)arthritis is suspected, aspiration of syno-
vial fluid or synovial biopsy may be helpful. Ultrasound may show synovitis in joints 
that are clinically difficult to assess and may help guide synovial fluid aspiration. Addi-




2-10 medium large joints
1-3 small joints (with or without involvement of large joints)
4-10 small joints (with or without involvement of large joints)







Low positive rheumatoid factor or low positive anti-citrullinated protein antibodies 
High positive rheumatoid factor or high positive anti-citrullinated protein antibodies
2
3
Acute phase reactants (0-1)
Normal C-reactive protein and normal erythrocyte sedimentation rate
Abnormal C-reactive protein or abnormal erythrocyte sedimentation rate
0
1





*Patients need at least 6 points or the presence of joint erosion to be classified as having rheumatoid arthritis.
Box 3 1987 American College of rheumatology classification criteria 
At least 4 items should be present; items 1-4 should be of at least 6 weeks’ duration
1  Morning stiffness for at least one hour
2  Synovitis in three or more joints
3  Synovitis in hands or wrists
4  Symmetrical distribution
5  Subcutaneous nodules
6  Positive rheumatoid factor
7  Radiographic changes on radiographs of hands or wrists 
how is rheumatoid arthritis diagnosed?
History
Patients have pain, stiffness, and limited joint movement. Presentation may be classic, 
with symmetrical polyarthritis of the small joints of the hands and feet, but monoar-
thritis or oligoarthritis, including large joints as first manifestation, is not uncommon.5 
Observational studies suggest that patients who present with monoarthritis or oligoar-
thritis are as likely to develop progressive joint damage as those who present with poly-
arthritis. Patients often report general symptoms, such as morning stiffness (not only 
in affected joints, lasting more than an hour), fatigue, fever, sweats, and weight loss.6 In 
early disease, functional limitations are determined by the presence of active synovitis, 
but in the long term joint damage is also a contributory factor.
Examination
Synovitis can be clinically diagnosed by examination of the joints (box 2). Palpation 
shows swelling within the joint, sometimes with bulging and pain on pressure. Move-
ment, particularly (over)extension or rotation, is limited, and force is reduced–for exam-
ple, when making a fist. Because the small joints of the feet may be difficult to assess 
separately, inflammation may be easier to detect if the metatarsal joints are squeezed 
together. Heat and redness may be apparent, but absence of these signs does not pre-
clude inflammation. In later stages of disease, rheumatic nodules or deformation might 
be seen, typically with ulnary deviation of the metacarpophalangeal joints. No single 
test or set of criteria is available to diagnose rheumatoid arthritis. Classification criteria 
have been developed for use in research populations only, although they are sometimes 
used in clinical practice. Until recently, the 1987 classification criteria of the American 
College of Rheumatology (ACR) were used (box 3).7 New classification criteria with a 
higher sensitivity in early disease were developed in 2010 (table).5 
Box 2 signs of inflammatory arthritis
Pain
Swelling




Morning stiffness (not only in swollen joints)
Squeeze test: put tangential pressure on the metatarsophalangeal and meta-
carpophalangeal joints; if tender, suspect synovitis
General symptoms such as fatigue, fever, weight loss, and sweats




Several methods are available to quantify joint damage on radiographs of hands and feet. The modified Sharp method 
is well validated and often used in clinical trials.29 In total, 44 joints of hands and feet are assessed for erosions (part A; 
score range per joint 0-5 in hands, 0-10 in feet) and 42 joints of hands and feet for joint space narrowing (part B; range 
per joint 0-4). The maximum score is 448. An increase in total score of 5 in one year is considered to be rapid radiological 
progression and carries a poor prognosis.
FiGure 1
Overview of swollen and tender joint counts as components of disease activity scores. Part (A) shows the joints assessed 
for swelling in the 44 swollen joint count (white and dark grey; assessed for the presence (score 1) or absence (0) of 
swelling). For the 28 swollen and tender joint counts only the joints depicted in dark grey are assessed for the presence 
or absence of swelling or tenderness. Part B shows the Ritchie articular index. For each joint, tenderness is graded from 0 
to 3 (0=not tender, 1=pain on pressure, 2=winced; 3=winced and withdrew). With this index joints are grouped, and for 
each group (depicted in separate grey teints; maximal 5 joints per group) the highest score is used. The white joints count 
as separate joints.
treated conventionally.12,13 The BeSt study used a disease activity score of 2.4 or lower to 
guide all treatments, including drug tapering and discontinuation steps, while compar-
ing four different treatment strategies. Patients starting with a combination of DMARDs 
and prednisone or infliximab showed earlier clinical improvement and reduced progres-
sion of joint damage.14 
A B
A B
tional radiological and laboratory assessments might be needed to exclude alternative 
diagnoses. Radiographs of hands, wrists, and feet are recommended early in the dis-
ease to assess early structural damage and should be repeated annually to monitor dis-
ease severity and response to treatment.6 In research settings, changes on ultrasound 
and magnetic resonance imaging seem to be predictive of future progression, but it is 
unclear if and how these modalities should be integrated into daily practice.
Autoantibodies
Laboratory studies, observational trials, and randomised trials have shown that rheuma-
toid factor, directed against IgG, and antibodies against citrullinated proteins are seen 
in about two thirds of patients with rheumatoid arthritis. Several observational studies 
have shown that the presence of autoantibodies predicts a more severe disease course. 
In patients with undifferentiated arthritis, the presence of anti-citrullinated protein anti-
bodies predicts progression to rheumatoid arthritis.9,10 Patients with and without these 
autoantibodies seem to differ genetically from one another, suggesting that anti-citrul-
linated protein positive and negative arthritis may be two distinct disease entities. Evi-
dence from laboratory studies suggests that these antibodies play a pathogenic role in 
the disease, although the exact mechanism is unknown. Both types of autoantibody 
can be present years before onset of disease.
What are the treatment goals?
The ultimate goal of treatment is sustained clinical and radiological remission after ces-
sation of anti-rheumatic drugs—essentially a “cure.” A systematic review and meta-anal-
ysis of randomised trials that informed the latest European League Against Rheumatism 
(EULAR) recommendations concluded that treatment should aim to suppress disease 
activity as soon as possible, reduce symptoms, and retard the progression of joint dam-
age and associated functional limitations.11 Several, partially overlapping, definitions of 
clinical remission are in use. In practice, clinical remission denotes absence of inflamma-
tion as determined by joint and laboratory evaluation and the patient’s assessment. In 
2011 the EULAR/ACR remission committee proposed new remission criteria that include 
no more than one swollen and one painful joint on examination, a patient’s global 
assessment of less than 10 mm on a 0-100 mm visual analogue scale, and normal con-
centrations of acute phase reactants.
evaluation of treatment response
For decades treatment was adjusted on the basis of the doctor-patient interview and 
clinical examination. More objective ways of calculating disease activity have made it 
possible to set predefined goals and change drugs accordingly. Box 4 and the figures 1 
and 2 show the most commonly used outcome measures in rheumatoid arthritis. The 
concept of tight control was introduced in the TICORA and CAMERA trials. Both trials 
found reduced disease activity and radiographic progression and increased function 
and clinical remission in patients whose treatment was regularly adjusted than in those 
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What drugs are effective early in disease?
Conventional disease modifying anti-rheumatic drugs
Many synthetic DMARDs are available for the treatment of rheumatoid arthritis, but 
methotrexate is the first line treatment. A recent meta-analysis found that it improves 
clinical and radiological outcomes; has an acceptable long term toxicity profile; is accept-
able to patients, with good adherence rates; and is cost effective.6,11,18 EULAR guidelines 
published in 2010 consider methotrexate to be safe and effective in combination with 
other DMARDs.11 Methotrexate also seems to increase the efficacy of biological agents 
when given concurrently. The most common side effects are gastrointestinal problems 
and reversible liver toxicity, which can be reduced by subcutaneous administration and 
dose reduction or concomitant use of folic acid, according to recent international con-
sensus guidelines.19 Other synthetic DMARDs that may be useful are sulfasalazine, leflun-
omide, hydroxychloroquine, and less often injectable gold, ciclosporin, and azathioprine. 
As with methotrexate, all conventional DMARDs need regular monitoring for safety.20 
A recent systematic review and meta-analysis found that leflunomide was as effective as 
methotrexate; that sulfasalazine and injectable gold reduced signs and symptoms of rheu-
matoid arthritis and structural damage; and that ciclosporin, minocycline, tacrolimus, and 
hydroxychloroquine showed some efficacy in reducing the number of swollen joints.18
Corticosteroids
A systematic review of randomised controlled trials found that low to moderate dose 
(7.5-15 mg/day) oral glucocorticoids reduce joint destruction and improve symptoms.21 
Glucocorticoids reduce disease activity quickly, so are useful as “bridging drugs” when 
treatment begins. Adding glucocorticoids to DMARD monotherapy or combinations 
of synthetic DMARDs retards the clinical course of disease and inhibits radiographic 
progression, an effect that can last for years.21 Randomised controlled trials have shown 
that temporary treatment with prednisolone combined with methotrexate and sulfas-
alazine (and hydroxychloroquine) early in the disease induces more rapid reduction of 
inflammation and, as a result, earlier reduction of clinical symptoms and prevention of 
radiological damage than DMARD monotherapy.22,23 Intra-articular glucocorticosteroids 
in combination with methotrexate can reduce local symptoms and may also prevent 
progression of joint damage. The optimal dose of glucocorticoids in combination treat-
ment is unknown. 
Because long term use of glucocorticoids may increase risk of cardiovascular disease, 
the occurrence of mood disturbances, and osteoporosis, experts advise cautious use 
of these drugs, with tapering as soon as symptoms are controlled.6,11 In 2007 a EULAR 
taskforce published recommendations for the use of oral glucocorticoids in rheumatoid 
arthritis with a focus on toxicity.
Biological agents
Several drugs have been developed that target cytokines and cells of the immune sys-
Current treatment strategies can achieve a mean Health Assessment Questionnaire 
score of 0.6, 43% clinical remission, and 13% drug-free remission.15 Recently, an inter-
national taskforce published 10 recommendations on targeted treatment, which were 
based on high level evidence and expert opinion.16 It recommended that clinicians base 
treatment on a shared decision between patient and rheumatologist; maximise long 
term health related quality of life through control of symptoms, prevention of struc-
tural damage, normalisation of function and social participation, particularly through 
“abrogation of inflammation”; and target treatment by measuring disease activity and 
adjusting treatment accordingly. 
When should treatment start?
A meta-analysis of trials and observational studies published in 2006 showed that early 
introduction of DMARDs prevents joint damage.17 Patients with more aggressive dis-
ease seemed to benefit most. Recent data from a large observational cohort suggest 
that the crucial “window of opportunity,” when the immune response is more respon-
sive to treatment and the disease course can be altered, may be as short as 12 weeks.8
Box 4 Clinical and radiological outcome measures
Disease activity
Composite indices incorporate the results of a joint assessment (figure 1), laboratory 
evaluation of inflammation (erythrocyte sedimentation rate or C reactive protein), 
and the patient’s opinion, measured on a 100 mm visual analogue scale. Most 
commonly used indices are the disease activity score (DAS) and the derived DAS28 
(see also www.dascalculator.nl). Alternative indices are the simplified disease 
activity index (SDAI) and clinical disease activity index (CDAI). 
Functional ability
The Health Assessment Questionnaire (HAQ) consists of questions on eight 
domains of daily activities: dressing and grooming, arising, eating, walking, hygiene, 
reach, grip, and chores or activities with four possible answers: 0, without any 
difficulty; 1, with some difficulty; 2, with much difficulty; and 3, unable to do. The 
use of aids or devices and help from another person is taken into consideration. The 
sum of the highest score per domain is divided by eight, resulting in a total score 
ranging from 0 to 3 (0=best; 3=worst). 
Progression of joint damage 
See figure 2.
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abatacept, or tociluzimab—can be considered, preferably in combination with meth-
otrexate.6,11 No evidence supports the use of one second line treatment over another. 
risk of cardiovascular disease
Recommendations on managing the risk of cardiovascular disease in patients with 
rheumatoid arthritis, based on systematic literature reviews, have recently been pub-
lished.27 Rheumatoid arthritis carries a higher than normal risk for cardiovascular dis-
ease, probably as a result of the increased prevalence of traditional risk factors and 
the inflammatory burden. Observational studies suggest that risk scores should be 
multiplied by 1.5 if two of the following criteria are met: presence of rheumatoid fac-
tor or anti-citrullinated protein antibodies, disease duration greater than 10 years, or 
presence of extra-articular manifestations. Ongoing cardiovascular risk assessment 
is recommended for all patients. To reduce risk, good control of disease activity is 
mandatory, as well as adequate management of cardiovascular risk according to local 
guidelines. 
An evidence-based approach to treatment
Early recognition of arthritis and rapid referral to a rheumatologist are essential. Begin 
treatment immediately after diagnosis and aim for clinical remission or low disease 
activity.6,11 Start treatment with a single DMARD, preferably methotrexate (although 
NICE recommends adding another DMARD), combined with short term glucocorti-
coids. .6,11,20 If no response is seen, consider introducing a TNF-α blocker rather than 
switching to a combination of traditional DMARDs.28 Some guidelines recommend 
TNF-α blockers and methotrexate as initial treatment in high risk patients.11,20 Consider 
cautiously reducing and stopping treatment in patients in stable clinical remission, with 
prompt reintroduction if the diseases recurs.6,11 
Further improvements in diagnostics and targeted treatments are needed to halt the 
disease process. The new classification criteria will enable patients with earlier stage dis-
ease to enter clinical trials. Future developments may enable chronicity and deteriora-
tion to be avoided and provide a cure for rheumatoid arthritis. 
summary points
• Rheumatoid arthritis is a common autoimmune disease that can lead to serious
functional limitations, joint destruction, extra-articular disease, poor quality of life, and 
premature death 
• Earlyrecognitionofarthritisandspeedyreferraltoarheumatologistareessential
• Treatment should start early and aggressively to prevent functional limitations and
structural damage
• Innovationsintreatmentandmonitoringhaveresultedinpatientsachievingearlyand
sustained clinical and radiographic remission 
• Methotrexate is the first line drug, but in high risk patients early combination of
methotrexate with prednisone or a tumour necrosis factor inhibitor improves outcomes 
tem that play a role in the disease process. These new treatments are generally referred 
to as “biologicals” (box 5).
Drugs that target TNF-α
The introduction of tumour necrosis factor α (TNF-α) inhibitors has changed treat-
ment and treatment targets greatly. Evidence from randomised controlled trials shows 
that the combination of methotrexate and a TNF-α inhibitor is better than either drug 
alone at reducing clinical symptoms and progression of joint damage in patients with 
early disease and in those who do not respond to conventional DMARDs.6,11 Five TNF-α 
blocking agents are currently licensed for the treatment of rheumatoid arthritis (box 5). 
Several cohort studies found a small but increased risk for bacterial infections in patients 
treated with methotrexate and TNF-α inhibitors.24 An increased incidence of tuberculo-
sis was seen in patients treated with TNF-α inhibitors, mainly as a result of reactivation 
of latent infections.25 Screening before starting treatment and anti-tuberculosis pretreat-
ment if appropriate have greatly reduced this complication. 
There is no convincing evidence that the overall risk for cancer is higher for patients 
given anti-TNF-α than for other patients with rheumatoid arthritis.24 
Other biologicals
Several biologicals with other targets have been developed and are being investigated.26 
Expert guidelines recommend TNF-α inhibitors as first choice of biological agent. If a 
patient does not respond to a first anti-TNF-α agent, then a second one—rituximab, 
Box 5 Biologicals
TNF-a inhibitors
Adalimumab: humanised monoclonal antibody against TNF-α
Certolizumab: Fab fragment of a humanised TNF-α inhibitor monoclonal antibody 
Etanercept: humanised soluble recombinant TNF-α type II receptor-IgG1 fusion 
protein
Golimumab: human monoclonal antibody against TNF-α 
Infliximab: a chimeric mouse-human monoclonal antibody against TNF-α
Others
Anakinra: human recombinant interleukin 1 receptor antagonist
Abatacept: an immunoglobulin and extracellular CTLA4 domain fusion protein 
that selectively inhibits T cell co-stimulation
Rituximab: chimeric monoclonal anti-CD20 antibody that depletes B cells
Tocilizumab: humanised monoclonal anti-interleukin 6 receptor antibody
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wait and see approach or time consuming radiographs and laboratory tests 
• Early treatment is essential for improving andmaintaining functional ability and
quality of life, and prevention of joint damage 
• Be aware of and treat risk factors for cardiovascular disease because rheumatoid
arthritis carries an increased risk
• Be aware of possible infectious episodes in patients treated with prednisone or
biologicals (or both), which may require earlier treatment 
Ongoing research
• Constructingpredictionmodelsincludingbiomarkerstooptimiseearlydiagnosisof






who have not been treated with disease modifying anti-rheumatic drugs 
• Identifyingmechanismsandprocessesthatcanbetargetedwithnewdrugs
• Identifyingtreatmentsandstrategiesthatcurerheumatoidarthritis
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i nt rO d uC t i O n
The treatment options for rheumatoid arthritis (RA) patients have increased substan-
tially in the past few decades. New insights led to new treatment paradigms, including 
early introduction of treatment, the use of various combination therapies (including tra-
ditional disease-modifying antirheumatic drugs (DMARDs), biologicals, corticosteroids) 
and response-driven treatment, in which remission appears to be an attainable goal. 
There have been numerous trials with head-to-head comparisons of different (combi-
nations of) drugs. However, extrapolation to clinical practice is usually difficult. Daily 
practice is much more dynamic than the regimens in comparative drug trials. Therefore, 
strategy trials have been published, in which the emphasis was not on the comparison 
of individual drugs but on the application of the available treatment options in a con-
tinuous, dynamic, ‘real life’ approach. In this review we discuss important lessons from 
those strategy trials, with a focus on new (follow-up) trials published during the last year. 
Choosing optimal treatment
One of the important issues tackled in strategy trials is: what is the optimal way to use 
DMARDs in clinical practice? It is clear that  RA-patients benefit from early introduc-
tion of DMARDs.1,2 With the rising number of drugs available for the treatment for 
RA, numerous treatment sequences and combinations are possible. Comparative drug 
studies showed that initial combination therapy, including DMARDs with predniso-
lone or anti-tumour necrosis factor (anti-TNF) (but not combination therapy with con-
ventional DMARDs alone3) gives earlier improvement and better outcomes than initial 
monotherapy in most patients.4–10 However, it is not clear whether this is also the case 
in a dynamic strategy, whether there is an optimal timing of combination therapy and 
how dynamic treatment should be directed. 
recent (follow-up) studies comparing combinations of conventional 
dmArds 
The Combination Anti-Rheumatic Drugs in Early RA (CARDERA) trial11 (table 1), a ran-
domised controlled trial (RCT) comparing methotrexate (MTX) + placebo with MTX 
along with prednisolone, ciclosporin or both, showed a significant reduction in the 
development of new erosions by adding either ciclosporin or prednisolone to MTX 
monotherapy. The lowest number of new erosions was seen with the combination of 
the three drugs. 
During the second year of the Ciclosporin, Methotrexate, Steroid in RA (CIMESTRA) 
trial12 (table 2) which had originally compared initial MTX monotherapy with a combina-
tion of MTX and ciclosporin, adding hydroxychloroquine (HCQ) to MTX monotherapy 
was compared to changing MTX and ciclosporin to MTX and HCQ. In both groups, 
patients were seen every 4 weeks with the absence of swollen joints as treatment goal. 
Individual swollen joints were injected with betamethason. After 2 years of treatment, 
the initial combination group continued to do better in terms of American College of 
ABs t r AC t
Purpose of review To give an overview of recent strategy trials for the treatment of 
rheumatoid arthritis (RA). 
Recent findings Strategy studies showed a clear benefit of dynamic result-driven 
treatment towards tight control of disease activity compared with ‘usual care’ in 
RA-patients. In addition, treatment given after short symptom duration gives 
better outcomes than later initiation of treatment. In many trials, combination 
therapies, especially combinations with prednisolone or biologicals, were superior 
to monotherapies. Moreover, combination therapies were more effective if given 
early in the disease as compared with a delayed introduction, giving support to the 
window-of-opportunity hypothesis. In the BeSt study, initial combination therapy 
could be successfully discontinued in half of the patients, emphasising that ‘initial’ 
would mean ‘temporary’. Less evidence is available about initial combination in 
comparison with combination therapy with a shorter delay. Larger tight-controlled, 
goal-steered, dynamic strategy trials comparing initial combination therapy with a 
short-delay combination therapy will help to translate the use of initial (temporary) 
combination therapy into normal daily practice. 
Summary Treatment strategy trials have demonstrated that in the majority of 
patients with RA the following approach is the most beneficial: goal-steered, dynamic 
treatment towards tight control of disease activity, including early introduction of (an) 
effective disease-modifying antirheumatic drug(s) in combination with prednisone or 
anti-tumour necrosis factor, which includes tapering of the medication if remission 
or low disease activity is achieved.
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sequent addition of MTX and HCQ. The aim was to achieve a DAS28<3.2 at 3-monthly 
visits, inducing dose increases in both arms. There is no mention of tapering. Sixty per-
cent in the initial combination therapy arm and 41% in the step-up to combination 
arm achieved European League Against Rheumatism (EULAR) good response and 45 
vs 33% achieved EULAR remission (p=NS, possibly because of small numbers) after 1 
year of treatment. Radiological damage progression after 1 year was 6.0 + 5.3 in the 
step-up group and 6.6 + 7.0 in the initial combination group (p=NS), which can in part 
be explained by the high erosion scores at baseline and the chronological reading of 
radiographs, but may also reflect the absence of corticosteroids and biologicals in the 
two strategies.
Verschueren, et al21 compared a DAS-guided step-down treatment strategy with con-
ventional DMARDs with a step-up strategy in recent-onset RA patients in daily practice. 
The treating physician determined which approach would be taken. The majority of 
patients (52 versus 19) were treated according to the step-up approach. With the restric-
tion that, precisely because of this study design, the groups are difficult to compare, the 
results showed earlier improvement, fewer side effects and fewer treatment failures in 
the step-down group than in the step-up group. These findings are in accordance with 
findings of the COBRA and the BeSt trials. 
In conclusion, recent (strategy) trials confirmed the beneficial effect of early combina-
tion therapy with conventional DMARDs, including prednisolone, in comparison with 
monotherapy. 
recent (follow-up) trials comparing combinations with biologicals
With the use of biologicals, the treatment of RA has changed considerably. Several trials 
confirmed that combination therapy with any of the available anti-TNF inhibitors and 
MTX led to better clinical responses, functional improvement, quality of life and less 
radiological damage progression compared to treatment with MTX and anti-TNF ther-
apy alone.4 In patients with established RA the 3-years results of the Trial of Etanercept 
and Methotrexate with Radiographic Patient Outcomes (TEMPO) trial22 showed that 
patients treated with a combination of etanercept and MTX had significantly better 
DAS, higher remission rates and more improvement in HAQ scores compared with 
patients treated with either drug alone. Treatment with etanercept, alone or with MTX 
combined, led to less radiological damage progression than treatment with methotrex-
ate monotherapy. In patients with recent-onset RA, the Combination Of Methotrexate 
and Etanercept Trial (COMET)23 showed a comparable beneficial effect of the combi-
nation of MTX and etanercept over treatment with MTX alone. Fifty percent of the 
patients treated with combination therapy achieved clinical remission compared to 
28% of patients treated with methotrexate alone (p<0.0001). Eighty percent and 59%, 
respectively, achieved radiographic non-progression (p<0.0001).
In the dynamic NEO-RACo trial,24 the original FIN-RACo combination therapy (MTX-
+SSZ+HCQ+prednisolone) and 5 doses of infliximab in the first 6 months of treatment 
was compared with the same combination with placebo. The aim was to achieve ACR 
Rheumatology (ACR) responses than the initial monotherapy group. As expected, the 
percentages of patients achieving ACR remission were not significantly different (41% 
vs 35%) between the two groups nor were the outcomes in functional ability (health 
assessment questionnaire (HAQ) score 0 vs 0.1) and in radiological progression from 
baseline to 2 years. 
The Combinatietherapie bij Reumatoïde Artritis (COBRA) trial6,13 was the first to explore 
the possibility of a step-down approach in treatment of RA. The combination MTX, 
sulfasalazine (SSZ) and a rapidly tapered high dose of prednisolone was more effective 
than SSZ alone, with a better clinical response and significantly less joint damage pro-
gression until 5 years of follow-up. A recent update on radiological progression rates 
after 11 years showed no longer a significant difference between the initial combination 
group and the initial monotherapy group, possibly because of the unequal dropout 
rates in both groups.14
The Finnish Rheumatoid Arthritis Combination therapy (FIN-RACo) trial7 showed that 
in patients with recent-onset RA combination therapy (SSZ, MTX, HCQ and prednis-
olone) is superior to SSZ monotherapy with significantly higher remission rates, less 
radiological damage and comparable toxicity, while aiming at remission. After 11 years of 
dynamic, remission-steered treatment, the initial combination group still had less radio-
logical progression compared to the initial monotherapy group (p=0.04).15 
The BeSt study16,17 is a randomised controlled trial in which four different, DAS-steered, 
dynamic (including tapering to drug free remission) treatment strategies are compared. 
Two groups (group 1, sequential monotherapy, and group 2, step-up combination ther-
apy) started with MTX monotherapy with introduction of combination therapy with 
infliximab or prednisolone in case of insufficient response to at least three conventional 
DMARDs. The other two groups (group 3, initial combination therapy with MTX, SSZ 
and prednisolone, and group 4, initial combination therapy with MTX and infliximab). 
The initial combination therapy groups showed an earlier improvement in DAS, HAQ 
and quality of life,18 earlier remission, and less radiological progression compared to 
the initial monotherapy groups. The dynamic study design aiming at a DAS 2.4 or less 
resulted in comparable results in functional ability in the four treatment groups from 
the end of the first year of treatment onwards, meanwhile enabling most patients in the 
initial combination therapy groups to taper their medication, and most patients in the 
initial monotherapy groups to increase or change their medication. Despite only a brief 
period of clinical differences in response early in the trial between the treatment arms, 
patients treated with initial combination therapy still had significantly less joint damage 
progression after 5 years as compared with the initial monotherapy groups. After 5 years, 
48% of patients are in clinical remission, defined as a DAS <1.6.19 Fourteen, 16, 10 and 19% 
of patients had by then successfully discontinued all antirheumatic drugs. The patients 
in sustained drug-free remission (>1 year) barely showed radiological progression after 
the discontinuation of DMARDs. 
Saunders, et al.20 compared initial combination therapy with conventional DMARDs 
(SSZ, MTX and HCQ) to a step-up regimen starting with SSZ monotherapy and sub-
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increased in the combination arm, whereas medication would be tapered and stopped if 
the DAS28 was 3.2 or less. As expected, patients treated with initial MTX and adalimumab 
combination therapy showed an earlier improvement in disease activity than patients 
treated with initial MTX monotherapy, with 64% versus 25% of patients achieving a low 
disease activity at 12 weeks (p=0.001). Because of the dynamic treatment protocol, after 1 
year, the proportion of patients with low disease activity was similar in both groups (65% 
versus 64%, p=0.98) and there were no differences in joint damage progression among 
the (small) groups. Interestingly, the total use of adalimumab did not differ between the 
groups. For a patient, a delay in clinical improvement of 3 months or more would be rele-
vant, leading to the suggestion that initial anti-TNF therapy may be the best option. 
In STRategies in Early Arthritis Management (STREAM), a study in relatively mild RA 
patients,29 remission-steered treatment with initial MTX monotherapy followed by addi-
tion of anti-TNF was compared to ‘conventional DMARD treatment’.  In both groups, 
high remission rates, good clinical responses and less radiological damage were seen, 
without significant differences. This might be due to relatively low patient numbers, due 
to the patient profiles or both. 
how to decide when to change medication?
With the introduction of superior (combinations of) drugs to suppress disease activity, 
the approach to treatment decisions has also changed. A rapid reduction in the number 
of inflamed joints and in erythrocyte sedimentation rate and C-reactive protein is now 
achievable. The TIght COntrol for Rheumatoid Arthritis (TICORA) trial showed that better 
disease control is possible with disease activity driven treatment than with observational 
therapy decisions,30 with significantly lower disease activity, higher proportions of patients 
with a good response, higher remission rates and less radiological damage compared to the 
conventional-treated patients. The Computer Assisted Management in Early Rheumatoid 
Arthritis (CAMERA) trial31 confirmed that tight-controlled treatment with a clear treatment 
goal is better than ‘traditional’ treatment. In this trial, decisions in the intensive arm were 
made based on a computerised decision program. The intensive treatment group showed 
significantly higher remission rates than the conventional treatment group (50% versus 37%, 
p=0.03) together with a higher turnover from low-dose MTX monotherapy to high-dose 
and combination therapy. In contrast to the TICORA trial, there was no clear difference in 
radiological progression between the two groups after 2-year follow-up. 
The BeSt study showed that, with continuous steering at low disease activity, a compara-
ble disease state can be achieved in all four groups, independent of initial treatment. The 
time to achieve low disease activity is longer in the initial monotherapy groups compared 
to the initial combination groups.16,32 Therefore, fewer treatment adjustments are needed 
when treatment starts with initial combination therapy. Post-hoc comparative studies of 
the results of the BeSt study with the conventionally treated RA patients from two Dutch 
Early Arthritis Cohorts also showed a clinical benefit of DAS-steered treatment.33 
In retrospect, it seems obvious that, regardless of the medication used, adjusting the 
medication in order to achieve a certain goal will lead to patients achieving that goal. 
remission. The addition of infliximab resulted in significantly higher remission rates (70% 
versus 53%) and significantly less radiological joint damage progression after 2 years (-0.2 
versus 1.4). 
Following the introduction of anti-TNF, several biologicals with different immunolog-
ical targets are developed. Abatacept and tocilizumab are approved as therapies for 
patients with rheumatoid arthritis, as was rituximab, previously used in the treatment 
of hematological malignancies. In most countries, reimbursement policies have made 
these drugs available only for patients who have failed on anti-TNF therapy. 
The newer biologicals were individually evaluated as add-on vs methotrexate (or some-
times other DMARDs) treatment. Only tocilizumab (anti-IL6) was compared as mono-
therapy against MTX monotherapy in a parallel design in MTX-naïve patients and was 
more effective than MTX monotherapy in ACR 20, 50 and 70 responses and DAS28 
remission.25 The effect on radiological progression remains to be determined. Other new 
candidate treatments need to be evaluated. No conclusions can be made about long-
term safety of the new biologicals.    
minimal delayed combination versus initial combination
The progression of time without effective treatment impairs functioning of RA-pa-
tients, and therefore needs to be shortened. The results of the BeSt study show that a 
delay of 6 to 9 months in clinical improvement, because of unsuccessful sequential or 
add-on treatment with conventional DMARDs, results in significantly more joint dam-
age progression compared with patients treated with initial combination therapy.26 This 
suggests that with delayed introduction of combination therapy the window of oppor-
tunity can be missed. Also, delayed infliximab could be less often discontinued than if 
employed as initial treatment. 
Although on the group level, initial combination therapy leads to better outcomes 
than delayed therapy, a part of the RA population responds well to MTX monother-
apy. Unfortunately, at this time it is not possible to predict who will respond to MTX 
alone. Therefore, an approach with a short period of MTX monotherapy, followed by 
immediate introduction of combination therapy in case of insufficient response might 
be appropriate. This approach was used in the SWEFOT trial27 in which 487 recent-on-
set RA patients started with MTX monotherapy. If the DAS28 was at least 3.2 after 3-4 
months, patients were randomised to either adding SSZ and HCQ to MTX (n=130) or 
adding infliximab to MTX (n=128). Unfortunately, the trial design does not allow us to 
compare this strategy to initial combination therapy. However, SWEFOT demonstrated 
that following failure on MTX monotherapy, patients who received infliximab added 
to MTX had significantly higher remission rates (42% versus 26%) and higher ACR50 
and 70 responses (29% and 13%, 16% and 8%, respectively) after 1 year than patient who 
received the combination of conventional DMARDs. 
The GUEPARD trial28 presents a parallel comparison between initial MTX monotherapy (32 
patients) and initial combination therapy with MTX + adalimumab (33 patients). If after 
3 months, DAS28 was more than 3.2, adalimumab was added to MTX monotherapy or 
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Until accurate prediction is possible, the risk of undertreatment (loss of function, joint 
damage progression) versus the risk of overtreatment (toxicity) needs to be considered. 
Other barriers for the implementation of early combination therapy involve cost issues 
and concerns about safety of the newest drugs. In addition, some combinations are 
found complex to administer.36 Given the evidence from various trials, it is reasonable 
to expect most patients to benefit most from initial treatment with a combination of 
drugs, including either prednisolone or a TNF-blocker. When the goal is achieved, the 
possibility of overtreatment should be anticipated by using a flexible protocol, which 
allows tapering and discontinuation of medication in a tight-controlled setting. 
New research is needed to go further. The continuous search for biomarkers of disease 
stage and predictors of treatment response is essential to proceed to more individu-
ally tailored treatment in the future. Given their obvious potential, the newer biolog-
icals need to be studied earlier in the disease course in comparison with established 
treatment strategies. Various treatment strategies should be compared, with no or with 
minimal treatment delay, looking at the induction of drug-free clinical and radiological 
remission, safety and total societal costs. It has to be confirmed that implementing the 
results of such studies into daily practice is possible and to the benefit of RA patients. 
Conclusion
From various trials, including the BeSt study, the following aspects of RA treatment turn 
out to be beneficial:
1  early introduction of effective treatment with minimal delay in introduction of 
combination therapy including prednisolone or TNF blockers; 
2 result-driven (for instance DAS ≤2.4 or remission) treatment;
3 tight controlled (based on measurement of disease activity) treatment 
These three aspects should be and are being implemented in the treatment of recent-on-
set RA patients. New trials will help to fine tune the timing of the most effective drugs, 
which include the newer biologicals.
Only the time of achievement may differ with the strategy. The next questions are: what 
goal should we aim at and how ‘tight’ should tight control be? 
As discussed, a number of trials implemented the concept of tight control in their pro-
tocol, but no large trials compared different treatment goals. Van Tuyl, et al.34 did a small 
(pilot) trial comparing treatment steered at achieving a low disease activity (DAS28≤3.2) 
or at achieving a low C-terminal cross-linking of type II (CTX-II) level (marker for car-
tilage degradation, ≤150 nmol/mmol). Twenty-one patients were randomised and 
treated with the same medication, starting with a combination of SSZ, MTX, HCQ and 
a tapered high dose of prednisolone. After 40 weeks, 19 of 21 patients were in remission 
(DAS28 ≤2.6). Because of the limited patient number, no conclusions could be drawn 
on the usefulness of CTX-II in treatment decisions. Following FIN-RACo and NEO-
RACo trials, the Dutch Rheumatoid Arthritis Monitoring Registry (DREAM) remission 
induction cohort has shown that in daily practice, a tight-controlled, DAS28 less than 
2.6-steered, initial MTX monotherapy-based treatment strategy results in a high per-
centage of patients progressing to combination therapy as well as a high percentage 
(51%) achieving remission after 1 year.35 
These results show that clinical remission seems to be an attainable goal. In general it is 
reasonable to expect that, if treatment is aimed at a lower level of disease activity, less 
loss of functioning and less joint damage will be observed, and more treatment adjust-
ments in more patients. The frequency of controls will depend mostly on local logistics. 
translation to clinical practice
The most important consequence to draw from the strategy trials described in this 
review is that result-driven treatment is better than what used to be routine, ‘observa-
tional’ care. Frequent visits to the outpatient clinic with treatment adjustments based 
on specific, validated tools are necessary to reach the predefined goal as soon as possi-
ble. And it seems reasonable to steer at achieving remission. 
Many trials have demonstrated that immediate suppression of disease activity leads to 
earlier clinical improvement and less joint damage progression, and that, on the group 
level, combination therapy is superior to treatment with DMARD monotherapy, with-
out a clear negative effect on toxicity (table 1 and 2). The BeSt trial, integrating tight con-
trol with DAS-steered therapy decisions while comparing four different treatment strat-
egies where various combinations of various drugs were introduced at various times in 
the treatment of patients with recent-onset RA, probably comes closest to mimicking 
modern daily practice in a clinical trial. 
The implementation into daily practice is a slowly going process. Regrettably, the bene-
fits of early aggressive treatment vs the risk of overtreatment prevent rapid implemen-
tation in individual patients. Ideally, treatment is tailored for each patient separately, 
based on clinical characteristics, laboratory markers or both. Unfortunately, the cor-
rect prediction whether a patient will respond well to a certain therapy turns out to 
be difficult. Ongoing research will contribute to the understanding of the pathogene-
sis of RA and improve prediction models by, ideally, identification of new biomarkers. 
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i nt rO d uC t i O n
Great improvements in the treatment of rheumatoid arthritis (RA) have been made 
in the pas few decades. The evidence for the benefit of the early use of (combinations 
of) disease-modifying antirheumatic drugs (DMARDs) and biological agents,1-6 together 
with the introduction of dynamic tightly controlled treatment aiming at a predefined 
goal,7-9 has led to a shift in traditional treatment paradigms. It is not known what clinical 
and radiological outcomes can be expected in the longer term in RA patients treated 
according to an early, intensive treatment approach.  
The BeSt (Behandel-Strategieën, Dutch for treatment strategies) study incorporated 
these new insights into early, goal-steered treatment by comparing four dynamic treat-
ment strategies rather than individual therapies, using antirheumatic drugs and com-
binations of drugs in various orders.10,11 Designed in the late 1990s, it was ambitious in 
aiming at low disease activity,12,13 and introducing  protocolised tapering and discontinu-
ation of all antirheumatic drugs when clinical remission is achieved. Furthermore, it pro-
vides a unique patient cohort because it is, as far as we know, the only RA trial in which 
patients are still monitored every 3 months after 5 years of follow-up and protocolised 
treatment adjustments continue to be made aiming at low disease activity. 
Here we present the clinical and radiological outcomes of the BeSt study after 5 years 
of follow-up. The main objectives were (1) to assess functional status, quality of life and 
the amount of joint damage after 5 years intensive, disease activity score (DAS)-directed 
treatment; (2) to assess whether initial improvements in functional ability and quality 
of life can be sustained; (3) to compare clinical outcomes and annual joint damage 
progression scores between the four treatment strategies; (4) to assess the percentage 
of patients in remission and drug-free remission and assess joint damage progression in 
these patients.
PAt i ents  An d  me t h O d s
study design
The BeSt study design has previously been published in detail.10 It is a randomised sin-
gle-blind clinical trial to evaluate the efficacy and safety of four treatment strategies in 
recent-onset RA patients. Based on 3-monthly disease activity measurements, treatment 
adjustments were made aimed at achieving and maintaining a DAS (44 joints) of 2.4 or 
less.12 It is designed and conducted by the Foundation for Applied Rheumatology Research, 
a collaboration between rheumatologists in the western part of The Netherlands. 
Patients
Between March 2000 and August 2002, 508 patients from 20 hospitals in The Netherlands 
with DMARD-naïve RA according to the 1987 American College of Rheumatology crite-
ria,14 ages 18 years or older, disease duration of 2 years or less, with active disease with six 
or more of 66 swollen joints and 6 or more of 68 tender joints, and either an erythrocyte 
ABs t r AC t
Objective: To compare clinical and radiological outcomes of four dynamic treatment 
strategies in recent-onset rheumatoid arthritis (RA) after 5 years follow-up.
Methods: 508 patients with recent-onset RA were randomly assigned into four 
treatment strategies: sequential monotherapy; step-up combination therapy; initial 
combination with prednisone; initial combination with infliximab. Treatment 
adjustments were made based on 3-monthly disease activity score (DAS) 
measurements (if DAS >2.4 next treatment step; if DAS ≤2.4 during ≥6 months taper 
to maintenance dose; if DAS <1.6 during ≥6 months stop antirheumatic treatment). 
Primary and secondary outcomes were functional ability, joint damage progression, 
health-related quality of life and (drug-free) remission percentages.
results: After 5 years, 48% of patients were in clinical remission (DAS <1.6) and 14% 
in drug-free remission, irrespective of initial treatment. After an earlier improvement 
in functional ability and quality of life with initial combination therapy, from 1 year 
onwards clinical outcomes were comparable across the groups and stable during 5 
years. The initial combination groups showed less joint damage in year 1. In years 
2-5 annual progression was comparable across the groups. After 5 years, initial 
combination therapy resulted in significantly less joint damage progression, reflecting 
the earlier clinical response. 
Conclusion: Irrespective of initial treatment, an impressive improvement in clinical 
and radiological outcomes of rheumatoid arthritis patients can be achieved with 
dynamic treatment aiming at reducing disease activity, leading to 48% remission, 
14% drug-free remission and sustained functional improvement. Starting with 
combination therapy resulted in earlier clinical improvement and less joint damage, 
without more toxicity. 
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therapy. In all groups, treatment adjustments were made based on 3-monthly disease 
activity measures, aiming at a DAS of 2.4 or less (low disease activity). The DAS was 
calculated by a trained nurse, who remained blinded to the treatment. If the DAS was 
greater than 2.4, the next treatment step was taken according to the fixed stepwise 
treatment protocol for each group (figure 1). If the DAS was 2.4 or less (low disease 
activity) for 6 months or longer, medication was tapered to a maintenance dose. Details 
of the drug doses in the different treatment steps were reported previously.10 Routine 
laboratory measurements were performed 3-monthly. For all strategy arms the protocol 
allowed discontinuation or reduction to the lowest tolerated dose of drugs that, in the 
opinion of the treating physician, caused side-effects. 
From the third year of treatment, patients who had tapered to low-dose monotherapy 
and had a DAS less than 1.615 for at least 6 months tapered and discontinued the last 
DMARD. If the DAS increased above 1.6, the last DMARD was immediately restarted, 
and could not be discontinued again. 
study endpoints and assessments
Primary outcomes 
Primary outcomes were functional ability measured every 3 months with the Dutch ver-
sion of the health assessment questionnaire16 (HAQ; 0, best; 3, worst) and  joint damage 
progression on radiographs of hands and feet measured with the Sharp-van der Heijde 
method (SHS; range 0-448 points).17 Annual radiographs of hands and feet at baseline 
and years 1, 2, 3, 4 and 5 were scored in one session per patient by two independent 
readers, blinded to treatment allocation, patient identity and in random time sequence. 
The mean scores of the two readers were used in the analysis. 
Secondary outcomes
Health-related quality of life was measured with the medical outcomes study short form 
36,18 3-monthly in the first 2 years of treatment and annually from year 2 onwards. Based 
on a reference population,19 two norm-based summary scales were derived: the physical 
component scale (PCS) and mental component scale (MCS). By definition, the mean PCS 
and MCS of the reference population are 50 (SD 10). Higher scores represent better health.
Remission and drug-free remission percentages were calculated, using DAS less than 1.6 
as the remission criterion.15 We calculated the SHS progression in patients in sustained 
drug-free remission (remission ≥1 year) in their first full year drug-free.   
Adverse events
All adverse events (self-reported, or evident from laboratory tests or yearly general 
physical examination) were recorded. Serious adverse events were defined as condi-
tions that are life threatening or leading to death, malignancies, conditions leading to 
(prolongation of) hospitalisation or conditions leading to significant or permanent 
disability.  
sedimentation rate of 28 mm/h or greater or a global health score of 20 mm or greater on 
a 100-mm visual analogue scale (0, best; 100, worst) gave informed consent. 
interventions 
Patients were randomly assigned into four treatment strategies. Group 1 (sequential 
monotherapy, n=126) and group 2 (step-up combination therapy, n=121) started both 
with methotrexate monotherapy, whereas group 3 (initial combination therapy with 
prednisone, n=133) and group 4 (initial combination therapy with methotrexate and 
the tumour necrosis factor  alpha inhibitor infliximab, n=128) started with combination 
FiGure 1 Treatment flow diagram. AZA, azathioprine;  CSA, ciclosporin A; HCQ, hydroxychloroquine; IFX, 












MTX 15 mg MTX 15 mg MTX 7.5 mg + SSA + pred
MTX 15 mg 
+ IFX 3 mg/kg
MTX 25 mg MTX 25 mg MTX 25 mg + SSA + pred
MTX 25 mg 
+ IFX 3 mg/kg
SSA MTX + SSA MTX + SSA + pred
leflunomide MTX + SSA + HCQ MTX 25 mg + IFX 3 mg/kg MTX + IFX 10 mg/kg
MTX 25 mg 
+ IFX 3 mg/kg
MTX + SSA 
+ HCQ + pred SSA
MTX 25 mg 
+ IFX 3 mg/kg MTX + IFX 10 mg/kg leflunomide
MTX + IFX 10 mg/kg leflunomide MTX + CSA + pred
gold MTX + IFX 10 mg/kg gold gold
MTX + CSA + pred MTX + CSA + pred AZA + pred AZA + pred
AZA + pred gold
MTX + pred
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FiGure 3 Pies representing the proportion of patients in each treatment step after 5 years follow-up. (A) 
sequential monotherapy, (B) step-up combination therapy, (C) initial combination with prednisone, (D) initial 
combination with infliximab. CSA, ciclosporin A; HCQ, hydroxychloroquine; IFX, infliximab; LEF, leflunomide; 
MTX, methotrexate; pred, prednisone; SSA, sulphasalazine.
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statistical analysis     
The software program SPSS version 16.0 was used, using the intention-to-treat princi-
ple for all results, except for the analysis of the proportions of patients in remission and 
drug-free remission where completer’s data were used. Characteristics at t=5 years were 
compared between the groups using analysis of variance, chi-square and Kruskal-Wal-
lis when appropriate. Baseline PCS and MCS scores were compared with the reference 
population with a two-sample t test.
The outcomes HAQ, SHS and quality of life (PCS, MCS) were longitudinally analysed 
using linear mixed models (LMM). For each outcome the covariance structure with the 
lowest Akaike value was used. 
To test whether there were differences in HAQ between the groups during 5 years 
of follow-up, a LMM with the outcome HAQ (21xHAQ per patient) was performed, 
with treatment group, time and their interaction as determinants (covariance matrix 
ARMA1.1). 
In the second LMM log-transformed SHS-scores (to approach normality) of all years 
were compared to investigate whether there were differences in joint damage progres-
sion between the treatment groups over time, with time, randomisation and the inter-
action time*randomisation as determinants, corrected for log SHS of baseline, baseline 
C-reactive protein, age, gender, anticyclic citrullinated peptide, rheumatoid factor and 
baseline body mass index (covariance matrix unstructured). 
Finally, LMM was used to assess whether there were differences in quality of life between 
the patients in the four treatment groups during 5 years of follow-up, with PCS and MCS 
as outcomes and randomisation and time as covariates (covariance matrix unstruc-
tured). This was done by calculating and comparing areas under the curve (AUC) 
between the treatment strategies under the custom hypothesis subcommand of the 
LMM (TEST in SPSS). 
In all analyses comparing treatment groups, each treatment group was assessed inde-
pendently and compared with the other groups one by one, without combining the 
results of treatment groups.
















Age, years 54 (13) 54 (13) 55 (14) 54 (14)
Women, n (%) 85 (68) 87 (72) 88 (66) 83 (65)
Symptom duration, weeks (median, IQR) 23 (14-54) 26 (14-56) 23 (15-53) 23 (13-46)
IgM rheumatoid factor positive, n (%) 84 (67) 77 (64) 86 (65) 82 (64)
DAS 4.5 (0.9) 4.5 (0.8) 4.4 (0.9) 4.3 (0.9)
HAQ, 0-3 scale 1.4 (0.7) 1.4 (0.6) 1.4 (0.7) 1.4 (0.7)




Chapter 4 5-year results of the BeSt study
  4
FiGure 4 Changes in HAQ, remission percentages, physical and mental component scale of the short form 
36 and Sharp-van der Heijde score during 5 years of follow-up. HAQ, health assessment questionnaire; MCS, 
mental component scale; PCS, physical component scale; SHS, Sharp-van der Heijde Score.
first year, the functional capacity had improved substantially to a comparable level in all 
four groups, and this improvement was sustained until 5 years of follow-up. At t=5 years 
there were no significant differences in functional capacity between the groups (mean 
HAQ 0.58). No major differences between limitations on the eight subscales of the HAQ 
were observed (data not shown). When taking into account all HAQ scores during 5 
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Baseline characteristics between the four treatment groups were comparable (table 1). 
Patients had high disease activity (mean DAS 4.4) at baseline with compromised func-
tional ability (HAQ 1.4).  Erosions on radiographs of hands and/or feet were present in 
72% of patients. During 5 years of follow-up, 72 patients (15%) withdrew from the study 
(figure 2), 15 (12%), 27 (22%), 20 (15%), and 12 (9%) in groups 1-4 (group 2 vs group 4 
p=0.05, other comparisons ns). 
treatment
The percentage of patients who had achieved the goal of DAS of 2.4 or less was similar 
in all groups (p=0.94, total 82%). The proportions of patients in each treatment step at 
t=5 years are depicted in figure 3. The initial monotherapy groups needed more treat-
ment adjustments before achieving a DAS of 2.4 or less than the initial combination 
therapies. After 5 years 25%, 21%, 45% and 65% of patients in groups 1-4 were still on the 
initial treatment. Fifty per cent of patients in group 4 had permanently discontinued the 
initial treatment with infliximab because of a continuous good response, and 46% of 
patients in group 3 had successfully tapered and stopped prednisone. In groups 1-3, 41%, 
12% and 21% had started delayed infliximab because of insufficient response to previous 
drugs, and 21%, 5%, and 11% were still treated with infliximab at t=5 years, compared with 
19% in group 4. In group 2, 26% had started prednisone because of insufficient response 
to step-up therapy with conventional DMARDs, and 6% were still treated with predni-
sone at t=5 years, compared with 14% in group 3 (median dose 5 mg in both groups). 
Details on annual prednisone and infliximab use are given in table 2.
Functional ability
Patients in the initial combination therapy groups experienced an earlier improvement 
in functional ability than the initial monotherapy groups (figure 4A). At the end of the 
tABel 2 The number of patients using prednisone and infliximab and the number of patients in the initial 
treatment at the end of each follow-up year. 
t=1 year t=2 years t=3 years t=4 years t=5 years
Sequential
monotherapy (n=126)
Prednisone 7 (6%) 6 (5%) 3 (2%) 5 (4%) 4 (3%)
Infliximab 2 (2%) 32 (25%) 25 (20%) 24 (19%) 21 (17%)
Initial treatment 48 (39%) 42 (33%) 36 (29%) 34 (27%) 31 (25%)
Step up combination 
therapy (n=121)
Prednisone 6 (5%) 15 (12%) 4 (3%) 6 (5%) 7 (6%)
Infliximab 2 (2%) 11 (9%) 6 (5%) 7 (6%) 4 (3%)
Initial treatment 43 (37%) 38 (31%) 28 (23%) 28 (23%) 25 (21%)
Initial combination with 
prednisone (n=133)
Prednisone 42 (32%) 22 (17%) 19 (14%) 19 (14%) 18 (14%)
Infliximab 3 (2%) 13 (8%) 12 (9%) 16 (12%) 11 (8%)
Initial treatment 94 (73%) 77 (58%) 64 (48%) 64 (48%) 60 (45%)
Initial combination with 
infliximab (n=128)
Prednisone 2 (2%) 9 (7%) 12 (9%) 7 (6%) 9 (7%)
Infliximab 53 (41%) 23 (18%) 23 (18%) 26 (20%) 23 (18%)
Initial treatment 102 (81%) 92 (72%) 90 (70%) 86 (67%) 83 (65%)
Results are displayed as n (%).
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after 5 years in these patients was 1.5 (IQR 0-7.8). Of the patients in sustained drug-free 
remission (definition ≥1 year, radiographs available in 41/48), 78% showed no joint dam-
age progression (defined as >0 SHS units) in the first year of drug-free remission. 
safety
During 5 years follow-up, 437 (86%) patients experienced at least one adverse event. 
In total, 251 serious adverse events occurred in 152 (30%) patients, equally distributed 
among the treatment groups and over time (table 3; figure 5). The majority of the adverse 
events was mild to moderate and did not lead to treatment adjustments. Eleven of the 
120 patients treated with initial combination with infliximab in group 4, and three of 52, 
none of 15 and three of 28 patients in groups 1-3 treated with delayed infliximab had an 
infliximab infusion reaction. During 5 years of treatment, the number of serious infec-
tions, malignancies and deaths (12 patients, table 3) were comparable across the groups. 
Figure 5 Distribution of serious adverse events among the treatment steps and over time. Each dot represent 
one serious adverse event.













n=126 n=121 n=133 n=128
Any adverse event during 5 years 110 (87) 103 (85) 112 (84) 112 (88) 0.84
Infections 56 (44) 51 (42) 53 (40) 61 (48) 0.62
Gastrointestinal 56 (44) 55 (46) 48 (36) 57 (45) 0.38
Dermal/mucosal 34 (27) 36 (30) 39 (29) 24 (19) 0.16
Neurological 27 (21) 30 (25) 22 (17) 25 (20) 0.43
Cardiovascular 20 (16) 21 (17) 36 (27) 26 (20) 0.11
Infusion reactions 3 / 52 0 / 15 3 / 28 11 / 120 0.58
Any SAE during 5 years 42 (33) 34 (28) 37 (28) 37 (31) 0.76
Serious infection (n) 13 5 7 9 0.22
Malignancies (n) 5 4 6 4 0.93
Death (n) 3 3 2 4 0.68
Values indicate the number (percentage) of patients, unless specified otherwise. SAE, serious adverse event. Causes of 
death were the following: pneumonia, pneumonia/encephalitis, non-small cell lung carcinoma (group 1); cerebrovascular 
accident, bronchial carcinoma, myocardial infarction (group 2); ovarian carcinoma, cerebrovascular accident (group 3); 
disseminated tuberculosis, myocardial infarction, septic arthritis, cerebrovascular accident (group 4) 
sequential monotherapy
step-up combination therapy
initial combo with prednisone
initial combo with infliximab
Time from baseline (years)
in groups 1, 2 and 3 independently, and patients in group 3 had better HAQ scores than 
patients in groups 1 and 2 independently (LMM, p<0.001 for group 3 and 4 vs groups 1 
and 2, p=0.01 for group 3 vs group 4). The mean HAQ score during follow-up was 0.70, 
0.70, 0.62 and 0.54 in groups 1-4, respectively.
Quality of life
Quality of life (PCS and MCS) was lower at the beginning of the study compared to the 
reference population (33 vs normal 50 for PCS (p<0.001) and 47 vs 50 normal for MCS 
(p<0.001), Figure 4C and 4D). The PCS improved earlier in groups 3 and 4 than in groups 
1 and 2. After 1 year the mean PCS was increased to a comparable level in all four groups 
(mean 45, SD 10) and sustained until 5 years of follow-up, without significant differences 
between the groups (mean PCS (AUC per month) 43.5, 43.3, 44.1, 45.0 for groups 1-4; PCS 
p=0.09 for 1 vs 4, p=0.08 for 2 vs 4, p>0.36 for other comparisons).
The mean MCS improved to 52 (SD 9), which is slightly better than the healthy reference 
population. After 5 years of follow-up, we observed no differences in mean MCS between 
the treatment groups (mean MCS (AUC per month) 51.8, 51.0, 50.9, 51.2 for groups 1-4). 
radiological damage   
In total, 2595 sets of radiographs were available, 479 (94%) from baseline and 446 (88%), 
436 (86%), 432 (85%), 421 (83%), 381 (75%) from years 1-5. The interobserver intraclass 
correlation coefficient of the two readers for 5-0 change scores was 0.98. After 5 years, 
there was significantly more radiological progression in groups 1 and 2 than in groups 
3 and 4, with median (mean) SHS progression of 3.5 (14.0), 2.5 (11.0), 1.0 (7.6) and 1.0 
(6.0) units for groups 1-4, respectively (groups 1-2 vs group 4 p<0.01; group 1 vs group 
3 p<0.001; other comparisons: ns). There were no differences in radiological joint dam-
age between groups 3 and 4. Annual SHS progression rates were the highest in year 
1 (mean 3.4), with significantly more progression in groups 1 and 2 than in groups 3 
and 4 (LMM p<0.05, figure 4E). In the following years, progression scores continued to 
increase (mean annual progression 1.5, 1.1, 1.5, 1.6 in years 2-5; LMM p<0.02 for each year 
compared with the preceding year) without differences between the four groups. 
remission and drug-free remission
After 5 years, 48% of patients were in clinical remission defined as DAS less than 1.6 
equally distributed among the groups (figure 4B). Of those, 46%, 51%, 65% and 81% of 
patients in groups 1-4 had achieved that on the initial therapy.  Patients in remission 
after 5 years had significantly less joint damage progression (mean 7.6 vs 10.7, median 
1.0 vs 2.5, p=0.001) and significantly better functional ability (mean HAQ 0.34 vs 0.79, 
p<0.001) than patients not in remission but with DAS of 2.4 or less.  
After 5 years, 14%, 16%, 10% and 19% of patients in groups 1-4 were in drug-free remission 
(overall p=0.18), with a median duration of 23 months (IQR: 15-25 months) in all treatment 
arms. At achieving drug-free remission the mean HAQ was 0.16 (SD 0.30), comparable to 
HAQ values of the general population (mean HAQ 0.34).20. The median SHS progression 
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radiographs and scoring methods, different medication schemes and control groups 
(sulphasalazine in COBRA and FIN-RACo vs methotrexate in BeSt) and different targets 
(remission in FIN-RACo, DAS ≤2.4 in BeSt, no targeted treatment in COBRA). 
Reported remission percentages vary widely (10-65%) in various studies with recent-on-
set RA patients,27 as a result of differences in remission definitions, patient characteristics 
and study designs.28 Given the patients’ disease severity and bad prognostic outlook at 
baseline, it is remarkable that after 5 years, 48% of patients were in clinical remission and 
31% of those in drug-free remission. The study is underpowered to evaluate whether 
there are differences in (drug-free) remission rates between the four treatment groups. 
As the patients all satisfied the 1987 American College of Rheumatology classification 
criteria for RA, they already had well established disease. It is tempting to speculate on 
the impact of starting effective, dynamic, DAS-directed therapy even earlier in the dis-
ease course.  
Our results underline the importance of early, targeted treatment in RA. Rheumatolo-
gists should be aware that both the immediate and later outlook of newly diagnosed 
patients depend on early reduction of disease activity and consequent treatment 
adjustments until this goal is achieved. Various tools have been developed to measure 
disease activity,12,13,29-31 but measuring alone is not enough. The gain from using these 
tools lies in setting a goal and adjusting therapy until it is achieved.7,8 There is insuffi-
cient evidence on what the target should be. Aiming at remission may possibly lead to 
even better treatment outcomes. The recommendations of an international taskforce 
on treating to target will hopefully encourage rheumatologists to adopt targeted treat-
ment in their daily practice.9 
Rather than comparing one static treatment with another, the BeSt study has integrated 
dynamic treatment into the trial protocol, to mimic daily practice. Taking it one step 
further, it has introduced protocolised tapering and discontinuation of medication into 
the trial design. We would like to encourage other research groups also to use a dynamic 
approach in future randomized clinical trials. 
In conclusion, with dynamic treatment with currently available drugs an impressive 
improvement in clinical and radiological outcomes of patients with recent-onset rheu-
matoid arthritis can be achieved, leading to 48% remission and up to 19% drug-free 
remission, irrespective of initial treatment. Starting with combination therapy resulted 
in earlier clinical improvement and less joint damage progression than starting with 
monotherapy, without more toxicity. With treatment adjustments aiming at low dis-
ease activity, in all four strategy groups the initial clinical improvement is maintained 
until 5 years follow-up without deterioration.
In group 4 one patient was treated for disseminated tuberculosis, despite 6 months previ-
ous treatment with isoniazide because of latent tuberculosis before the start of infliximab, 
according to then current guidelines and the study protocol. She subsequently died of 
other infectious complications (year 2). No other tuberculosis occurred in the trial. 
d i s Cus si O n 
The BeSt study shows that with dynamic treatment with currently available drugs, an 
impressive clinical and radiological gain can be made in the majority of patients pre-
senting with severe RA, resulting in significant and sustained improvements in daily 
functioning and quality of life over time and adequate suppression of joint damage pro-
gression, irrespective of initial treatment. Contrary to expectations, by aiming at low dis-
ease activity, 48% of patients achieved early clinical remission, showing the least damage 
progression and the best functional ability of all. Up to 19% of patients even achieved 
drug-free remission, enjoying a functional ability that is similar to the general popula-
tion, without having damage progression. 
Patients treated with initial combination therapy showed a more rapid improvement 
in disease activity, daily functioning and quality of life than patients treated with initial 
monotherapy, as shown earlier.10 The earlier clinical response in the first 6-9 months of 
treatment was reflected in significantly less joint damage progression in the initial com-
bination therapy groups compared to the initial monotherapy groups in year 1. 
After 5 years of follow-up, the initial differences in joint damage progression are still pres-
ent, although the annual progression rates in year 2-5 were comparable between the 
groups. Starting with combination therapy or reserving it for later did not affect toxicity. 
The initial combination arms showed an earlier clinical response than the initial mono-
therapy groups, but medication costs are substantially higher in the beginning of the 
study in the combination arms, especially in the initial combination arm with inflix-
imab.21 This raises questions upon the cost-effectiveness of the early start of biological 
agents.22 An early clinical response has been suggested to be relevant for maintenance 
of paid work.23,24 In line with this, the cost-utility analysis of the BeSt study after 2 years 
showed that patients treated with initial combination therapy groups were able to keep 
more paid work than initial monotherapy groups,21 which might (partly) compensate 
higher medication costs in groups 3 and 4. We are currently working on the 5-year 
cost-utility analysis that will elucidate which strategy is most cost-effective in the long 
term.
The long-term follow-up of the COBRA and FIN-RACo trials suggested a difference 
in slope in the amount of joint damage after 1-2 years between the combination and 
the monotherapy arms, whereas we did not observe a difference in annual progression 
from year 1 until year 5 between initial monotherapy and initial combination therapy.25,26 
Differences in study design and patient populations might have contributed to this dis-
crepancy and harms direct comparison: continuous protocollary (BeSt) versus non-pro-
tocollary treatment after 1-2 years (COBRA, FIN-RACo), differences in frequencies of 
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i nt rO d uC t i O n
The introduction of (combinations) of disease-modifying antirheumatic drugs 
(DMARDS), corticosteroids and biologicals early in the disease course has improved the 
clinical and radiological outcomes of rheumatoid arthritis (RA) patients considerably.1–6 
Further improvement has been made by treating patients according to a predefined 
target and adjusting therapy until that goal is reached.7,8.
An frequently used tool for treating to target is the disease activity score (DAS) and its 
simplifications, originally developed to compare treatment outcomes in clinical trials.9 
The DAS can be used as a tool to guide treatment decisions in individual patients.7
Furthermore, it is known from previous research that the DAS is related to the functional 
capacity of RA patients.10–12 It remains unclear whether actively aiming at a decrease in 
DAS will, independent of follow-up duration and even if the DAS level is already low, 
results in improvement in functional ability. Therefore, the objective of this analysis was 
to assess the association between a change in DAS and functional ability (as measured 
with the health assessment questionnaire (HAQ)) during 5 years of DAS-steered treat-
ment in patients with recently diagnosed RA, while taking into account the absolute 
level of disease activity and follow-up duration. 
PAt i ents An d me t h O d s
We used 5-year follow-up data from a cohort of 508 patients with active RA, all fulfill-
ing the American College for Rheumatology (ACR) classification criteria for RA13 and 
a disease duration ≤2 years, treated with the aim of achieving low disease activity.14 
Treatment adjustments were made based on 3-monthly DAS calculations done by a 
research nurse blinded for treatment allocation. If the DAS was >2.4, the rheumatolo-
gist adjusted medication according to the previously described protocol per treatment 
arm.14 If the DAS was ≤2.4 for at least 6 consecutive months, medication was tapered 
until monotherapy at a low maintenance dose was achieved. Once this was done, and 
if DAS was <1.6 for at least 6 consecutive months, the last medication was tapered and 
stopped, but restarted again as soon as DAS was ≥1.6. Functional capacity was mea-
sured every 3 months using the Dutch version of the HAQ.15 A decrease in HAQ of at 
least 0.22 is considered to be a clinically meaningful improvement.16
statistical analysis
A linear mixed model (LMM), which combines multiple measurements per patient, 
uses all available data during follow-up, takes into account missing values and corrects 
for within-patient correlation, was used to assess the longitudinal relationship between 
DAS and HAQ. Twenty follow-up measurements of HAQ per patient, collected during 
5 years follow-up, were used as outcome. 
The DAS 3 months earlier (previous DAS), the change in DAS in the preceding 3 months 
(delta DAS), and the time since baseline (log-transformed to approach linearity) were 
ABs t r AC t
Objective: To assess the relationship between a decrease in disease activity score 
(DAS) and functional ability during 5 years of DAS-steered treatment in recent-
onset rheumatoid arthritis (RA) patients, taking into account absolute DAS levels 
and follow-up duration.
Methods: Data from the BeSt study were used, in which treatment was aimed at 
achieving DAS ≤2.4. The longitudinal relationship between 3-monthly measured DAS 
and health assessment questionnaire (HAQ) score was assessed using linear mixed 
modelling during 5 years of treatment, with DAS and HAQ 3 months earlier, change 
in DAS in last 3 months (delta DAS), time (log-transformed) and their interactions 
as determinants.
Results: Predictors for HAQ were: previous DAS, delta DAS, ln time, the interaction 
previous DAS*delta DAS, and previous HAQ. The interaction ln time*delta DAS was 
non-significant, indicating that the association between delta DAS and HAQ was 
independent of follow-up duration. A decrease from a higher DAS was associated 
with a smaller HAQ decrease than for a similar decrease from a lower DAS, indicating 
a non-linear relationship between DAS and HAQ. 
Conclusion: At any time during 5 years of follow-up, a decrease in DAS was associated 
with a better functional ability. The magnitude of HAQ improvement depends on the 
DAS decrease and on the absolute DAS level.
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tABle 1 Linear mixed model (LMM) results of predictors of outcome HAQ during 5 years of DAS-steered treatment. 
Variable ß 95% CI Explained variance* (%)
Ln (time) 0.044 0.031-0.057* 20
Previous HAQ 0.234 0.213-0.255* 20
Previous DAS 0.213 0.200-0.226* 28
Delta DAS (current DAS  – previous DAS) 0.183 0.166-0.200* 37
Previous DAS*delta DAS 0.022 0.016-0.027* 37
DAS, disease activity score; HAQ, health assessment questionnaire; ln (time), natural logarithm of time since baseline; LMM, linear 
mixed model.  
The intercept is -0.037 with a p-value of 0.15 ß represents results of final multivariable LMM. In the right-hand column the increasing 
explained variance of the model is given (compared to a LMM with only a random intercept), by adding first a random slope with ln 
time (explained variance 18%), and then one by one variables as shown in the table.
*p<0.05.
FiGure 1 Matrix representation of predicted health assessment questionnaire (HAQ) score improvement after 3 months 
(A) and after 5 years of follow-up (B) based on HAQ and disease activity score (DAS) 3 months earlier, and change in DAS 
in the 3 preceding months. Clinically relevant HAQ decrease of ≥ 0.22 are shown in dark grey, smaller decreases in white, 
combinations that are unlikely to occur in real life (HAQ-DAS discrepancies) in lighter grey.






















'lighter grey. The matrix illustrates the positive association between delta DAS and HAQ, 
indicating that with a larger decrease in DAS, the outcome HAQ will be lower. This pos-
itive relationship did not change significantly during 5 years follow-up. The model also 
shows that a decrease in DAS resulting in a still high DAS has less impact on improving 
added to the model as explanatory variables, as well as the two-way interactions pre-
vious DAS*delta DAS, delta DAS*ln time and previous DAS*ln time and the three-way 
interaction previous DAS*delta DAS*ln time. The previous HAQ (3 months earlier) was 
added to the model (first order autoregression) to model change in HAQ rather than 
absolute HAQ scores. This allows a longitudinal interpretation of the data (ie, a change 
in DAS is associated with a change in HAQ) rather than a cross-sectional interpretation 
(patients with a high DAS have on average high HAQ). The following potential con-
founders were added one by one: treatment strategy, baseline body mass index (BMI), 
age, sex, symptom duration, anti-citrullinated peptide antibody (ACPA) status, rheu-
matoid factor (RF) status, baseline C-reactive protein (CRP) and Sharp-van der Heijde 
Score (SHS) at baseline and in the following years. As well as the variables described 
above added as fixed effects, two random effects were added (random slope with ln 
time and a random intercept) to correct for between-patients variance. The covariance 
structure with the lowest Akaike value was used (unstructured), that is, the covariance 
structure that fitted the model best, while taking into account the number of estimated 
parameters. SPSS version 16.0 (SPSS Inc., Chicago, Illinois, USA) was used for the analyses.
r e sults
In the first LMM with all covariates and interactions, the three-way interaction previous 
DAS*delta DAS*ln time was not significantly associated with HAQ (p=0.25) and hence 
omitted from the analysis. In the next analysis the covariates and two-way interactions 
were added one by one. The previous DAS, delta DAS, ln time, and the previous HAQ 
significantly predicted HAQ (table 1). Furthermore, the two-way interaction previous 
DAS*delta DAS was significantly associated with HAQ, indicating that the association 
with delta DAS depends on the absolute level of DAS and that there was a non-lin-
ear relationship between DAS and HAQ. The two-way interaction delta DAS*ln time 
showed no significant association, indicating that the relationship of delta DAS with 
HAQ was not dependent on the progression of time since the start of treatment. Treat-
ment strategy, sex, baseline BMI, age, symptom duration, ACPA, RF, CRP and SHS and 
SHS in the following years did not change the ß values nor the p values of the variables of 
interest (data not shown) and were therefore excluded from the analysis. The regression 
formula to predict the next HAQ is as follows:  
Outcome HAQ = -0.037 + (0.044*ln time) + (0.213*previous DAS) + (0.183*delta DAS) 
+ (0.022*previous DAS*delta DAS) + (0.234*previous HAQ) + [corr] + error
in which the regression coefficients of the LMM (table 1) are filled in and [corr] rep-
resents the correction for random patient effects (mean zero). To visualise the effect of 
this formula, a matrix was constructed, showing the estimated improvement in HAQ 
for various levels of DAS, delta DAS, and previous HAQ at different time points (fig-
ure 1). Clinically significant HAQ improvements are shown in dark grey boxes, clinically 
non-significant HAQ improvements in white and less common or impossible combi-
nations of variables (for instance DAS decrease more than previous DAS) are shown in 
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HAQ than a similar decrease resulting in a low DAS, given a similar previous HAQ. To 
illustrate, at DAS 4.5 and HAQ 1.5, a subsequent DAS improvement at 3 months of 1.0 
was associated with a HAQ improvement of 0.5, whereas at DAS 2.4 and HAQ 1.5 the 
estimated HAQ improvement was 0.9.
d i s Cus si O n 
This study shows that during 5 years of DAS-steered treatment in patients with 
recent-onset RA, a decrease in DAS is associated with a decrease in HAQ. The magni-
tude of HAQ improvement depends on the size of DAS decrease and on the absolute 
DAS level, but the DAS-HAQ association is independent of follow-up duration during 5 
years. There appears to be no ‘lowest optimum’ for the DAS, since further lowering the 
residual disease activity, is likely to further decrease the HAQ and potentially improve 
the patient’s functional ability, unless there is little to gain.
The matrix based on the prediction formula derived from the linear mixed model illus-
trates the relationship between DAS, previous DAS, delta DAS, time and HAQ, and 
its interactions. It shows how a change in DAS results in a change in HAQ, taking into 
account time since baseline and absolute HAQ level. 
By showing the relationship between DAS and HAQ in a DAS-steered treated cohort, 
our results expand on several previous studies in non-DAS steered cohorts.11 Welsing, et 
al.12 showed that the positive relationship between DAS and HAQ could no longer be 
observed after 9 years, possibly due to an increasing impact of joint damage on HAQ 
over time. We demonstrated that the positive association between DAS and HAQ in our 
cohort remains stable during 5 years of follow-up and we propose that this association 
might remain longer since the amount of joint damage is limited.17 Longer follow-up time 
would clarify this issue. We observed no deterioration of functional ability during 5 years 
of follow-up, in contrast to earlier studies in which the HAQ worsened after 3-6 years.10,12 
As demonstrated by the BeSt study inclusion criteria14, the patients included in this analysis 
probably have more severe RA than ‘the average’ new RA patient would have, especially 
when the new 2010 ACR/European League Against Rheumatism (EULAR) classification 
criteria for RA are applied.18 Since we showed that a decrease in DAS from a lower DAS 
level has more impact on HAQ than a similar decrease from a higher DAS level (given a 
similar HAQ three months earlier), we propose that these results underline the impor-
tance of aiming at lower disease activity, including in patients with milder disease. 
Although various studies illustrate that DAS-steered treatment results in better out-
comes than non-DAS-steered treatment, it appears that in daily practice old routines 
are difficult to change. Van Hulst, et al. found that rheumatologists adjusted medication 
only in one of three visits where disease activity was above target (67% of visits).19 Our 
results argue against reluctance in treatment adjustments and clearly emphasise the 
importance to actively aiming to decreasing DAS. 
In conclusion, our results may encourage physicians to adjust treatment to aim at a 
lower DAS in order to achieve better functional ability for their patients.
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i nt rO d uC t i O n
Measuring disease outcome in rheumatoid arthritis (RA) is important to evaluate 
response to treatment. Recent recommendations for the management of RA propose 
measurement by validated composite scores including joint counts.1,2 
The disease activity score (DAS) was the first composite measure developed to assess 
and compare disease activity in patients and patient groups. The DAS includes a swollen 
joint count in 44 joints, the Ritchie articular index (RAI)3 for evaluation of joint tenderness 
in 53 joints, erythrocyte sedimentation rate (ESR) and a visual analogue scale (VAS) for 
patients' global assessment of disease activity (PGA) or of general health (GH).4 However, 
the DAS with VAS–PGA is not yet validated. The DAS28 was introduced as a simplifica-
tion with a no–yes swollen and tender joint count (TJC) in 28 individual joints.5 
Although in general the usefulness and importance of the DAS and DAS28 are well 
accepted,6 implementation in daily practice remains challenging. Some find that the 
DAS28 unjustly neglects the feet, but other scores might be too time consuming.7,8 The 
RAI may be subjective and complicated, as it is a 0–3 graded evaluation of the severity 
of tenderness and uses joint groups of which only the highest score per group counts. 
Alternatives to the DAS, including more than 28 joints without the RAI, might be more 
attractive to use in daily routine or clinical trials. This study aims to evaluate three varia-
tions of the DAS compared with the original DAS. In addition, we compared DAS, DAS 
variations and DAS28 using VAS–GH or VAS–PGA.
PAt i ents An d me t h O d s
Data from the BeSt trial were used, a randomised clinical trial with 3-monthly assess-
ments aiming at a DAS of 2.4 or less by subsequent treatment adjustments.9 All fol-
low-up visits included a full 68/66 graded joint count for tenderness and swelling, as 
well as measurements of VAS–GH, VAS–PGA and ESR. The current analysis was per-
formed based on 467 patients with complete data at 1 year follow-up. 
The DAS and DAS28 were calculated using the following formulae: DAS = 0.5398√(RAI) 
+ 0.06465(SJC44) + 0.330ln(ESR) + 0.00722(VAS) and DAS28 = 0.56√(TJC28) + 
0.28√(SJC28) + 0.70ln(ESR) + 0.014(VAS).
DAS alternatives were derived as follows: the DAS 0–1 was calculated by the substitu-
tion of a RAI greater than 0 with ‘1’, while the RAI ‘0’ score remained ‘0’, resulting in a 
maximum TJC of 26. The DASTJC53 was calculated with a '0'=no/'1'=yes TJC in the 53 
joints originally assessed within the RAI, but without grouping, resulting in a maximum 
TJC of 53. The DAS TJC44 was calculated with a TJC of '0'=no/'1'=yes in the same 44 
joints that are assessed for swelling in the DAS. All DAS variations, as well as the original 
DAS and DAS28, were calculated with VAS–PGA and VAS–GH. 
Pearson’s correlation coefficients were calculated between the original DAS and DAS 
alternatives. The mean of these two measurements and the mean difference was calcu-
lated at year 1 and displayed in Bland–Altman plots with limits of agreement of 1.96*SD 
ABs t r AC t
Objective: To evaluate three disease activity score (DAS) alternatives without the 
Ritchie articular index (RAI). To compare the use of patient's global assessment 
of disease activity (PGA) versus global assessment of health (GH) in DAS, DAS 
alternatives and DAS28.
Methods: Data from the BeSt study were used, a treatment strategy trial in early 
rheumatoid arthritis patients aiming at a DAS ≤2.4. DAS alternatives were DAS 0–1, 
with the RAI (0–3) reduced to a no–yes (0–1) score, DAS tender joint count 53 (DAS 
TJC53), with a 0–1 TJC in 53 separate joints and DAS TJC44 in 44 joints. Correlation 
patterns, mean difference from original DAS, classification differences in disease 
activity level and patient percentages with radiological damage progression per level 
were determined for all scores.
Results: In the majority of patients the scores were equal and correlation was high. 
Mean differences with the DAS at year 1 were −0.03 for DAS 0–1, 0.18 for DAS TJC53 
and 0.11 for DAS TJC44. Classification agreement between scores was high (k year 1 
0.76–0.98). Patient percentages with joint damage progression were similar for all 
scores. DAS, DAS alternative and DAS28 perform similarly using either PGA or GH.
Conclusion: DAS variants without the RAI perform comparably to the original DAS 
and may be chosen as alternatives. PGA can replace GH in the DAS, the alternatives 
and DAS28.
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patients with RRP within categories of disease activity level using either VAS. Overall, 
there are few patients with RRP in patients categorised as in remission or LDA by all 
composite scores. Differences in disease activity between treatment arms (eg, treatment 
groups 1 and 2 vs 3 and 4) could be confirmed with all indices. 
d i s Cus si O n
The original DAS is sometimes criticised for being complicated because it includes the 
RAI. We compared three alternatives with the original DAS, with various tender joint 
Table 1 Classification of patients per disease activity category at year 1 according to the different indices, as compared 
with the original DAS ( n=467)
DAS
Remission LDA MDA HDA
DAS PGA Remission 143 7 0 0
LDA 5 152 3 0
MDA 0 2 123 0
HDA 0 0 3 29
DAS 0-1 GH Remission 148 2 0 0
LDA 0 159 3 0
MDA 0 0 126 2
HDA 0 0 0 27
DAS 0-1 PGA Remission 143 8 0 0
LDA 5 151 6 0
MDA 0 2 122 2
HDA 0 0 1 27
DAS TJC53 GH Remission 142 0 0 0
LDA 6 126 1 0
MDA 0 35 105 0
HDA 0 0 23 29
DAS TJC53 PGA Remission 138 6 0 0
LDA 10 118 0 0
MDA 0 37 102 0
HDA 0 0 27 29
DAS TJC44 GH Remission 142 5 0 0
LDA 6 125 3 0
MDA 0 31 105 0
HDA 0 0 21 29
DAS TJC44 PGA Remission 139 11 0 0
LDA 9 118 4 0
MDA 0 32 101 0
HDA 0 0 24 29
DAS28
Remission LDA MDA HDA
DAS28 PGA Remission 172 12 1 0
LDA 6 76 11 0
MDA 1 5 137 3
HDA 0 0 9 36
DAS, disease activity score; GH, patient's assessment of general health on a visual analogue scale; HDA, high disease activity; LDA, low 
disease activity; MDA, moderate disease activity; PGA, patient's global assessment of disease activity on a visual analogue scale; TJC, 
tender joint count.
mean difference. Patients were categorised according to previously published cut-offs 
into remission, low disease activity (LDA), moderate disease activity (MDA) or high dis-
ease activity (HDA).10–14 Percentage agreement and κ statistics were calculated to assess 
agreement between categorisation. 
An area under the curve (AUC) DAS was calculated between 3 and 12 months for all scores 
separately using the formula: (0.5*DAS3months + DAS6 months + DAS9 months + 0.5*DAS12 months)/3. 
Baseline scores were excluded from the analysis to avoid skewness due to required HDA 
at inclusion. 
The AUC DAS results, indicating disease activity over time, were categorised into remis-
sion, LDA, MDA and HDA. Next, the percentages of patients with a greater than 5 point 
Sharp van der Heijde score (SHS) progression between baseline and year 1 (consistent 
with the smallest detectable change and indicating rapid radiological progression) were 
compared in all categories for all disease activity scores. Finally, the ability of DAS alter-
natives to detect treatment differences at 3 months follow-up was assessed using the 
difference in scores between baseline and 3 months.
r e sults
All patients had early (<2 years) RA and active disease at baseline with a mean (SD) DAS 
of 4.4 (0.9). At year 1 (n=467) median (range) RAI was 3.0 (0–52), RAI 0–1 3.0 (0–23), 
TJC53 4.0 (0–50), TJC44 3.0 (0–44) and TJC28 2.0 (0–28). 
Correlation was high for all DAS alternatives compared with the original DAS, and 
ranged between 0.96 and 0.99 (p≤0.01) at baseline and between 0.97 and 1.00 (p≤0.01) 
at year 1. Correlation between VAS–PGA and VAS–GH at five time points was limited 
(P=0.5–0.8, p≤0.01). Nevertheless, for the original DAS, DAS alternatives and DAS28, 
all versions with VAS–GH correlated excellently to corresponding versions with VAS–
PGA(range r=0.99–1.00, p≤0.01), both at baseline and year 1. 
Figure 1 illustrates high agreement between DAS alternatives and the original DAS. DAS 
0–1 shows a high accordance with the original DAS, whereas DAS TJC53 and DAS TJC44 
are occasionally higher, as demonstrated by the higher mean difference and broader 
agreement limits. However, most scores remain unchanged compared with the orig-
inal DAS. DAS, DAS alternatives and DAS28 perform similarly using either VAS–PGA 
or VAS–GH. Categorisation of all patients by different DAS is presented in table 1. The 
percentage of overall agreement for all separate DAS at year 1 was high (range 82.9–
98.5%), chance corrected agreement as calculated by Cohen’s k ranged from 0.76 to 
0.98. Significant disagreement between categorisation, for example LDA versus HDA or 
remission versus HDA was very rare (table 1). Chance corrected agreement for all scores 
with VAS–GH versus VAS–PGA ranged from 0.85 to 0.94. Both correlation and (chance 
corrected) agreement between the original DAS and alternatives using either VAS score 
did not change over time (data not shown). 
The percentages of patients with rapid radiological progression (RRP; >5 points SHS in 
year 1) are represented in table 2. All DAS alternatives show comparable percentages of 
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FiGure 1 Bland-Altman plots illustrating the agreement between the DAS variants and the original DAS (A-G) 
and between DAS28 and DAS28 PGA (H). Mean of the two measurements (x-axis) versus the mean difference 
between the two values (y-axis) at year 1 (n=467). (A) Disease activity score (DAS) 0–1 global health (GH). (B) 
DAS 0–1 patient's global assessment of disease activity (PGA). (C) DAS tender joint count in 53 joints (TJC53). 
(D) DAS TJC53 PGA. (E) DAS tender joint count in 44 joints (TJC44). (F) DAS TJC44 PGA. (G) DAS PGA. (H) 
Disease activity score in 28 joints (DAS28) PGA versus DAS28 GH. 
this early severe RA population, leading to an infrequency of graded joint scores above 
one, which explains the overlap between DAS 0–1 and DAS. If in daily practice RAI 
scores of 3 are more prevalent, we expect a greater difference between the original DAS 
and alternative versions in higher activity levels. In modern practice, in which treatment 
is aimed at achieving remission (or at least LDA), high grading may become rare. All our 
results regarding the DAS28 and DAS variants are valid at the group level and for the 
vast majority of patients; however, for some individual patients differences between 
scores may be larger. 
In conclusion, we have shown that scoring the presence or absence of tenderness in 
individual joints to calculate a disease activity score performs as well as scoring a graded 
tenderness score in joint groups. In daily practice or clinical studies, using a DAS alterna-
tive may be much easier than the original DAS with RAI. The score based on the assess-
ment of tenderness in the same 44 joints assessed for swelling may be most practical. 
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scores and patient’s assessment (by VAS) of either disease activity or GH. We found very 
small differences in performance of all scores. Correlation between all alternatives and 
the original DAS is high. All scores classify patients similarly in remission, LDA, MDA and 
HDA. Differences in disease activity between treatment arms could be confirmed with 
all indices. The percentage of patients with RRP is comparable for original and alterna-
tive scores in different disease activity levels. 
Our results on the use of VAS–PGA and VAS–GH demonstrate that either can be used 
and affirm the single study on this subject by Khan, et al.15 Although individual VAS 
scores itself correlate only moderately, which indicates that they cover a different con-
cept, when used as part of the DAS, DAS alternatives or DAS28 the total effect is neg-
ligible, mostly because of the limited weight that is given to this component. When 
categorising patients in disease activity levels we see that DAS TJC53 and DAS TJC44 are 
classifying more MDA and HDA, less LDA and similar remission percentages. This can 
be explained because both DAS TJC53 and DAS TJC44 assess more joints separately, 
causing a small shift to a higher disease activity category. However, the vast majority of 
remission patients have none to one painful joint in which disease activity by any score, 
and thus remission percentages, remain the same. DAS28 shows a different pattern with 
more patients assessed as being in remission and consequently a smaller LDA group, 
in line with discussions about the remission definition of DAS28.16 The percentage of 
patients with RRP in DAS28 remission was higher compared with the (alternative) DAS. 
The slightly higher disease activity measured with both DAS TJC44 and DAS TJC53 with 
corresponding higher classification leads to less radiological damage in the HDA group 
of these scores. Differences are nonetheless very small. The percentages of patients with 
RRP were not influenced by the use of VAS–PGA or VAS–GH, neither in the alternative 
DAS nor in the original DAS28. 
A limitation of the current study is caused by the rapid reduction in disease activity in 
tABle 2 Percentage (numbers) of patients with rapid radiological damage progression (SHS >5 points) in the 
first year of the study categorised according to the ‘mean’ disease activity level between 3 months and 1 year 
for all indices (n=386)
Remission LDA MDA HDA
DAS 9.9 (8/81) 11 (13/118) 19 (28/146) 39 (16/41)
DAS PGA 10 (8/78) 12 (14/118) 18 (27/147) 37 (16/43)
DAS 0-1 GH 9.9 (8/81) 11 (13/119) 21 (31/151) 37 (13/35)
DAS 0-1 PGA 10 (8/78) 12 (14/121) 20 (30/150) 35 (13/37)
DAS TJC53 GH 9.1 (6/66) 12 (13/106) 17 (25/151) 33 (21/63)
DAS TJC53 PGA 10 (7/68) 11 (12/105) 17 (26/150) 32 (20/63)
DAS TJC44 GH 11 (8/73) 11 (12/108) 19 (28/147) 29 (17/58)
DAS TJC44 PGA 10 (8/75) 12 (12/104) 18 (26/147) 32 (19/60)
DAS28 12 (13/102) 8.3 (5/60) 17 (29/169) 36 (18/50)
DAS28 PGA 11 (12/107) 8.2 (5/61) 18 (30/167) 35 (18/51)
DAS, disease activity score; GH, patient's assessment of general health on a visual analogue scale; HDA, high disease 
activity; LDA, low disease activity; MDA, moderate disease activity; PGA, patient's global assessment of disease activity on 
a visual analogue scale; TJC, tender joint count.
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i nt rO d uC t i O n 
Assessing disease activity and the response to treatment is of vital importance in rheuma-
toid arthritis (RA), both in clinical trials and in daily practice. By early and effective suppres-
sion of inflammation, severe joint destruction and functional disability can be prevented.1,2 
The use of a tightly controlled treatment approach, including frequent disease activity mea-
surements and treatment towards a preset goal, have further improved outcomes.3-6 
In order to measure disease activity, several composite scores have been developed 
such as the Disease Activity Score (DAS),7 Disease Activity Score in 28 joints (DAS28),8 
the Clinical Disease Activity index (CDAI)9 and the Simplified Disease Activity Index 
(SDAI)10 as a combination of variables might represent actual disease activity better 
than single measures.11 We recently validated three new variants of the original DAS with 
adjusted tender joint counts (TJCs).12 
All composite scores on continuous scales can be subdivided into categories (remission, low 
disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA)), 
which nowadays are also being used as tools to guide treatment decisions for individual 
patients. Beside these index-based criteria, an international taskforce from the American 
College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) 
recently developed new remission criteria for clinical practice and clinical trials.13  
In previous studies the number of indices compared, patient numbers or duration of 
follow-up duration were limited and few studies related disease activity levels to func-
tional ability or radiological damage progression in time. Little is known about the per-
formance of the new ACR/EULAR remission criteria in comparison with existing index-
based remission definitions.14 To be able to compare the results of registries or clinical 
trials reliably using different composite scores, a more extended comparison is needed. 
The aims of this study were: (1) to compare the classification of disease activity accord-
ing to nine composite scores into remission, LDA, MDA and HDA; (2) to compare 
remission percentages of composite scores and the new ACR/EULAR remission criteria; 
and (3) to relate these levels of disease activity to physical functioning and progression 
of joint damage.  
me t h O d s
Patients
Five-year follow-up data of the BeSt study were used in which 508 patients with 
recent-onset rheumatoid arthritis with a disease duration  ≤2 years  were randomised 
into four dynamic treatment strategies: 1) sequential monotherapy; 2) step-up combi-
nation therapy; 3) initial combination therapy with prednisone and 4) initial combina-
tion therapy with infliximab.  Details have been described elsewhere.15 Treatment was 
adjusted based on 3-monthly measurements of disease activity.  If DAS was >2.4, the 
next step of the protocol was taken. If DAS was ≤2.4 for ≥6 months, the medication 
was tapered to monotherapy in a maintenance dose. From the third year the last dis-
ABs t r AC t
Objective: To compare nine disease activity indices and the new American College 
of Rheumatology (ACR)/European League against Rheumatism (EULAR) remission 
criteria in rheumatoid arthritis (RA) and to relate these to physical function and joint 
damage progression. 
Methods: Five-year data from the BeSt study were used, a randomised clinical trial 
comparing four treatment strategies in 508 patients with recent-onset RA. Every 
three months disease activity was assessed with nine indices (Disease Activity Score 
(DAS), DAS-C reactive protein (DAS-CRP), Disease Activity Score in 28 joints (DAS28), 
DAS28-CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index 
(CDAI) and three DAS versions with adjusted tender scores) and categorised into 
remission, low, moderate and high disease activity (LDA, MDA, HDA). In addition, 
ACR/EULAR clinical trial and practice remission was assessed 3-monthly with 28 and 
68/66 joint counts. For each index, Generalized Estimating Equations analyses were 
performed to relate disease activity levels and the absence/presence of remission to 
3-monthly assessments of physical functioning and annual radiological progression.
Results: From the composite indices, CDAI and SDAI were the most stringent 
definitions of remission and classified more patients as LDA. DAS28 and DAS28-
CRP had the highest proportions of remission and MDA and a smaller proportion 
of LDA. ACR/EULAR remission percentages were comparable to CDAI/SDAI 
remission percentages. The variant including CRP and 68/66 joint counts was the 
most stringent.  For all indices, higher levels of disease activity were associated with 
decreased functioning and more radiological damage progression. Despite differences 
in classification between the indices, no major differences in relation to the two 
outcomes were observed. 
Conclusion: The associations of nine composite indices and ACR/EULAR remission 
criteria with functional status and joint damage progression showed high accordance, 
whereas the proportions of patients classified in the disease activity levels differed. 
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tABle 1 Overview of composite indices
Formula Remission LDA MDA HDA
DAS 0.5398√(RAI) + 0.06465(SJC44) 
+ 0.330ln(ESR) + 0.00722(VASpatient [mm])
<1.6 ≥1.6 and ≤2.4 >2.4 and ≤3.7 >3.7
DAS CRP 0.54√(RAI) + 0.065(SJC44) + 0.17ln(CRP[mg/l]+1) 
+ 0.0072(VASpatient [mm]) + 0.45
<1.6 ≥1.6 and ≤2.4 >2.4 and ≤3.7 >3.7
DAS28 0.56√(TJC28) + 0.28√(SJC28) + 0.70ln(ESR) 
+ 0.014(VASpatient [mm])
<2.6 ≥2.6 and ≤3.2 >3.2 and ≤5.1 >5.1
DAS28 CRP 0.56√(TJC28) + 0.28√(SJC28) + 0.36ln(CRP[mg/l]+1) 
+ 0.014(VASpatient [mm])  + 0.96
<2.6 ≥2.6 and ≤3.2 >3.2 and ≤5.1 >5.1
SDAI TJC28 + SJC28 + VASphysician (cm) 
+ VASpatient (cm) + CRP (mg/dl)
≤3.3 >3.3 and ≤11 >11 and ≤26 >26
CDAI TJC28 + SJC28 + VASphysician (cm) 
+ VASpatient (cm)
≤2.8 >2.8 and ≤10 >10 and ≤22 >22
DAS 0-1 0.5398√(RAI_wg) + 0.06465(SJC44) + 0.330ln(ESR) 
+ 0.00722(VASpatient [mm])
<1.6 ≥1.6 and ≤2.4 >2.4 and ≤3.7 >3.7
DAS TJC53 0.5398√(TJC53) + 0.06465(SJC44) + 0.330ln(ESR) 
+ 0.00722(VASpatient [mm])
<1.6 ≥1.6 and ≤2.4 >2.4 and ≤3.7 >3.7
DAS TJC44 0.5398√(TJC44) + 0.06465(SJC44) + 0.330ln(ESR) 
+ 0.00722(VASpatient [mm])
<1.6 ≥1.6 and ≤2.4 >2.4 and ≤3.7 >3.7
LDA, low disease activity; MDA, moderate disease activity; HDA, high disease activity; DAS, disease activity score; ESR, 
erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28, disease activity score in 28 joints, SDAI, simplified disease 
activity index; CDAI, clinical disease activity index; DAS 0-1, disease activity score with ‘Ritchie articular index’ without 
grading; TJC53, tender joint count in 53 joints; TJC44, tender joint count in 44 joints RAI, ritchie articular index; SJC44, 
swollen joint count in 44 joints; VASpatient, patient’s assessment of global health on a visual analogue scale;  TJC28, tender 
joint count in 28 joints; SJC28, swollen joint count 28 joints; VASphysician, physician’s assessment of disease activity on a 
visual analogue scale.
      
LDA, MDA and HDA, or as remission yes/no. All analyses were corrected for baseline 
HAQ, time, age, gender and treatment group with additional correction for time*time in 
the continuous HAQ analysis to approach linearity. For each disease activity level (remis-
sion, LDA, MDA, HDA or remission yes/no) and per composite score the mean HAQ 
scores (continuous outcome) and probabilities of an HAQ score above the cut-off point 
(dichotomous outcome) were estimated within the GEE model. For this purpose the Esti-
mated Marginal Means subcommand was used which fills in the regression equation by 
fixing continuous values of covariates at their means and estimates HAQ values for each 
level of a categorical variable. This option was used to avoid differences in distribution of 
confounders between different disease activity levels and composite scores. 
To assess the relationship between the level of disease activity according to the different 
composite indices, ACR/EULAR remission and the progression of joint damage, four 
GEE analyses were performed for each composite index: first with the absolute annual 
Sharp-van der Heijde progression score (SHS) progression per year as a continuous out-
come and then with the annual SHS progression as a dichotomous outcome (cut-off 
points  ≥1, ≥3 and ≥5 SHS units progression per year). Since x-rays were taken annually 
and disease activity was measured every three months, for the analysis including com-
posite scores only the mean disease activity per year was calculated by the following 
formula: (0.5*DAS1 + DAS2 + DAS3 + DAS4 + 0.5*DAS5)/4 and categorised into remis-
sion, LDA, MDA and HDA. For single missing values we used a last observation carried 
forward method before calculating mean disease activity per year. This categorical mean 
ease-modifying antirheumatic drug (DMARD) could be tapered and discontinued if 
DAS was <1.6 for ≥6 months in patients on monotherapy at the maintenance dose. The 
last DMARD was restarted if DAS was ≥1.6.
Clinical assessments
Every three months the following variables were collected: 66 swollen joint count (SJC), 
68 TJC, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), patient’s assess-
ment of global health (VAS-GH) on a visual analogue scale (0-100 mm) and physician’s 
global assessment of disease activity (VAS-PGA)
At each timepoint disease activity was calculated according to the following composite 
indices (table 1): the original DAS with ESR or CRP (DAS; DAS-CRP), DAS28 with ESR 
or CRP (DAS28; DAS28-CRP), SDAI, CDAI, and three variants of the original DAS with 
adjustments in the TJC of the score.12 In the first adjustment (DAS 0-1) the same joints 
and joint groups were used as in the Ritchie Articular Index (RAI) but scoring only 
absence (0) or presence (1) of tenderness instead of grading tenderness from 0 to 3. In 
the second adjusted version (DAS-TJC53), grading and assessment of joint groups were 
omitted: all 53 joints of the RAI counted separately for the absence or presence of ten-
derness. In the last version only the 44 joints (equal to the joints assessed for swelling) 
were assessed for the absence or presence of tenderness (DAS-TJC44). Furthermore, the 
presence or absence of ACR/EULAR remission was assessed using the following compo-
nents: SJC ≤1, TJC ≤1, VAS global health ≤1 cm and CRP ≤1 g/dl. Four variants were used: 
a clinical trial definition including CRP and a clinical practice definition excluding CRP, 
each with a 28/28 SJC/TJC and with a 68/66 SJC/TJC.     
At each time point patients were classified as being in remission (yes/no) according to 
nine composite indices and ACR/EULAR remission criteria, or in LDA, MDA or HDA 
according to nine composite indices based on previously published cut-off points (table 
1).16–20 For the three simplifications of the original DAS, the cut-off points of the original 
DAS were used.
Outcome assessments
Every 3 months functional capacity was assessed using the health assessment question-
naire (HAQ).21 Joint damage was assessed on annual x-rays from baseline until year 5 per 
patient in random order using the Sharp-van der Heijde method22 by two independent 
readers blinded to patient identity. The mean scores of the two readers were used.
statistical analysis
SPSS Version 17.0 was used for all analyses. To assess the relationship between the level of 
disease activity according to the nine disease activity indices, ACR/EULAR remission cri-
teria and HAQ, four Generalised Estimating Equations (GEE) analyses were performed per 
index, first with HAQ per patient as a continuous outcome and with HAQ per patient as 
a dichotomous outcome for three cut-off points (HAQ >1.0, HAQ >0.5, HAQ >0).
The disease activity level was added as an explanatory variable categorised as remission, 
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spider diagrams
Spider diagrams (figure 1 A,B) illustrate the classification in disease activity categories 
according to the different composite indices. Irrespective of the composite score used, 
more patients were classified in HDA categories in year 1 than in year 5, reflecting treat-
ment efficacy. From the composite indices, CDAI and SDAI had the most stringent 
definitions of remission and thus classified a relatively high proportion of patients in 
the LDA category. The proportions of patients in MDA and HDA were comparable 
between CDAI, SDAI, DAS and DAS-CRP. DAS28 and DAS28-CRP had the highest pro-
portions remission and MDA and a relatively small proportion of patients in LDA. Of 
the adjusted DAS versions, DAS 0-1 was very comparable with the original DAS. The 
absolute DAS-TJC53 and, to a lesser extent, the DAS-TJC44 were slightly higher than the 
original DAS, resulting in higher percentages of patients in the HDA. Figure 1 C,D show 
the remission percentages of the composite indices and ACR/EULAR remission criteria. 
The most stringent definition is the clinical trial definition with 66/68 joints. Clinical trial 
remission criteria showed lower remission percentages than clinical practice remission 
criteria, as did the criteria including a full 68/66 joint count compared with the criteria 
based on 28-joint counts. 
relation with functional ability
In general, predicted HAQ values among the disease activity levels based on the com-
posite indices showed high agreement (table 2). As expected, HAQ values are lower 
when the level of disease activity was lower. Although CDAI and SDAI classified fewer 
patients as being in remission, CDAI and SDAI remission was not associated with lower 
HAQ scores than other indices (table 2). Compared with other indices, DAS28 variants 
classified the highest proportion of patients in the remission and MDA categories, and 
fewer patients in LDA category, but HAQ levels in remission, LDA and MDA were com-
tABle 2 Mean predicted HAQ for patients in remission, LDA, MDA and HDA. Covariates and factors appearing 
in the model are fixed at the following values: baseline HAQ 1.4; visit 10.6; age 53.9; treatment group 1; female 
gender.
Remission LDA MDA HDA
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
DAS  0.48 (0.40 – 0.55) 0.61 (0.53 – 0.69)  0.83 (0.75 – 0.91) 1.24 (1.14 – 1.33)
DAS CRP 0.49 (0.41 – 0.57)  0.63 (0.55 – 0.71)   0.87 (0.79 – 0.95) 1.27 (1.17 – 1.38)
DAS28 0.49 (0.41 – 0.57)  0.60 (0.52 – 0.68)   0.76 (0.67 – 0.84)  1.20 (1.10 – 1.29)
DAS28 CRP  0.52 (0.44 – 0.60)  0.62 (0.54 – 0.70)   0.80(0.72 – 0.89) 1.28 (1.18 – 1.38)
SDAI 0.47 (0.39 – 0.55)  0.60 (0.52 – 0.68)  0.83 (0.75 – 0.92) 1.24 (1.14 – 1.33)
CDAI  0.46 (0.38 – 0.54)  0.60 (0.52 – 0.68)  0.83 (0.74 – 0.91)  1.18 (1.09 – 1.28)
DAS 0-1   0.48 (0.40 – 0.56) 0.61 (0.53 – 0.70)   0.84 (0.76 – 0.92) 1.26 (1.16 – 1.36)
DAS TJC53 0.47 (0.39 – 0.55)  0.60 (0.52 – 0.68)   0.77 (0.69 – 0.85) 1.13 (1.03 – 1.22)
DAS TJC44   0.48 (0.40 – 0.56)  0.60 (0.52 – 0.68)   0.78 (0.70 – 0.86)  1.14 (1.05 – 1.24)
CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS, Disease Activity Score; DAS 0-1, Disease Activity Score 
with RAI 0-1; DAS28, Disease Activity Score in 28 joints, HAQ, Health Assessment Questionnaire; HDA, high disease 
activity; LDA, low disease activity; MDA, moderate disease activity; SDAI, Simplified Disease Activity Index; TJC44, tender 
joint count 44 joints; TJC53, tender joint count 53 joints. 
disease activity level per year or remission yes/no was added as an explanatory variable. 
Remission per year was defined as ≥3/4 visits remission. 
The SHS analyses were corrected for total SHS at the beginning of each year, time, pres-
ence of cyclic citrullinated peptides (CCP) antibodies, treatment group, age and gender. 
Mean progression scores and probabilities for progression were estimated for index and 
each disease activity level using estimated marginal means. 
The GEE method with M-dependence covariance structure was used to correct for 
within-patient correlation since HAQ and joint damage progression was repeated mea-
sured over time.
results
At baseline, patients (n=508) had active disease with a mean (SD) DAS of 4.4 (0.9) and 
a mean (SD) HAQ of 1.4 (0.9). Mean (SD) / median (IQR) SHS at baseline was 7.1 (10.2) 
/ 3.0 (0.5 – 9.5).
FiGure 1 Spider diagrams showing the cumulative percentage of patients in remission, low, moderate and high 
disease activity according to the different composite indices at (A) 1 year ( n=415) and (B) 5 year (n=317). Bar 
charts show the percentage of patients in remission (≥3 visits) during (C) year 1 (n=424) and (D) year 5 (n=267) 
per remission definition. ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; CRP, 
C-reactive protein; DAS, Disease Activity Score; DAS 0-1, Disease Activity Score with RAI 0-1; DAS28, Disease 
Activity Score in 28 joints; HDA, high disease activity; LDA, low disease activity; MDA, moderate disease 
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varies between 9% and 12% for progression of ≥3 (table 5). The chance of progression ≥3 
units in CCP-negative patients in remission was lower (3-4% SHS progression ≥3 units, 
data not shown). Patients in SDAI and CDAI remission had comparable chances of pro-
gression of ≥3 units as other indices (9% vs 9-12%). The probability for progression of 
≥3 units in the LDA category was slightly lower with SDAI, CDAI and DAS28 than with 
other indices. The four versions of the ACR/EULAR remission criteria were comparably 
related to joint damage progression (table 6). The probability of annual SHS progression 
of ≥3 units for patients in remission was 9-12% compared with 24-28% for patients not 
  
tABle 4 Mean predicted Δ SHS for patients in remission, LDA, MDA and HDA. Covariates and factors 
appearing in the model are fixed at the following values: previous SHS 10.3; year 2.8; age 53.8; treatment group 
1; anti-CCP positive patients; female gender. 
Remission LDA MDA HDA
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
DAS    3.5 (-0.1 – 7.0)  5.5 (2.4 – 8.7)  7.3 (4.1 – 10.6)  11.7 (7.4 – 16.0)
DAS CRP 4.1 (1.0 – 7.2)  5.4 (2.3 – 8.6) 6.7 (3.6 – 9.8)  11.7 (7.1 – 16.4)
DAS28   3.6 (0.1 – 7.0) 4.6 (1.4 – 7.8)   6.9 (3.8 – 10.0) 10.8 (6.8 – 14.8)
DAS28 CRP   3.5 (0.0 – 7.1) 5.5 (2.3 – 8.7) 8.1 (4.8 – 11.3) 13.2 (8.5 – 17.8)
SDAI   4.0 (0.8 – 7.3) 4.7 (1.4 – 8.0)   7.4 (4.2 – 10.6) 11.5 (7.3 – 15.7)
CDAI   3.9 (0.6 – 7.1) 4.7 (1.4 – 7.9)   7.4 (4.2 – 10.6)   11.0 (6.9 – 15.0)
DAS 0-1    3.4 (-0.1 – 6.9)  5.5 (2.3 – 8.6)   7.2 (4.0 – 10.4)  12.7 (8.2 – 17.1)
DAS TJC53   3.5 (0.2 – 6.9)  4.8 (1.5 – 8.1)  6.9 (3.7 – 10.1)   9.9 (6.0 – 13.8)
DAS TJC44   3.6 (0.3 – 7.0)  4.9 (1.6 – 8.2)   7.2 (4.0 – 10.4)  10.2 (6.3 – 14.2)
CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS, Disease Activity Score; DAS 0-1, Disease Activity Score 
with RAI 0-1; DAS28, Disease Activity Score in 28 joints; HDA, high disease activity; LDA, low disease activity; MDA, 
moderate disease activity; SDAI, Simplified Disease Activity Index; SHS, Sharp-van der Heijde score; TJC44, tender joint 
count 44 joints; TJC53, tender joint count 53 joints
tABle 5 Estimated probability (95% CI) for SHS progression ≥3 units in patients in remission, LDA, MDA and 
HDA. Covariates and factors appearing in the model are fixed at the following values: previous SHS 10.3; year 
2.8; age 53.8; treatment group 1; anti-CCP positive patients; female gender. 
Remission LDA MDA HDA
Probability (95% CI) Probability (95% CI) Probability (95% CI) Probability (95% CI)
DAS  0.10 (0.06 – 0.15) 0.18 (0.12 – 0.25)  0.31 (0.21 – 0.40) 0.59 (0.44 – 0.74)
DAS CRP  0.12 (0.07 – 0.18)  0.19 (0.13 – 0.26)  0.33 (0.23 – 0.43) 0.61 (0.46 – 0.76)
DAS28  0.09 (0.05 – 0.14)   0.14 (0.08 – 0.20) 0.27 (0.19 – 0.35)  0.55 (0.40 – 0.69)
DAS28 CRP 0.10 (0.06 – 0.15)  0.18 (0.12 – 0.24)   0.34 (0.24 – 0.43)  0.66 (0.49 – 0.82)
SDAI  0.09 (0.03 – 0.14)  0.15 (0.10 – 0.20) 0.32 (0.23 – 0.41)  0.54 (0.40 – 0.68)
CDAI  0.09 (0.04 – 0.15)  0.15 (0.10 – 0.21)  0.34 (0.25 – 0.44) 0.50 (0.37 – 0.63)
DAS 0-1  0.10 (0.05 – 0.15) 0.19 (0.12 – 0.25)  0.31 (0.22 – 0.40)  0.66 (0.51 – 0.81)
DAS TJC53 0.10 (0.05 – 0.14) 0.17 (0.11 – 0.23)  0.29 (0.20 – 0.38) 0.46 (0.34 – 0.58)
DAS TJC44  0.09 (0.05 – 0.14)  0.18 (0.12 – 0.24)  0.31 (0.22 – 0.40) 0.47 (0.35 – 0.60)
CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS, Disease Activity Score; DAS 0-1, Disease Activity Score 
with RAI 0-1; DAS28, Disease Activity Score in 28 joints; HDA, high disease activity; LDA, low disease activity; MDA, 
moderate disease activity; SDAI, Simplified Disease Activity Index; SHS, Sharp-van der Heijde score; TJC44, tender joint 
count 44 joints; TJC53, tender joint count 53 joints.
parable to other indices. Patients in HDA according to the DAS-TJC53 and DAS-TJC44 
have lower HAQ scores than patients in HDA according to other indices.
Similar results were seen with regard to the probability of a HAQ score >0.5 as outcome 
(table 3). Overall, 34-91% of patients were limited in functioning depending on their dis-
ease activity level. HDA corresponds with a higher chance of functional limitations. In 
general there was little difference between the percentages of HAQ scores >0.5 for all 
composite scores, but the same subtle differences were found as were seen previously. 
In the analysis including ACR/EULAR remission definitions, the same pattern was found 
(table 6). Predicted HAQ scores and probabilities for a HAQ score >0.5 were comparable 
for all definitions, with SDAI, CDAI and ACR/EULAR remission at the lower end of range. 
Very little difference was found within the group of ACR/EULAR remission definitions. 
relation to the progression of joint damage
Table 4 shows predicted values of SHS progression for patients in different disease activ-
ity levels according to the nine indices. All indices showed similar joint damage pro-
gression in different disease activity levels, and all composite indices showed a dose 
response with a higher level of disease activity levels yielding more joint damage pro-
gression. Although CDAI and SDAI classified fewer patients as being in remission, CDAI 
and SDAI remission were not associated with less damage progression. In the HDA cat-
egory, patients with DAS-TJC53 an DAS-TJC44 had somewhat less SHS progression than 
patients in HDA according to other indices (table 4). 
Predicted probabilities for SHS progression ≥3 units for patients in remission, LDA, MDA 
and HDA categories according to the nine indices are shown in table 5. The proportions 
of SHS progression between different composite indices were very comparable. The per-
centage of CCP-positive female patients in remission showing joint damage progression 
tABle 3 Estimated probability for HAQ scores >0.5  in patients in remission, LDA, MDA and HDA Covariates 
and factors appearing in the model are fixed at the following values: baseline HAQ 1.4; visit 10.6; age 53.9; 
treatment group 1; female gender. 
Remission LDA MDA HDA
Probability (95% CI) Probability (95% CI) Probability (95% CI) Probability (95% CI)
DAS   0.34 (0.27 – 0.40)  0.49 (0.42 – 0.57) 0.69 (0.63 – 0.75)   0.90 (0.86 – 0.93)
DAS CRP  0.34 (0.27 – 0.41)  0.52 (0.44 – 0.59) 0.73 (0.67 – 0.79)  0.90 (0.85 – 0.94)
DAS28   0.36 (0.29 – 0.43)  0.48 (0.40 – 0.55) 0.63 (0.56 – 0.70)  0.87 (0.83 – 0.92)
DAS28 CRP   0.39 (0.32 – 0.46) 0.51 (0.44 – 0.58) 0.68 (0.62 – 0.75)   0.90 (0.86 – 0.94)
SDAI 0.31 (0.25 – 0.38)  0.47 (0.40 – 0.55)  0.70 (0.63 – 0.76) 0.86 (0.81 – 0.91)
CDAI 0.31 (0.25 – 0.38)  0.47 (0.39 – 0.54)  0.70 (0.64 – 0.76)  0.85 (0.80 – 0.89)
DAS 0-1  0.34 (0.27 – 0.41)  0.50 (0.43 – 0.58)  0.70 (0.64 – 0.76)  0.91 (0.88 – 0.95)
DAS TJC53  0.34 (0.28 – 0.41)  0.49 (0.42 – 0.56) 0.65 (0.59 – 0.72)  0.85 (0.80 – 0.89)
DAS TJC44  0.35 (0.28 – 0.41)  0.49 (0.41 – 0.56) 0.66 (0.59 – 0.72)  0.85 (0.81 – 0.90)
CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS, Disease Activity Score; DAS 0-1, Disease Activity Score 
with RAI 0-1; DAS28, Disease Activity Score in 28 joints, HAQ, Health Assessment Questionnaire; HDA, high disease 
activity; LDA, low disease activity; MDA, moderate disease activity; SDAI, Simplified Disease Activity Index; TJC44, tender 
joint count 44 joints; TJC53, tender joint count 53 joints. 
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tABle 6 Estimated mean predicted HAQ scores and mean SHS progression scores and estimated probability 
for HAQ scores >0.5 and  SHS progression ≥3 units in patients in remission versus no remission. Covariates 
and factors appearing in the HAQ model are fixed at the following values: baseline HAQ 1.4; visit 10.6; age 53.9; 
treatment group 1; female gender. Covariates and factors appearing in the SHS model are fixed at the following 
values: previous SHS 10.3; year 2.8; age 53.8; treatment group 1; anti-CCP positive patients; female gender
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ACR, American College of Rheumatology; CCP, cyclic citrullinated peptide; CDAI, Clinical Disease Activity Index; CRP, 
C-reactive protein; DAS, Disease Activity Score; DAS 0-1, Disease Activity Score with RAI 0-1; DAS28, Disease Activity Score 
in 28 joints; SDAI, Simplified Disease Activity Index; SHS, Sharp-van der Heijde score; TJC44, tender joint count 44 joints; 
TJC53, tender joint count 53 joints. 
ACR 68/66 trial: ACR/EULAR remission definition for clinical trials including a 68/66 joint count; ACR 28 trial: ACR/EULAR 
remission definition for clinical trials including a 28 joint count; ACR 68/66 practice: ACR/EULAR remission definition 
for clinical practice including a 68/66 joint count; ACR 28 practice: ACR/EULAR remission definition for clinical practice 
including a 28 joint count
                             
sion (≥3 units) was 9-12% in anti-CCP-positive patients. This suggests that there is (sub)
clinical inflammation in patients in clinical remission, even with stricter definitions. An 
additional explanation might be that there is a delay between inflammation measured 
with clinical parameters and progression of joint damage visible on conventional x-rays. 
Part of the joint damage progression seen in patients in clinical remission might reflect 
disease activity that was present before the onset of clinical remission.33 Our results 
emphasise that a comprehensive definition of disease remission needs to include radio-
logical outcome. 
in remission. Probabilities for progression as well as absolute SHS progression values 
were comparable for all definitions. Comparable patterns were seen for annual SHS pro-
gression of ≥1 and ≥5 units (data not shown).
d i s Cus si O n
We compared classification into remission, LDA, MDA and HDA or remission yes/no 
with nine composite disease activity scores and ACR/EULAR remission criteria and 
assessed the relationship with functional ability and radiological damage progression. 
Although the proportions of patients classified varied between some of disease activity 
levels and definitions, the associations of all composite scores and remission definitions 
with HAQ and SHS showed overall high agreement. All showed a good dose-response 
relationship of disease activity with HAQ and SHS progression. 
This analysis expands on earlier studies comparing composite indices. We compared 
composite scores including 28-joint counts and also the original DAS and several adjust-
ments. Previous studies showed that DAS28 classifies more patients in remission,23-26 
while SDAI and CDAI are more strict in classifying remission23,27 as reflected by lower 
remission percentages, which is in line with our results. In general, the studies that link 
composite scores to functional ability and radiological progression show that DAS28, 
SDAI and CDAI correlate comparable with HAQ and Larsen scores. They demonstrate 
that levels of disease activity of these indices discriminate between levels of functional 
state and radiological damage.9,17,28,29 We showed that all nine composite indices had a 
comparable relationship with radiological joint damage or physical functioning. Omit-
ting grading in TJCs and/or omitting scoring tender joints in joint groups did not change 
this relationship. The same is true if acute phase reactants are left out (CDAI and clinical 
trial ACR/EULAR remission criteria).  
Which index should be preferred will depend on the reason for using the index and on 
personal preferences. In clinical practice, composite scores without an acute phase reac-
tant or a limited joint count can be used whereas, in a clinical trial setting, a more elaborate 
composite score can be valuable. If treatment is aimed at remission, strict remission criteria 
carry a higher risk of overtreatment. However, a less strict definition may lead to residual 
disease activity and thereby undertreatment. SDAI, CDAI and ACR/EULAR remission crite-
ria classified the lowest proportion of patients in remission than the other indices but were 
not associated with lower HAQ scores and did not lead to clinically significant less joint 
damage progression. DAS28 and DAS28-CRP classified the highest proportion of patients 
in clinical remission without compromising on HAQ and joint damage progression. How-
ever, within these indices patients’ feet are not examined, which may not be appreciated. If 
LDA should be the target, DAS28 variants may be less useful because DAS28 and DAS28-
CRP classified fewer patients in LDA and remission together than other indices without 
leading to better HAQ and less joint damage progression.  
Our results emphasise earlier reports that clinical remission does not necessarily coin-
cide with radiological remission.30-32 The predicted probability for joint damage progres-
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Previous studies have shown that, early in the disease course active inflammation 
(reflected in composite indices) is the main determinant of functional limitations while, 
in more established disease, joint damage becomes more important.1,34,35 We analysed 
the association between disease activity levels and HAQ in patients with limited joint 
damage during a 5-year follow-up period. In more advanced disease the dose response 
between disease activity levels and HAQ is probably less pronounced and/or HAQ val-
ues among remission patients may be higher.    
There is a large body of evidence supporting the benefit of targeted treatment. Less is 
known on what the target should be.5,36 RCTs directly comparing LDA and remission 
as targets are lacking. In the BeSt study treatment was aimed at LDA. There is little 
difference between the mean HAQ in LDA (~0.60) and in remission (~0.50). How-
ever, progression rates in patients in LDA are considerably higher than those patients 
in remission, suggesting that treatment should aim at remission. It is not known what 
the gain would be on clinical and radiological outcomes while risking higher turnover 
in treatment options.
When outcomes are dichotomised, only part of the data is being used, in contrast to 
using data on a continuous scale. Joint damage progression, (and, to a lesser extent 
HAQ) does not follow a Gaussian distribution. Although the GEE method is relatively 
robust against violations of the normal distribution, it is impossible to disentangle the 
complete effect of the distribution on continuous outcomes and predicted means. 
This may explain part of the high predicted annual progression rate, which can also be 
explained by unfavourable characteristics like anti-CCP positivity and treatment group. 
With dichotomous outcomes, the distribution is not a problem. Therefore we decided 
to show both.   
The strengths of our study are that we compared the most widely used composite 
indices for RA and recently published ACR/EULAR remission criteria with different joint 
counts and related the classification of these indices to HAQ and joint damage progres-
sion (SHS) in a large group of patients. Also, all indices/criteria were repeatedly measured 
over time, increasing the number of observations, and were incorporated in the GEE 
analyses. One limitation might be that ‘old’ ACR remission criteria were not included in 
the analyses as not all components of these criteria were gathered 3-monthly. 
In conclusion, although there are differences in classification between 9 different disease 
activity composite indices and ACR/EULAR remission definitions for RA, the associa-
tions with functional status and joint damage progression are highly comparable. The 
choice of composite index is dependent on its intended use. 
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i nt rO d uC t i O n
Current rheumatoid arthritis (RA) treatment strategies are aimed at achieving low 
disease activity as soon as possible, to improve structural and functional outcome, 
using frequent treatment adjustments when necessary. Adding a tumour necrosis fac-
tor (TNF) blocker to methotrexate has proved to be an effective way to achieve low 
disease activity in a short period of time, with less joint damage progression than mono-
therapy.1,2 
Treatment with TNF blockers is expensive and has a possible risk of adverse events. 
Therefore, discontinuation of TNF blockers once the treatment goal has been achieved 
could be beneficial for both society and individual patients. In 25–70% of patients 
who achieved low disease activity, TNF blockers could be stopped without losing low 
disease activity.3-7 Predicting which patients have a high chance of sustained low disease 
activity after the cessation of TNF blockers is necessary to avoid disease flares and a 
potentially increased risk of infusion reactions after the re-introduction of intravenous 
TNF blockers.8 
In the BeSt study, a study comparing four different treatment strategies, infliximab was 
the TNF blocker used in combination with methotrexate, either after failure on at least 
three non-biological disease-modifying antirheumatic drugs (DMARD), or as initial 
treatment. In this post-hoc analysis with a median follow-up duration of 7.2 years, we 
investigated whether and how often low disease activity was sustained after the cessa-
tion of infliximab and if predictors for successful cessation exist. Second, we looked at 
joint damage progression after infliximab cessation and we assessed the success and 
safety of re-introduction.
 
me t h O d s
Patients
Between 2000 and 2002, 508 patients were included in the BeSt study, a multicentre 
randomised single blind clinical trial designed to compare four different treatment 
strategies in DMARD-naive patients with recent-onset, active RA. All patients fulfilled 
the 1987 American College of Rheumatology classification criteria for RA.The ethics 
committees of all participating centres approved the study protocol and patients gave 
their written informed consent. 
Treatment strategies were sequential monotherapy, step-up combination therapy 
(groups 1 and 2, both starting with methotrexate), initial combination therapy with 
methotrexate, sulfasalazine and prednisone (group 3) and initial combination therapy 
with methotrexate and infliximab (group 4). Treatment was adjusted to the next step in 
the protocol in the case of a disease activity score (DAS) greater than 2.4 or side effects. 
In groups 1–3, methotrexate plus infliximab were started after patients had failed on 
three treatment steps with non-biological DMARD including prednisolone (groups 2 
and 3) or without (group 1). If the DAS remained at 2.4 or less for at least 6 months, 
ABs t r AC t
Objective: To describe the disease course after the cessation of infliximab in early 
rheumatoid arthritis patients with disease activity score (DAS)-steered treatment and 
to identify predictors of persistent low disease activity.
Methods: In a post-hoc analysis of the BeSt study, disease activity and joint damage 
progression were observed in patients treated with methotrexate plus infliximab, who 
discontinued infliximab after achieving low disease activity (DAS ≤2.4) for 6 months. 
Predictors were identified using Cox regression analysis.
Results: 104 patients discontinued infliximab, of whom 77 had received infliximab 
plus methotrexate as initial treatment. Mean DAS at the time of infliximab cessation 
was 1.3, median symptom duration was 23 months and median Sharp-van der Heijde 
score was 5.5. The median follow-up was 7.2 years. Infliximab was re-introduced after 
loss of low disease activity in 48%, after a median of 17 months. The joint damage 
progression rate did not increase in the year after cessation, regardless of flare. After 
re-introduction of infliximab, 84% of these patients again achieved a DAS ≤2.4. In the 
multivariable model, smoking, infliximab treatment duration ≥18 months and shared 
epitope (SE) were independently associated with the re-introduction of infliximab: 
6% of the non-smoking, SE-negative patients treated <18 months needed infliximab 
re-introduction.
Conclusion: Cessation of infliximab was successful in 52%, with numerically higher 
success rates in patients initially treated with infliximab. Of the 48% who flared, 84% 
regained low disease activity. The joint damage progression rate did not increase in 
the year after cessation. Smoking, long infliximab treatment duration and SE were 
independently associated with re-introduction of infliximab.
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hypothesised to have additional predictive value were added one by one. Model fit was 
tested using Martingale residuals. Overall goodness of fit was examined by adding to 
the model risk groups, constructed by categorising the ranked prognostic indices, to 
test whether this would significantly improve the model likelihood.11
r e sults
low disease activity
Infliximab was discontinued after achieving a DAS of 2.4 or less for 6 months or longer 
in 104 patients (figure 1): 77/120 from the initial infliximab treatment group and 27/109 
from the delayed treatment group (p<0.001). The mean DAS at the time of cessation 
was 1.3 ± 0.6 (SD). The median infliximab treatment duration was 11 months (IQR 9–17). 
The median symptom duration at the time of cessation was 23 months (IQR 15–35). In 
20 patients the infliximab dose had been increased from 3 to 6 mg/kg, to 7.5 mg/kg in 
13 patients and to 10 mg/kg in five patients before a DAS of 2.4 or less was achieved. 
After the cessation of infliximab, the DAS remained 2.4 or less in 43/77 patients (56%) 
from the initial treatment group and 11/27 (41%) from the delayed treatment group. 
Methotrexate was then successfully tapered (with 2.5 mg every 4 weeks) to a mainte-
nance dose (≤10 mg/week) in 34 patients (62%), without differences between the initial 
and delayed treatment groups (p=0.58). Subsequently, 15 patients (27%) from the initial 
treatment group achieved drug-free remission. None in the delayed treatment group 
achieved drug-free remission yet.
treatment group
In the delayed treatment group, the median (IQR) time from baseline to starting 
infliximab was 14 months. Patients in the delayed treatment group had a higher baseline 
DAS and needed longer infliximab treatment before infliximab could be discontinued 




54 patients (43/77, 11/27) 
persistent DAS ≤ 2.4




2 patients not yet 
DAS ≤ 2.4
4 patients stop: 
infusion reaction





DAS ≤ 2.4: stop IFX
infliximab was stopped, after stepwise (10–7.5–6–3) tapering to 3 mg/kg per 8 weeks 
in those patients who had previously had a dose increase. Infliximab was immediately 
restarted if the DAS increased to over 2.4. In patients who had also tapered or stopped 
methotrexate, first methotrexate was increased to 25 mg/week. Next, infliximab was 
re-introduced if the DAS remained greater than 2.4. The complete study design has 
been published previously.9,10 
We analysed all 104 patients in groups 1–4 who discontinued infliximab after the DAS 
was 2.4 or less for 6 months, who had at least one year of follow-up after reaching this 
point. The median follow-up duration from the time of infliximab discontinuation was 
7.2 years (range 14–103 months).
study endpoints
After cessation of infliximab, whether patients had to restart infliximab due to a DAS 
greater than 2.4 was monitored. Radiographs of the hands and feet were taken at yearly 
intervals. For the x-ray ‘at cessation’, the x-ray taken closest to the visit at cessation was 
used. For stop visits in between 2 yearly visits, the yearly visit before cessation was cho-
sen. All available x-rays of the hands and feet, from baseline and 1, 2, 3, 4 and 5 year fol-
low-up were scored blind for patient identity and random in time using the Sharp-van 
der Heijde score (SHS). Joint damage progression in the year before and after cessation 
was defined as an increase in the average score for those years of two independent rea-
ders. Smokers were defined as patients smoking cigarettes, cigars or a pipe at baseline. 
statistical analysis
Baseline and disease characteristics were compared between patients from the initial 
and the delayed infliximab treatment group, using the X2, Student’s t or Mann–Whitney 
U test. Joint damage progression and health assessment questionnaire (HAQ) scores 
were compared for patients with sustained DAS of 2.4 or less and patients who had to 
restart infliximab using the X2 and Mann–Whitney U test. To compare damage progres-
sion in the years before and after cessation and HAQ scores at and after cessation, the 
Wilcoxon signed-rank test was used. To take into account the difference in follow-up 
after cessation between patients, we used Cox regression analyses to identify predictors 
of successful cessation, after verifying that the proportional hazards assumption was 
not violated.11 The dependent variable was time to the re-introduction for patients who 
restarted infliximab, 1 August 2010 for patients with sustained DAS of 2.4 or less who 
were still under follow-up, and time to last follow-up visit for patients lost to follow-up. 
We examined the association between baseline characteristics and clinical parameters 
at the time infliximab was stopped, with successful cessation of infliximab. Because of 
the number of variables tested, we considered p<0.01 to be significant. 
To identify independent predictors, variables that showed an association (p<0.10) with 
sustained DAS of 2.4 or less in the univariable analyses were entered in a multivariable 
Cox regression analysis using a stepwise forward selection procedure with a Wald signif-
icance less than 0.05 as the inclusion criterion. Subsequently, other variables that were 
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Joint damage
Radiographs 1 year before, in the year of, and 1 year after infliximab cessation were avail-
able in 90/104 patients. Median damage progression was 0 both for patients who had 
an increase of the DAS to over 2.4 in the first year after cessation and patients whose 
DAS remained at 2.4 or less (p=0.56). The average damage progression did not increase 
in the year after cessation compared with the year before cessation: 0.0 (IQR 0.0–0.8) 
versus 0.0 (IQR 0.0–1.5), p=0.06. Four patients showed radiographic progression greater 
than 5 (figure 2). One of these patients had restarted infliximab in that year, the other 
three continued to have a DAS of 2.4 or less (mean area-under-the-curve DAS 2.0 in 
that year).
Functional ability after cessation
HAQ scores at 1 and 3 years after cessation were similar to HAQ scores at cessation in 
both restarters and patients with sustained DAS of 2.4 or less. Five years after cessation, 
restarters had a median HAQ of 0.7, versus 0.3 at cessation, p=0.02. For patients with 
sustained DAS of 2.4 or less, the median HAQ remained 0.1. Patients who flared in that 
year or the year before had higher median HAQ scores than patients who did not flare 
in those years: 0.4 versus 0.1 in year 1, 0.5 versus 0.1 in year 3 and 0.8 versus 0.4 in year 5, 
but these differences were not significant.
Predictors
Univariable Cox analyses showed that smoking, longer symptom duration at cessation, 
longer infliximab treatment duration, physician’s assessment of disease activity, total 
erosion score at the time of infliximab cessation and previous yearly change in SHS were 
associated with the re-introduction of infliximab (table 2). Treatment timing (delayed 
vs initial infliximab) and positivity for shared epitope (SE) showed a trend. Univariable 
FiGure 2 Probability plot of joint damage progression 1 year after cessation (90 patients with radiographic 
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than patients in the initial treatment group. At the time of infliximab discontinuation, 
patients in the delayed treatment group had longer symptom duration and a higher 
SHS, HAQ and patient’s assessment of disease activity. There were almost twice as many 
smokers in the delayed treatment group (table 1).
re-introduction of infliximab
In 50/104 patients (48%), infliximab was restarted after the DAS had increased to over 
2.4 in a median of 17 months (IQR 3–47). Infliximab was discontinued for 1 year or 
more in 29 patients (58%). In 84%, 27/34 from the initial and 15/16 from the delayed 
infliximab treatment groups, a DAS of 2.4 or less was regained after the re-introduc-
tion of infliximab within a median 3 months (IQR 2–5). In five patients (10%), who had 
initially had a good response to re-introduction, infliximab was later abandoned for 
another DMARD. Five patients had an infusion reaction after the re-introduction of 
infliximab. These infusion reactions were reported as non-serious, but the reason for 
four patients to discontinue infliximab. In comparison, eight of 120 patients from the 
initial treatment group (group 4) of the BeSt study had an infusion reaction during their 
first treatment with infliximab (p=0.46). Serious infections (requiring hospital admis-
sion) occurred in 40/1000 patient-years after the re-introduction of infliximab, com-
pared with 16/1000 patient-years during the first treatment with infliximab and 10/1000 
patient-years during the cessation of infliximab.
tABle 1 Patient demographic and disease characteristics at inclusion and at cessation of infliximab in the 
initial versus delayed infliximab treatment group.
All (n=104) initial (n=77) delayed (n=27) p-value
Female gender (n (%)) 68 (65) 47 (61) 21 (78) 0.12
Age (years) 56 (46 – 61) 56 (45 – 61) 55 (50 – 62) 0.83
RF positive (n (%)) 68 (65) 45 (58) 23 (85) 0.012
ACPA positive (n (%)) 76 (73) 56 (73) 20 (74) 0.89
SE positive (n (%))* 66 (75) 48 (74) 18 (78) 0.67
Smoking positive (n (%)) 36 (35) 22 (29) 14 (52) 0.029
BMI (kg/m2) 26 (23 – 28) 26 (23 – 27) 26 (23 – 28) 0.59
Symptom duration at cessation (months) 23 (15 – 35) 19 (13 – 27) 44 (33 – 64) <0.001
IFX treatment duration at cessation (months) 11 (9 – 17) 9 (8 – 14) 16 (11 – 23) <0.001
DAS at inclusion (mean (SD)) 4.2 (0.8) 4.1 (0.7) 4.7 (0.9) <0.001
DAS at cessation (mean (SD)) 1.3 (0.6) 1.3 (0.6) 1.4 (0.6) 0.50
Remisssion at cessation (n (%)) 69 (66) 51 (66) 18 (69) 0.78
HAQ at inclusion 1.3 (0.9 – 1.7) 1.3 (0.8 – 1.8) 1.1 (1.0 – 1.5) 0.72
HAQ at cessation 0.1 (0.0 – 0.6) 0.2 (0.0 – 0.5) 0.4 (0.1 – 0.9) 0.012
SHS at inclusion 3.5 (0.5 – 10.5) 4.8 (0.5 – 10.9) 1.5 (0.5 – 9.0) 0.40
SHS at cessation 5.5 (1.0 – 16.0) 4.8 (0.5 – 13.9) 13.0 (3.0 – 30.6) 0.029
Data are presented as median (IQR) unless stated otherwise. 
*SE had missing data for 16 patients.
ACPA, anti-citrullinated protein antibodies; BMI, body mass index; DAS, disease activity score; HAQ, health assessment 
questionnaire; RF, rheumatoid factor; SE, shared epitope; SHS, Sharp-van der Heijde score.
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present, 94% did not need infliximab re-introduction. Of the 40% who had one predic-
tor present, 42% needed infliximab re-introduction, compared with 67% of the patients 
with two or more risk factors. Because SE is rarely known in clinical practice and SE 
and anti-citrullinated protein antibody (ACPA) status are highly correlated, we repeated 
the analyses using ACPA instead of SE. ACPA was not. an independent predictor in 
the original model, nor after omitting smoking. However, of the 18 patients who were 
non-smokers, had short treatment duration and were ACPA negative, only two (11%) 
needed infliximab re-introduction (figure 3D).
tABle 3 Independent predictors of increase in DAS to greater than 2.4 with restart of infliximab (multivariable 
model) 
HR (95% CI) HR (95% CI) after adjustment*
SE positive 3.5 (1.2 – 10.2) 3.7 (1.3 – 10.6)
Smoking positive 2.4 (1.3 – 4.6) 2.1 (1.1 – 4.2)
Treatment duration ≥18 months 2.8 (1.3 – 6.1) 2.4 (1.1 – 5.4)
Delayed treatment infliximab NA 1.8 (0.9 – 3.7)
*model including treatment timing.
DAS, disease activity score; SE, shared epitope.
FiGure 3 Kaplan–Meier plots showing the percentage of patients with persistent disease activity score (DAS) of 2.4 or less 
after the cessation of infliximab (IFX) over time for all patients (A), per treatment group (B) and per number of risk factors 
with shared epitope (SE) (C) and with anti-citrullinated antibodies instead of SE (D).
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tABle 2 HR for clinical and demographic parameters and increase of DAS to greater than 2.4 with restart of 
infliximab (univariable analysis)
HR (95% CI) Initial infliximab Delayed infliximab
Female gender 1.1 (0.6 – 2.0)
Age 1.00 (0.98 – 1.02)
RF positive 1.2 (0.6 – 2.1)
ACPA positive 1.5 (0.8 – 3.1) 1.9 (0.8 – 4.5) 1.1 (0.3 – 3.4)
SE positive 3.9 (1.4 – 11.0) 3.2 (1.0 – 10.9) 7.0 (0.9 – 54.2)
Smoking 2.4 (1.4 – 4.3) 2.9 (1.5 – 5.8) 1.2 (0.4 – 3.2)
BMI 1.04 (0.96 – 1.12)
Infliximab delayed 2.0 (1.1 – 3.7)
Symptom duration (months) 1.02 (1.01 – 1.03) 1.01 (0.99 – 1.03) 1.02 (0.995 – 1.05)
Treatment duration (months) 1.05 (1.02 – 1.07) 1.07 (1.01 – 1.13) 1.03 (0.999 – 1.07)
Infliximab dose increase 1.2 (0.7 – 2.2)
DAS 1.1 (0.7 – 1.9)
DAS <1.6 vs DAS ≤2.4 0.98 (0.5 – 1.8)
HAQ 1.5 (0.8 – 3.0)
ESR 1.00 (0.98 – 1.02)
CRP 0.98 (0.93 – 1.02)
Tender joint count 1.08 (0.93 – 1.27)
Swollen joint count 0.97 (0.77 – 1.22)
Radiographic damage 1.02 (1.00 – 1.03)
Erosion score 1.03 (1.01 – 1.06) 1.03 (0.99 – 1.07) 1.03 (0.99 – 1.07)
Joint space narrowing 1.03 (1.00 – 1.06) 1.03 (0.99 – 1.07) 1.02 (0.98 – 1.07)
Yearly change in SHS 1.07 (1.02 – 1.13) 1.08 (1.01 – 1.15) 1.06 (0.98 – 1.15)
Disease activity (VAS) 1.01 (0.99 – 1.02)
General health (VAS) 1.00 (0.99 – 1.02)
Morning stiffness (VAS) 1.01 (1.00 – 1.03)
Pain (VAS) 1.01 (1.00 – 1.03)
Disease activity (doctor VAS) 1.03 (1.01 – 1.06) 1.03 (1.00 – 1.06) 1.09 (1.01 – 1.18)
*adjusted for age, gender and, with the exception of ‘infliximab delayed’, treatment timing.
ACPA, anti-citrullinated protein antibodies; BMI, body mass index; CRP, C-reactive protein; DAS, disease activity score; 
ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; RF, rheumatoid factor; SE, shared epitope; 
SHS, Sharp-van der Heijde score; VAS, visual analogue scale (measured in mm).
analyses for the delayed and initial treatment groups separately showed similar effect 
sizes, with the exception of smoking (lower HR) and SE (higher HR) in the delayed 
treatment group (table 2). The multivariable analyses yielded a model with smoking, SE 
and treatment duration, adjusted for treatment timing. Treatment duration was dichot-
omised with 18 months (fourth quartile) as the cut-off value. The possible interaction 
between smoking and SE could not be assessed due to small numbers. Smoking (HR 
2.1, 95% CI 1.1 to 4.2), treatment duration of 18 months or longer (HR 2.4, 1.1 to 5.4) and 
the presence of SE (HR 3.7, 1.3 to 10.6) were independently associated with the re-in-
troduction of infliximab (table 3). Infliximab-free survival was investigated based on the 
number of predictors present (figure 3). Of the 18% of patients who had no predictors 
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patient selection, because restarters had longer symptom duration and possibly more 
severe RA, which is associated with a higher infection risk.12,13  
To our knowledge, the inverse association between smoking and SE and successful 
infliximab cessation has not previously been reported. Both characteristics are associ-
ated with more severe disease.14,15 Smoking, but not SE, might be associated with poor 
response to TNF blockers.15-18 Smoking and SE are associated with increased ACPA lev-
els,19 but neither our analysis nor the analysis by Saleem, et al.6 showed a strong associ-
ation between ACPA and successful cessation, although this may be due to relatively 
small numbers. For daily practice this is disappointing, because it is not current routine 
to test for SE. Our analyses did show that of the non-smoking, ACPA-negative patients 
with short infliximab treatment duration, only 11% needed to restart infliximab.
In the BeSt study, the tapering and cessation of infliximab was DAS steered. Therefore, 
the association between shorter infliximab treatment duration and continued DAS of 
2.4 or less after cessation correlated with the time to achieve a DAS of 2.4 or less for 6 
months consecutively while on infliximab. 
Previously, we reported that patients from the BeSt study who received infliximab as ini-
tial treatment were more likely to achieve a DAS of 2.4 or less and discontinue infliximab 
than patients from the delayed treatment group.20 In the current analysis, an association 
was found between successful cessation and initial treatment. As patients in groups 1–3 
only started methotrexate plus infliximab after failing on three treatment steps, they had 
longer symptom durations at the time of infliximab cessation, and probably more diffi-
cult-to-treat RA than the unselected patients who started with initial methotrexate plus 
infliximab. The differences in disease characteristics at baseline between the initial and 
delayed treatment groups corroborate this (table 1). Despite these differences, we com-
bined patients from both groups for the analysis, because we set out to find predictors 
of successful cessation irrespective of treatment timing, and to gain power. In separate 
analyses for the two groups, we found similar effect sizes, with the exception of smoking 
in the delayed treatment group, possibly due to small numbers and a higher proportion 
of smokers in this group. Previously, we compared the response to infliximab in both 
treatment groups using propensity scores to adjust for the differences at baseline. As 
the current subanalysis compares selected patients from the two treatment groups who 
discontinued infliximab because of a sustained DAS of 2.4 or less, this method cannot 
be applied. The association between treatment timing and successful cessation was also 
described by Saleem, et al.,6 but that study had comparable limitations. The observed 
association is thus affected by patient selection based on earlier failure on at least three 
non-biological DMARD treatment steps and the initiation of infliximab after a ‘delay’ of 
on average 14 months. Of course in daily practice, in which TNF blockers are currently 
reserved for patients who fail on non-biological DMARD, one must assume that similar 
selection processes are at work. 
A second limitation of this subanalysis is that for 16/104 patients, the SE status was not 
known. We included SE in the multivariable model because of the strong association with 
successful cessation. This resulted in the exclusion of the patients with missing SE data. 
d i s Cus si O n
In the BeSt study, 45% of patients treated with infliximab were able to discontinue inflix-
imab. Eighty per cent of these patients could stop for at least 1 year, and 52% did not restart 
during a median follow-up of 7.2 years. In the year after infliximab cessation, significant 
joint damage progression was rare, regardless of disease flare. Retreatment with infliximab 
was successful in 84%. Smoking, SE and long infliximab treatment duration (≥18 months) 
were independent predictors of the re-introduction of infliximab.
Our results are in line with previous reports, although there are differences in patient char-
acteristics, requirements to discontinue or restart TNF blockers and the duration of fol-
low-up. Quinn, et al.7 were the first to report on the successful cessation of a TNF blocker 
(infliximab), in seven of 10 patients with early RA, regardless of disease activity (which in 
general was low). Brocq, et al.3 reported on 21 patients with advanced RA who were in 
remission after delayed treatment with a TNF blocker (six as monotherapy). Five patients 
successfully stopped the TNF blocker for 12 months. The 16 who flared regained remission 
after retreatment. Saleem, et al6 reported a 40% overall success rate in 2 years in 47 patients 
who had achieved remission and discontinued TNF blockers. Remission was maintained 
in 60% of patients who had the TNF blocker as initial treatment, compared with three of 
20 patients who had had delayed treatment (10 had failed on a previous TNF blocker). 
The Remission Induction by Remicade in RA (RRR) study by Tanaka, et al.4 has a com-
parable sample size to ours, and infliximab was also discontinued if a DAS of 2.4 or less 
was repeatedly achieved. The rate of successful discontinuation of infliximab in 1 year 
was 55%, compared with 80% in 1 year in the BeSt study. This may be due to a high per-
centage of BeSt patients who had received infliximab as initial treatment, whereas in 
the RRR study, all patients received infliximab after failure on various systemic DMARD. 
The differences in patient characteristics and follow-up duration may also explain why 
Tanaka, et al.4 found remission at cessation to be predictive of maintaining a DAS of 2.4 
or less, whereas we did not. 
The percentage of infusion reactions after retreatment was not increased when com-
pared with infusion reactions during initial treatment in group 4 of the BeSt study, so 
the hypothesis of Takeuchi, et al.8 of an increased risk of infusion reactions after the 
re-introduction of infliximab was not confirmed. This might be explained by the design 
of the BeSt protocol: methotrexate is continued after the cessation of infliximab until 
sustained remission is achieved on the maintenance dose, and in patients in drug-free 
remission who flare, first methotrexate is re- introduced and increased before inflix-
imab can be restarted. The presence of antibodies to infliximab was not tested. The rate 
of serious infections was higher after the re-introduction of infliximab compared with 
during the initial treatment period or the period of infliximab cessation. The difference 
between infection rates during cessation and after retreatment may be the result of 
physicians choosing intravenous over oral antibiotics in patients using a TNF blocker, 
longer exposure to infliximab or of longer and more active disease duration. The differ-
ence in serious infections between first time infliximab users and restarters could reflect 
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In conclusion, infliximab can be successfully stopped for at least 1 year in 80% of 
patients. Joint damage does not increase in this year, regardless of flare. After a median 
period of 7.2 years, 52% had not restarted infliximab. Even temporary cessation can ben-
efit both the individual patient and, given the high costs of TNF blockers, society as a 
whole. Non-smoking, SE-negative or ACPA-negative patients who needed less than 18 
months of infliximab treatment very rarely have to restart infliximab due to an increase 
of the DAS to over 2.4. However, not all of those who have to restart infliximab regain a 
DAS of 2.4 or less, and restarting infliximab carries a (small) risk of (mild) infusion reac-
tions. We therefore recommend that in particular for patients with one or more of the 
above-mentioned risk factors, infliximab discontinuation has to be carefully considered 
on an individual basis.
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i nt rO d uC t i O n
As a result of the increasing percentage of patients achieving remission with the intro-
duction of early, intensive goal-steered therapy,1 more often the dilemma is whether a 
patient with rheumatoid arthritis (RA) in prolonged remission could discontinue dis-
ease-modifying antirheumatic drugs (DMARDs) or whether treatment should be con-
tinued. Stopping DMARDs while keeping remission would be beneficial with respect 
to adverse events and costs. On the other hand, discontinuation of DMARDs could 
contribute to a relapse of disease with potential harmful consequences. 
Historically, the question whether DMARD therapy can be discontinued has often 
been asked. Several small studies from the 1970s/1980s assessed the need for long-term 
DMARD maintenance therapy in patients treated according to the pyramid ‘go low 
go slow’ approach.2-8 These studies reported high relapse rates after discontinuation of 
DMARDs (range 58%-100%). Later, ten Wolde, et al. performed a randomised clinical 
trial in 285 patients with long-standing inactive RA 9,10 and reported flare rates of 38% 
in the placebo (discontinuation) group versus 22% in the group continuing DMARD 
therapy. Data on withdrawal of DMARDs in patients with established disease have 
recently been summarised in a meta-analysis.11
Since the approach of RA treatment has shifted towards early intensive goal-steered 
treatment, the discontinuation of DMARDs has rarely been studied.12,13 There are few 
data on the safety of withdrawing DMARDs, the chance of flares and the response 
to reintroduction of DMARDs.10 In addition, it is unclear whether a flare after a drug-
free remission episode can be predicted. With prediction subgroups of patients might 
be identified in which medication can be safely withdrawn versus other subgroups in 
whom treatment should be continued.
The protocol of the BeSt study, a randomised clinical trial in recent-onset RA, allowed 
discontinuation of DMARDs in patients in prolonged remission under strict control 
of disease activity.14 The objectives of this analysis were: (1) to assess the flare rate in 
patients in drug-free remission; (2) to describe the severity of relapse; (3) to identify pre-
dictors for relapse; and (4) to assess the response to reintroduction of DMARDs. 
me t h O d s
 
study design and patients
Five-year data of the BeSt study were used. Details of the design have been described 
elsewhere.15 In summary, 508 patients with recent-onset active RA according to the 1987 
RA classification criteria (disease duration <2 years)16 were randomised into four treat-
ment strategies: sequential monotherapy (n=126), step-up combination therapy (n=121), 
initial combination therapy with prednisone (n=133), and initial combination therapy with 
methotrexate and the tumour necrosis factor α inhibitor infliximab (MTX+IFX, n=128). 
Treatment was adjusted based on 3-monthly disease activity score (DAS) measurements 
(Disease Activity Score 44 joints, DAS44), aiming at DAS ≤2.4.17,18 If DAS was >2.4 the next 
abSTRaCT
Objectives: To determine the relapse rate after discontinuing treatment in patients 
with rheumatoid arthritis (RA) in sustained clinical remission, to identify predictors 
of a relapse and to evaluate treatment response after restarting treatment.  
Methods: Five-year data from the BeSt study were used, in which 508 patients with 
recent-onset RA were randomised into four dynamic treatment strategies, aiming 
at a disease activity score (DAS) ≤2.4. When DAS was <1.6 for ≥6 months the last 
disease-modifying antirheumatic drug (DMARD) was tapered and discontinued. If 
DAS increased to ≥1.6, the last DMARD was immediately reintroduced. 
Results: During a 5-year period, 115/508 patients (23%) achieved drug-free remission. 
Of these, 53 patients (46%) restarted treatment because DAS was ≥1.6 after a median 
of 5 months, 59 patients (51%) remained in drug-free remission for a median duration 
of 23 months, and 3 (3%) were lost to follow-up. In those who restarted treatment, 
mean (SD) DAS increased from 1.13 (0.73) at remission before tapering to 2.18 (0.65) 
at restart, reflecting an increase in all four components of DAS. Multivariable 
predictors for restarting treatment were anti-cyclic citrullinated peptide (anti-CCP), 
last DMARD sulphasalazine, low baseline health assessment questionnaire score and 
high mean DAS until remission. Of the 53 patients who restarted treatment, 39 (74%) 
again achieved remission 3-6 months after the restart. The median (IQR) damage 
progression in those who restarted treatment during the year of DAS increase was 0 
(0-1) Sharp-van der Heijde units. 
Conclusion: During 5 years DAS-steered treatment, nearly 25% of patients with 
RA achieved drug-free remission; 46% restarted DMARD monotherapy because of 
a relapse, the large majority of whom again achieved clinical remission within 3-6 
months without showing radiological progression during the relapse. 
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MTX mono1 11 9 1
SSA mono2 0 4 1
Leflunomide mono3 3 0 0
MTX + IFX4 0 2 0




MTX mono1 8 4 1
MTX + SSA5 4 3 0
MTX + SSA + HCQ5 2 1 0
MTX + SSA + HCQ + pred5 0 1 0
Next steps 0 0 0
Initial combination 
with prednisone
MTX + SSA + pred6 10 12† 0
MTX + CSA + pred7 0 2 0
Next steps 0 0 0
Initial combination 
with infliximab
MTX + IFX4 19 13 0
SSA mono2 2 2 0
Next steps 0 0 0
For each treatment group, the medication step at which the drug-free remission was reached is shown separately 
for the sustained drug-free remission patients, restarters and patients lost to follow up. Before the protocol allowed 
discontinuation of the last DMARD, patients had to taper their medication to DMARD monotherapy in a maintenance 
dose. If subsequently DAS fell to <1.6 for ≥6 months, the last DMARD could be tapered/discontinued. Details on 
tapering and discontinuation are shown below.  
1   First MTX was tapered to 10 mg/week if DAS ≤2.4 during ≥6 months. Subsequently, MTX was tapered to 0 if DAS 
<1.6 during ≥6 months on MTX 10 mg/week.
2   SSA was tapered to 0 if DAS <1.6 during ≥6 months on SSA 2000 mg/day.
3   First leflunomide was tapered to 10 mg every other day if DAS ≤2.4 during ≥6 months. Subsequently, leflunomide 
was discontinued if DAS <1.6 during ≥6 months on leflunomide 10 mg every other day.
4   First IFX was discontinued and MTX was tapered to 10 mg/week if DAS ≤2.4 during ≥6 months. Subsequently, MTX 
was tapered to 0 if DAS <1.6 during ≥6 months on MTX 10 mg/week.
5   First, the step-up combination was tapered to MTX monotherapy, and then to MTX 10 mg/week if DAS ≤2.4 during 
≥6 months. Subsequently, MTX was tapered to 0 if DAS <1.6 during ≥6 months on MTX 10 mg/week.
6   First prednisolone and MTX were tapered to 0 if DAS ≤2.4 during ≥6 months. Subsequently, SSA was tapered to 0 if 
DAS <1.6 during ≥6 months on SSA 2000 mg/day.
7   First prednisolone and CSA were tapered to 0 if DAS ≤2.4 during ≥6 months. Subsequently, MTX was tapered to 0 if 
DAS <1.6 during ≥6 months on MTX 10 mg/week.
†   One patient tapered to MTX 10 mg/week due to SSA toxicity.
 CSA, ciclosporin A; DMARD, disease-modifying antirheumatic drug; HCQ, hydroxychloroquine; IFX, infliximab; MTX, 
monotherapy; pred, prednisolone; SSA, sulphasalazine.
tABle 1 Overview of the distribution of patients who achieved drug-free remission during 5 years of follow-up 













Drug-free ever 31 24 24 36
       Still drug-free at t=5  year 14 (45) 14 (58) 10 (42) 21 (58)
       Restarted DMARD monotherapy 15 (48) 9 (38) 14 (58) 15 (42)
       Lost to follow-up 2 (6) 1 (4) 0 (0) 0 (0)
Data are presented as n (%). 
DMARD, disease-modifying antirheumatic drug.
   
step of the protocol was taken. If DAS was ≤2.4 for ≥6 months, treatment was tapered 
to the maintenance dose. For details on treatment steps per arm see figure 1 in chapter 4. 
discontinuation of dmArd therapy
Remission was defined as a DAS <1.6.19 Two years after inclusion, the protocol allowed 
tapering and discontinuation of the last DMARD if patients fulfilled the following con-
ditions: (1) DMARDs in maintenance dose according to the protocol (2) clinical remis-
sion (defined as DAS <1.6) for ≥6 months. 
For MTX monotherapy, sulphasalazine (SSA) monotherapy, leflunomide and intramus-
cular gold, the maintenance doses were 10 mg/week, 2000 mg/day, 10 mg every other 
day and 50 mg every other week, respectively. All combinations were first tapered to 
MTX monotherapy which was then tapered to 10 mg/week, with the exception of the 
COBRA combination (MTX, SSA, prednisone)20 which was tapered to SSA 2000 mg/
day as maintenance dose, and the combination azathioprine and prednisolone which 
was tapered to azathioprine 2 mg/kg/day.
Discontinuation of the last DMARD occurred by tapering MTX with 2.5 mg/4 weeks 
and SSA with 500 mg/4 weeks; maintenance doses leflunomide, gold and azathioprine 
were simply discontinued.
restart of dmArd therapy
If the DAS was ≥1.6, the last tapered DMARD was immediately restarted in mainte-
nance dose and could not be discontinued twice. Patients who remained drug-free 
until year 5 will be referred to as ‘sustained drug-free remission patients (SDFR)’ whereas 
patients who restarted before 5 years will be called ‘restarters’.
statistical analysis
The software program SPSS version 17.0 was used for all statistical analyses. Among 
the patients who achieved drug-free remission, variables associated with restarting 
treatment were identified by univariable logistic regression using characteristics from 
baseline and from the last visit before tapering the last DMARD to 0. A multivariable 
logistic regression with univariable logistic determinants (p<0.10) was used to iden-
tify independent predictors for restart using a backward selection procedure (p<0.05). 
Subsequently, the multivariable predictors from the backward procedure were entered 
in a new logistic regression model. Variables that were not associated with restarting 
treatment in the univariable logistic regression were then added one by one to assess 
whether they had additional predictive value.  
r e sults
After 5 years 115/508 (23%) patients achieved drug-free remission with no significant 
differences between the groups (p=0.20, table 1). Of these, 53 (46%) restarted treatment 
after a median (IQR) period of 5 (2–16) months. Fifty-nine (51%) remained in drug-free 
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remission with a median (IQR) duration of 23 (15–25 months) at 5 years, and 3 (3%) 
were lost to follow-up. Details of the treatment steps at which drug-free remission was 
reached are given in table 2. 
In the restarters, mean (SD) DAS increased from 1.13 (0.73) at remission before tapering 
to 2.18 (0.65) at restart, reflecting an increase in all four components of DAS: median 
(IQR) erythrocyte sedimentation rate (ESR) increased from 7 (5–14) to 19 (7–28), swol-
len joint count from 0 (0–0) to 2.5 (0–4), Ritchie Articular Index21 from 0 (0–1) to 3 
(1–6), and visual analogue scale (VAS) global health from 15 (2–22) to 28 (15–55). In 
38/53 of patients (72%) the highest disease activity during the flare was ≤2.4 (low disease 
activity), in 12/53 (23%) between 2.4-3.7 (moderate disease activity) and in 3/53 (6%) it 
was >3.7 (high disease activity). 
The presence of anti-cyclic citrullinated peptide (anti-CCP), rheumatoid factor, lower 
VAS global health and lower health assessment questionnaire (HAQ) at baseline were 
univariably associated with restarting treatment (table 3). Furthermore, baseline Sharp-
van der Heijde (SHS) tended to be higher in those who restarted treatment than in 
SDFR patients (ns). None of the characteristics at the time of remission were associated 
with restarting treatment. In the multivariable analysis, the presence of anti-CCP was 
the strongest independent predictor for restart, followed by a higher mean DAS until 
remission, lower baseline HAQ and SSA as last DMARD (table 4). Both restarters and 
SDFR patients had good functional ability during their remission (table 3), comparable 
to HAQ scores of the general population (age- and sex matched: median [IQR] HAQ 
0.20 [0.15– 0.34] and 0.18 [0.10–0.49] for restarters versus SDFR, respectively).22
Of the 53 restarters, 25 (47%) again achieved clinical remission within 3 months after 
restarting treatment with the last used DMARD in maintenance dose and another 14 
(26%) within 6 months. Eleven patients (21%) achieved a DAS ≤2.4, one patient (2%) did 
not achieve a DAS ≤2.4 and two patients (4%) were lost to follow-up. The large majority 
of patients did not show joint damage progression in the first year after discontinuation 
of DMARDs, with a median (IQR) SHS progression of 0 (0–1) units in the restarters 
during the year of DAS increase compared with 0 (0–0) in the SDFR patients in the first 
year completely drug-free (p=0.44, Mann-Whitney-U test, figure 1).
tABle 4 Multivariable predictors for a flare during a drug-free remission period
OR 95% CI
Anti-CCP positive 7.5 2.9 – 19.4
Weighted mean DAS44 until remission 4.7 1.5 – 15.2
Baseline HAQ 0.41 0.19 – 0.88
Last DMARD: MTX Reference Reference
                         SSA 3.5 1.5 – 15.2
                         other NA NA
anti-CCP, anti-cyclic citrullinated peptide; DAS44, disease activity score (44 joints); DMARD, disease modifying 
antirheumatic drug; HAQ, health assessment questionnaire; MTX, methotrexate; NA, not applicable due to low patient 
numbers; SSA, sulphasalazine







Age, mean (SD) 57 (13) 55 (15) 1.01 (0.99 – 1.04)
Female gender, n (%) 29 (55) 33 (56) 0.95 (0.45 – 2.01)
Symptom duration (wks), median (IQR) 24 (13 – 56) 20 (11 – 40) 1.00 (0.99 – 1.02)
DAS44, mean (SD) 4.2 (0.8) 4.3 (0.9) 0.82 (0.53 – 1.24)
HAQ, median (IQR)* 1.13 (0.56 – 1.38) 1.25 (0.75 – 1.88) 0.53 (0.29 – 0.97)*
SJC44, median (IQR) 13 (10 – 18) 15 (10 – 21) 0.97 (0.92 – 1.03)
RAI, median (IQR) 11 (8 – 14) 11 (7 – 16) 0.97 (0.92 – 1.03)
VAS global health, mean (SD)* 47 (31 – 61) 53 (41 – 70) 0.98 (0.96 – 1.00)*
ESR, median (IQR) 36 (18 – 51) 31 (15 – 45) 1.01 (0.99 – 1.02)
CRP, median (IQR) 18 (9 – 38) 20 (6 – 45) 1.00 (0.99 – 1.01)
SHS, median (IQR) 2.5 (1.0-7.0) 1.5 (0 – 6.0) 1.03 (0.98 – 1.09)
Erosive yes, % 24 (43) 32 (60) 2.0 (0.95 – 4.4)
Anti-CCP positive, %* 37 (70) 18 (31) 5.3 (2.4 – 11.8)*
RF positive, %* 37 (70) 26 (44) 2.9 (1.3 – 6.4)*
Sequential monotherapy (group 1) 15 (28) 14 (24) Reference
Step-up combination therapy (group 2) 9 (17) 14 (24) 0.60 (0.20 – 1.8)
Initial combination with prednisone (group 3) 14 (26) 10 (17) 1.3 (0.44 – 3.9)
Initial combination with infliximab (group 4) 15 (28) 21 (36) 0.67 (0.25 – 1.79)
II Characteristics at visit before discontinuation
DAS44, mean (SD) 1.1 (0.4) 0.9 (0.5) 1.55 (0.67 – 3.58)
HAQ, median (IQR) 0.00 (0.00 – 0.25) 0.00 (0.00 – 0.13) 1.61 (0.50 – 5.20)
SJC, median (IQR) 0 (0 – 0) 0 (0 – 0) 1.18 (0.80 – 1.74)
TJC, median (IQR) 0 (0 – 1) 0 (0 – 0) 1.01 (0.73 – 1.40)
VAS global health, mean (SD) 15 (2 – 22) 10 (2 – 20) 1.01 (0.98 – 1.04)
ESR, median (IQR) 7 (5 – 15) 6 (4 – 15) 0.99 (0.96 – 1.03)
CRP, median (IQR) 5 (2 - 10) 3 (2 – 7) 1.02 (0.95 – 1.10)
SHS, median (IQR) 5.0 (1.5 – 9.5) 1.5 (0 – 7.8) 1.04 (0.99 – 1.10)
Last DMARD: MTX, n (%) 35 (66) 44 (75) Reference
                         SSA, n (%) 17 (32) 12 (20) 1.8 (0.75 – 4.2)
                         other, n (%) 1 (2) 3 (5) NA
DAS44, weighted mean until remission (SD) 1.6 (0.5) 1.5 (0.5) 1.6 (0.7 – 3.7)
HAQ, weighted mean until remission (SD) 0.35 (0.34) 0.29 (0.27) 2.0 (0.5 – 6.9)
In the upper part of the table baseline variables are shown and, in the bottom part of the table, characteristics at the visit 
before the last DMARD has been tapered are given. The weighted mean DAS44 and HAQ until remission represents the 
mean DAS44 and HAQ from baseline until the visit when the last DMARD is discontinued. 
*p<0.05 without correction for multiple testing. 
anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS44, disease activity score (44 joints); DMARD, 
disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; IQR, 
interquartile range; MTX, methotrexate; n, number of patients; NA, not applicable due to low patient numbers; RAI, 
Ritchie articular index; RF, rheumatoid factor; SHS, Sharp-van der Heijde score; SJC44, swollen joint count 44 joints; SSA, 
sulphasalazine; VAS, visual analogue scale (mm).
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Tanaka, et al recently published the RRR study on discontinuation of infliximab in 
patients with RA after attaining low disease activity.23 As in our study, medication was 
withdrawn and reintroduced at a predefined cut-off and the occurrence of a flare was 
registered. This study differs from the BeSt study in several ways. First, in the RRR study, 
infliximab was discontinued while methotrexate was continued whereas, in the BeSt 
study, all antirheumatic treatment was withdrawn. Second, in the RRR study, infliximab 
was discontinued and reintroduced at the low disease activity cut-off point. No clinical 
remission was required. Furthermore, the disease duration at inclusion was higher in the 
RRR study (5.9 versus 0.4 years). Despite these differences in study design, the observed 
chance of a flare was remarkably comparable (45% versus 46%) and, as we found, the 
majority of patients responded well to reintroduction of treatment after a relapse.
The presence of CCP2 antibodies is one of the strongest known predictors for a worse 
disease course in RA.24 In line with this, anti-CCP positive patients have a lower chance 
of achieving drug-free remission.14 In addition, we found that among the patients 
achieving drug-free remission, the presence of anti-CCP was the strongest predictor for 
the occurrence of a flare. Nevertheless, 30% of the patients in sustained drug-free remis-
sion are anti-CCP positive, indicating that, even in anti-CCP positive patients, successful 
drug-free remission is possible.
Surprisingly, low HAQ at baseline was predictive for restarting treatment in the univariable 
and the multivariable analysis. The univariable results of VAS general health pointed in the 
same direction. This suggests that if patients are able to improve more in HAQ – that is, if 
patients have gained more (mean HAQ improvement 1.14 vs 0.83 in SDFR vs restarters) - 
they have a higher chance of retaining remission after discontinuation of drugs.  
Patients who discontinued MTX maintenance therapy had a higher chance of retaining 
remission than patients who discontinued SSA. Although the patient numbers are low, 
these results may suggest that SSA is less potent in inducing sustained remission after 
discontinuation than MTX. Additional research is needed to confirm this finding.
We hypothesised that patients with a DAS just below the cut-off score of 1.6 might 
have a higher chance of relapse than patients with a lower DAS. We therefore assessed 
whether the level of inflammation at the time of remission, as measured with the DAS 
and its components was predictive for a flare. There appeared to be no association 
between inflammation measures and the risk of flare, indicating that the ‘depth’ of the 
DAS remission is not useful in predicting whether the remission will be maintained after 
discontinuation of DMARDs. ‘Deeper’ remission is not ‘truer’ remission in that sense. 
During the relapse the duration and severity of a higher level of disease activity seems 
limited. DMARDs in a low maintenance dose were restarted immediately if DAS rose to 
≥1.6 and the large majority again achieved clinical remission within 3-6 months. During 
the flare the DAS increased to a low disease activity level in 72% of patients; few expe-
rienced high disease activity during the flare. The temporarily higher DAS level might 
have contributed to the slightly higher (non-significant) joint damage progression in 
the restarters than in the SDFR patients. Another explanation could be that the restart-
ers had less favourable characteristics than the SDFR patients, including a higher per-
d i s Cus si O n
We implemented discontinuation of DMARDs early in the course of the disease in 
patients with RA in clinical remission, treated according to an early, aggressive and 
dynamic treatment approach. Twenty-three percent of patients could discontinue their 
DMARDs because of remission during ≥6 months: 51% of them remained in drug-free 
remission (median 23 months) and 46% restarted treatment. The majority of these 
restarters again achieved clinical remission within 3-6 months after restarting DMARDs 
without suffering joint damage progression. 
Earlier reported relapse rates were comparable or higher (38-100%) 2-9,11,13 than the 46% 
relapse rate in our study. The largest well-designed study by ten Wolde, et al 9 in patients 
with established RA showed a relapse rate in the same range as the rate we found 
in our early RA cohort (38% versus 46%). Direct comparison of these relapse rates is 
difficult owing to different definitions of relapse/remission and differences in patient 
populations. In the older studies,2-8,11 the majority of patients had long standing disease 
with significant joint damage and poor functional ability. We report discontinuation of 
DMARDs early in the disease course with the key advantage that patients in drug-free 
remission had limited joint damage and enjoyed a functional ability comparable to an 
age- and sex-matched healthy reference population.22  
FiGure 1 Cumulative probability plot showing radiological joint damage progression in the first year after 
stopping the last disease-modifying antirheumatic drug in patients who remained in clinical remission (circles) 
versus patients who restarted treatment (triangles). The dashed line represents a clinical relevant progression. 
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centage of anti-CCP positive patients, leading to a higher risk of progression.24 This is 
supported by the observation that, before discontinuing DMARDs, restarters already 
had more joint damage than patients retaining remission (median SHS 5.0 vs 1.5). 
Since DMARDs were stopped in all patients in prolonged remission, it is unknown what 
the flare rate would have been if treatment had been continued. Ten Wolde, et al found 
that, in patients who continued therapy, the flare rate was also considerable (22%) but 
significantly lower than in patients discontinuing treatment (38%).9 Being aware of 
the differences in patient population, these findings suggest that part of the flares we 
observed could have happened even if DMARDs were continued. 
In summary, in 23% of patients with recent-onset RA, DMARDs could be discontin-
ued because of prolonged clinical remission. Based on strict criteria, almost half of 
them had to restart treatment. The presence of anti-CCP was the strongest predictor 
for restarting treatment. The large majority of patients who lost remission remained in 
low disease activity, regained clinical remission shortly after reintroduction of low-dose 
mono-therapy and showed no joint damage progression in the year of the restart. 
We therefore propose that, under continued tight control, discontinuation of the last 
DMARD can be considered in patients in stable clinical remission. The final decision 
whether or not to withdraw treatment in an individual patient should be made by the 
physician and patient together, carefully weighing the advantages and disadvantages. 
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i nt rO d uC t i O n
 
In rheumatoid arthritis (RA) it is well-established that inflammation, joint damage and 
functional limitations are interrelated.1-3 Therefore, the treatment of rheumatoid arthritis 
is aimed at decreasing disease activity as soon as possible in order to restrict limitations in 
functional ability and to prevent the progression of joint damage. Although the generally 
accepted concept that inflammation leads to joint damage forms the basis for current 
treatment approaches, the number of studies assessing this relationship on the individual 
joint level are limited. There are several earlier studies on the relationship between clinical 
signs of synovitis and individual joint damage,4-8 but in these studies no correction was 
made for the fact that multiple joints per patient were included in the analyses, incor-
rectly assuming that these measurements all came from different patients. Because of 
patient characteristics it is likely that within one patient two joints behave more similar 
than two joints from two different patients, that is within one patient measurements of 
multiple joints are considered to be correlated. This within-patient correlation needs to 
be taken into account. In the two studies that did correct for within-patient correlation, 
foot joints are either not included9 or not studied separately.10 Furthermore, the influence 
of treatment with conventional disease-modifying antirheumatic drugs (DMARDs), cor-
ticosteroids and biologicals on the relationship between clinical signs of synovitis and pro-
gression of joint damage in individual joints is unclear. Clinical trials with tumour necrosis 
factor (TNF)-blocking therapies showed a disconnect between inflammation and joint 
damage progression in patients treated with methotrexate and TNF inhibitors at patient 
level.11-14 It can be questioned whether this dissociation exists at joint level.
Therefore, the first objective of our study was to examine the relationship between clin-
ical signs of synovitis (swelling and tenderness) and joint damage progression (erosions, 
joint space narrowing [JSN], total Sharp-van der Heijde score (SHS)) in the individual 
joints of the hands and feet of patients with RA. The second aim was to assess the influ-
ence of different types of treatment on these relationships.
me t h O d s
The first year follow-up data from the randomised, single-blind Behandel Strategieën 
(BeSt) study were used for our analysis. Details of the BeSt study design have been 
published previously.15 Briefly, 508 patients with recent-onset RA were randomised into 
four treatment strategies: sequential monotherapy (group 1, n=126), step-up combina-
tion therapy (group 2, n=121), initial combination therapy with prednisone (group 3, 
n=133) and initial combination therapy with methotrexate (MTX) and the TNF-α inhib-
itor infliximab (group 4, n=128). Treatment was adjusted based on 3-monthly measure-
ments of disease activity aimed at achieving a disease activity score (DAS) ≤2.4 (ie, the 
cut-off value for low disease activity).16,17 
The study was approved by the Medical Ethics Committees of the participating hos-
pitals, and all patients gave written informed consent. The study was designed by the 
ABs t r AC t
Objectives: To assess the relationship between joint tenderness, swelling and joint 
damage progression in individual joints and to evaluate the influence of treatment 
on these relationships. 
Methods: First-year data of the Behandel Strategieën (BeSt) study were used, in 
which patients recently diagnosed as having rheumatoid arthritis (RA) were randomly 
assigned into four different treatment strategies. Baseline and 1-year x-rays of the 
hands and feet were assessed using the Sharp-van der Heijde score (SHS). With 
generalised estimating equations, 3-monthly assessments of tender and swollen joints 
of year 1 were related to erosion progression, joint space narrowing (JSN) progression 
and total SHS progression at the individual joint level (definition >0.5 SHS units) in 
year 1, corrected for potential confounders and within-patient correlation for multiple 
joints per patient. 
Results: During year 1, 59% of all 13959 joints analysed were ever tender and 45% 
ever swollen, 2.1% showed erosion progression, 1.9% JSN progression and 3.6% SHS 
progression. Swelling and tenderness were both independently associated with 
erosion and JSN progression with comparable OR, although with higher OR in the 
hands than in the feet. Local swelling and tenderness were not associated with local 
damage progression in patients initially treated with infliximab. 
Conclusion: Clinical signs of synovitis are associated with erosion and JSN progression 
in individual joints after 1 year in RA. A disconnect between synovitis and joint 
damage progression was observed at joint level in patients who were treated with 
methotrexate and infliximab as initial treatment, confirming the disconnect between 
synovitis and the development of joint damage in tumour necrosis factor blockers 
seen at patient level. 
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outcomes used in the GEE were JSN progression and SHS progression (erosion and/or 
JSN), respectively, both defined as yes (>0.5 units) or no (≤0.5 units), based on 30 joints 
per patient (same joints as for erosion progression except IP1s of thumbs as these are 
not assessed for JSN with the SHS method). The GEE corrects for within-patient correla-
tion. The exchangeable correlation matrix was used in all analyses, assuming an equal 
correlation between all joints. For all three outcomes, the same covariates were added 
stepwise to the model in the following order: swelling (ever [≥1 out of 5 assessments])/
never [0 out of 5 assessments]) alone, than tenderness (ever/never) alone, than swelling 
and tenderness together and finally swelling, tenderness and the interaction swelling* 
tenderness together. All analyses were corrected for the following known predictors 
for joint damage progression and potential confounders: total SHS baseline, erosions at 
baseline (>0.5 units yes/no per joint for the outcome erosion progression), JSN at base-
line (>0.5 units yes/no per joint for the outcome JSN progression), SHS at baseline (>0.5 
units yes/no per joint for the outcome SHS progression), age, gender, baseline body 
mass index, rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP)2 status 
(double positive, RF-positive or CCP2-positive, or double negative), treatment group 
and baseline ESR. The analyses were repeated for the hands and feet separately to assess 
whether there was a difference in strength of association. To analyse whether there was 
a ‘dose-response’ for swelling and tenderness, a GEE with the outcomes erosion progres-
sion,  JSN progression, and SHS progression with a categorical variable (never, once and 
≥2x swollen/tender during year 1) was performed for swelling and tenderness separately, 
corrected for the variables described above. 
To assess whether the association between clinical signs of synovitis and joint damage 
progression was different for clinical synovitis at baseline (ie, before the start of treat-
ment) compared with clinical synovitis during follow-up assessments (ie, during treat-
ment), swelling and tenderness in each joint were categorised in: (1) never, (2) only at 
baseline, (3) only at a follow-up assessment (once), (4) only at follow-up assessments 
(twice or more) and (5) at baseline and during follow-up assessment(s). A GEE model 
with this categorical variable as determinant was performed for all three joint damage 
progression outcomes, again corrected for the variables described above.
Finally, a separate GEE analysis was performed for each treatment strategy to study the 
influence of the treatment strategies on the relationship between clinical signs of synovitis 
and joint damage progression, corrected for the potential confounders as described above.
r e sults
Baseline characteristics between the four groups were comparable, as previously 
described.15 At baseline, patients had active disease, with a mean (SD) DAS of 4.4 (0.9) 
and a mean (SD) HAQ of 1.4 (0.7). The mean (SD) SHS at baseline was 7.1 (10.2), 3.7% of 
all joints had erosions (>0.5 units), 5.3% had JSN (>0.5 units) and 8.1% of all joints had 
SHS >0.5 units. During year 1, 45% of the 13959 joints used in the analysis were at least 
once swollen and 59% were at least once tender. During year 1, 2.1% of all joints showed 
investigators and supported by a government grant from the Dutch College of Health 
Insurance Companies, with additional funding from Centocor (Horsham, Pennsylvania, 
USA) and Schering-Plough Ltd. Data collection, trial management, data collection, data 
analysis and preparation of the manuscript were performed by the authors. 
Patients
Between March 2000 and August 2002, 508 patients from 20 hospitals in The Nether-
lands with DMARD-naïve RA according to the 1987 American College of Rheumatology 
criteria,18 age ≥18 years, disease duration ≤2 years, active disease with ≥6 of 66 swollen 
joints and ≥6 of 68 tender joints and either an erythrocyte sedimentation rate (ESR) 
≥28 mm/h or a global health score of ≥20 mm on a 100 mm visual analogue scale (VAS; 
0, best; 100, worst) were included. 
Assessment of radiological damage progression
Radiographs of the hands and feet of each patient taken at baseline and year 1 were scored 
in one session per patient in random time sequence using the SHS (range 0 to 448 points)19 
by two independent readers blinded to patient identity and treatment allocation. Mean 
baseline and 1-year follow-up SHS of the two readers were used. Erosion progression in an 
individual joint was defined as an increase of >0.5 in erosion score, JSN progression for each 
joint was defined as an increase in JSN score of >0.5 and SHS progression was defined as an 
increase in SHS score (JSN + erosions) per joint of >0.5 SHS units.
Clinical examination
Clinical joint assessments were performed every 3 months by trained nurses, blinded 
for treatment allocation. Per joint, swelling was assessed as 0 (absence) or 1 (presence). 
Joint tenderness was assessed per joint using the Ritchie articular index (RAI)20 recoded 
for the current analysis as 0 (absence) or 1 (presence, ie, RAI 1, 2 or 3).  In total, five 
clinical assessments were performed in the first year of the study: one at baseline and 
four during follow-up. We evaluated whether each joint was never (0 out of 5 assess-
ments), once (1 out of 5 assessments) or twice or more (≥2 out of 5 assessments) swol-
len and/or tender during year 1. 
statistical analyses
Statistical analyses were performed with the software program SPSS version 16.0 (SPSS, 
Chicago, Illinois, USA). The current analysis included only clinical data from the joints of 
fingers and toes that were evaluated using the SHS. Generalized Estimating Equations 
(GEE) analyses were used to study the association between clinical signs of synovitis 
and joint damage progression at the joint level. The first outcome used in the GEE 
was erosion progression defined as yes (>0.5 units) or no (≤0.5 units), based on 32 
joints per patient (hands: 10 metacarpophalangeal joints [MCPs], 8 proximal interpha-
langeal joints [PIPs], 2 interphalangeal joints of the thumbs [IP1s]; feet: 10 metatarsal 
joints [MTPs], 2 interphalangeal joints of the first toes [IP1s]). The second and third 
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FiGure 2 The figures show the proportions of patients with erosion progression, joint space narrowing 
progression, or both, stratified for the absence of baseline damage, baseline erosion(s) only, baseline JSN only, 
baseline erosion(s) and JSN.
compared to 1.5 (1.0 – 2.5) in the joints that were at least once recorded as swollen and/or 
tender (p<0.001; Mann Whitney U test). Joints with JSN at baseline had a higher chance 
to show JSN progression than erosion progression, whereas among the joints with baseline 
erosions the chance for erosion and JSN progression was comparable (figure 2). 
Gee results
The GEE model showed that a joint that was swollen at least once during year 1 had 
a higher risk for progression than a joint that was never swollen (table 1: model 1). The 
same was true for joint tenderness (table 1: model 2). Both swelling and tenderness con-
tributed independently to the increased risk for progression (table 1: model 3), but with 
lower OR than when added separately. The association was comparably strong for swell-
ing and tenderness and as strong for erosion as well as JSN progression. In all models 
the potential confounders were added. Independent baseline predictors for joint dam-
age progression in the individual joint, that did not influence the association between 
swelling and tenderness and damage progression (uncorrected data not shown) were: 
a higher total SHS at baseline, the presence of baseline damage in the same joint, lower 
age, a higher ESR, presence of anti-CCP2 and RF and initial  mono-therapy (table 1). 
The interaction term swelling*tenderness was not significantly associated with the out-
comes erosion progression, JSN progression and SHS progression and was therefore 
omitted from the analysis. Repeating the GEE analyses in the joints without baseline 
damage gave comparable results (data not shown).  
The association between swelling/tenderness and joint damage progression was stron-
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erosion progression (295/13959 joints), 1.9% showed JSN progression (251/13084 joints) 
and 3.6% (477/13084 joints) showed SHS progression. 
In total, 3.4%, 3.1% and 5.7% of the joints that were ever swollen and tender during year 1 
showed erosion progression, JSN progression and SHS progression, respectively, compared 
with 1.1%, 0.9% and 1.9% of joints that were never swollen or tender (figure 1 A), indicating 
that although there was more progression in joints that were swollen or tender, the vast 
majority of swollen and tender joints did not progress during year 1. However, 30 to 40% 
of joints with progression of erosion and/or JSN were never recorded as swollen during the 
5 assessments during year 1 (figure 1 B). The percentages of joints that were swollen and/
or tender during year 1 were similar for joints showing erosion progression, JSN progres-
sion or SHS progression. Of the 477 joints with SHS progression >0.5, 87 joints were never 
recorded as swollen or tender. Of those 87 joints, 23 (26%) had baseline damage, compared 
to 96 (25%) of the 390 progressive joints with swelling and/or tenderness. Median (IQR) 
SHS progression in the clinically uninvolved joints with SHS progression was 1.0 (1.0 – 1.6) 
FiGure 1 Distribution of swollen and tender joints and erosion progression, joint space narrowing progression 
and SHS progression. (A) The percentage of joints showing erosion progression, joint space narrowing 
progression and SHS progression depicted among swollen (ever) and tender (ever) joints. (B) The percentage 
of swollen (ever) and tender (ever) joints among the progressive and non-progressive joints. JSN, joint space 
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2), with the strongest association between swelling and erosion progression . In the feet, 
swelling and tenderness were not independently associated with the outcome erosion 
progression, although swelling was still independently associated with JSN progression 
and SHS progression. 
In the hands and feet combined, a ‘dose-response’ was observed (table 3), indicating 
that a joint that was swollen or tender twice or more had a higher risk for progression 
than if it was swollen or tender only once, that is, a more persistent synovitis carried a 
higher risk for local damage progression. 
The development of swelling and tenderness during follow-up despite treatment (even 
if present during only 1 assessment) was associated with a higher chance for erosion 
progression, but not for JSN progression, than the presence of swelling and tenderness 
at the baseline assessment, that is, before treatment (table 4). 
Table 5 displays the GEE results for the four treatment strategies separately. In patients 
treated with sequential monotherapy (group 1), step-up combination therapy (group 2) 
or initial combination with prednisone (group 3), swelling and tenderness were signifi-
cantly  related to the outcomes erosion progression, JSN progression and SHS progres-
tABle 2 GEE results (OR (95% CI)) for the outcomes erosion progression, joint space narrowing progression 
and Sharp-van der Heijde progression yes/no, for hands and feet separately
Erosion progression JSN progression SHS progression
Hands
Swollen, ever 10.0 (4.0 – 24.7) 2.4 (1.4 – 3.8) 3.5 (2.2 – 5.3)
Tender, ever 2.9 (1.4 – 6.1) 2.1 (1.1 – 4.2) 2.5 (1.5 – 4.1)
Feet
Swollen, ever 1.4 (0.95 – 2.1) 2.3 (1.4 – 3.7) 1.5 (1.1 – 2.1)
Tender, ever 1.02 (0.7 – 1.6) 0.9 (0.6 – 1.4) 0.99 (0.69 – 1.4)
All corrected for: total SHS baseline, erosions at baseline yes/no per joint (for outcome erosion progression), JSN at baseline yes/
no per joint (for outcome JSN progression), SHS at baseline yes/no per joint (for outcome SHS progression), age, gender, body mass 
index, rheumatoid factor (RF)/anti-CCP2 status (double positive, RF-positive or CCP2-positive, double negative), treatment group and 
erythrocyte sedimentation rate.
CCP, cyclic citrullinated peptide; GEE, generalised estimating equations; JSN, joint space narrowing; SHS, Sharp-van der Heijde score.
 
tABle 3 GEE results (OR (95% CI)) for the outcomes erosion progression, joint space narrowing progression 
and Sharp-van der Heijde progression yes/no, showing a dose response for both swelling and tenderness
Erosion progression JSN progression SHS progression
Swollen never Reference Reference Reference
Swollen, 1x 1.4 (1.00 – 2.3) 1.7 (1.2 – 2.4) 1.5 (1.2 – 2.0)
Swollen, ≥2x 3.0 (2.0 – 4.5) 3.2 (2.1 – 4.8) 2.7 (2.0 – 3.7)
Tender never Reference Reference Reference
Tender, 1x 1.6 (1.03 – 2.4) 1.4 (0.94 – 2.1) 1.5 (1.1 – 2.1)
Tender, ≥2x 3.9 (2.6 – 5.9) 3.7 (2.2 – 5.2) 3.3 (2.4 – 4.5)
All corrected for: total SHS baseline, erosions at baseline yes/no per joint (for outcome erosion progression), JSN at 
baseline yes/no per joint (for outcome JSN progression), SHS at baseline yes/no per joint (for outcome SHS progression), 
age, gender, body mass index, rheumatoid factor (RF)/anti-CCP2 status (double positive, RF-positive or CCP2-positive, 
double negative), treatment group and erythrocyte sedimentation rate.
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tABle 5 GEE results (odds ratios (95% confidence intervals)) for the outcomes erosion progression, joint 
space narrowing progression and Sharp-van der Heijde progression yes/no in the four treatment strategies
Erosion progression JSN progression SHS progression
Sequential monotherapy
Swollen, ever 3.0 (1.8 – 4.9) 4.5 (2.5 – 8.0) 2.9 (1.9 – 4.3)
Tender, ever 3.5 (1.9 – 6.7) 2.2 (1.02 – 4.8) 2.5 (1.4 – 4.3)
Step-up combination therapy
Swollen, ever 1.6 (0.9 – 3.1) 1.7 (0.98 – 3.1) 1.6 (1.0 – 2.5)
Tender, ever 2.7 (1.1 – 6.8) 3.1 (1.5 – 6.5) 2.9 (1.6 – 5.0)
Initial combination with prednisone
Swollen, ever 3.8 (1.5 – 9.4) 2.9 (1.5 – 5.9) 3.2 (1.7 – 6.3)
Tender, ever 1.8 (0.7 – 4.6) 2.4 (1.2 – 5.1) 2.1 (1.2 – 3.6)
Initial combination with infliximab
Swollen, ever 0.9 (0.4 – 2.0) 1.2 (0.8 – 2.8) 1.2 (0.7 – 2.1)
Tender, ever 1.4 (0.8 – 2.5) 2.0 (0.8 – 4.9) 2.0 (1.1 – 3.5)
All corrected for: total SHS baseline, erosions at baseline yes/no per joint (for outcome erosion progression), JSN at baseline yes/
no per joint (for outcome JSN progression), SHS at baseline yes/no per joint (for outcome SHS progression), age, gender, body mass 
index, rheumatoid factor (RF)/anti-CCP2 status (double positive, RF-positive or CCP2-positive, double negative), treatment group and 
erythrocyte sedimentation rate.
CCP, cyclic citrullinated peptide; GEE, generalised estimating equations; JSN, joint space narrowing; SHS, Sharp-van der Heijde score.
joint swelling and JSN progression in the feet, we did not find a statistically significant 
association between joint swelling or tenderness and erosion progression. This may be 
due to less accurate joint assessments of the feet, and a fewer number of assessable 
joints in the feet than in the hands (10 MTPs + 2 IP1s joints vs 18-20 MCPs, PIPs, IP1s 
joints). To the best of our knowledge, there are no mechanisms proposing that local 
inflammation affects local joint damage differently in the hands and feet. 
The presence of tenderness might be seen as less specific for local inflammatory activity 
than the presence of swelling.21 Our analysis showed, however, that joint tenderness con-
tributes independently of swelling to an increased risk for progression in the individual 
joint. Therefore, to identify joints at risk for damage progression, separate clinical assess-
ments of swelling and tenderness are warranted, as is required when calculating the DAS. 
As expected, the association between clinical signs of synovitis and joint damage pro-
gression explains only part of the total variability of joint damage progression in patients 
with RA. The risk for damage progression in an individual joint depends on patient 
characteristics, local joint circumstances, as well as treatment. Age, the baseline pres-
ence of erosions or JSN in the joint, total baseline joint damage, presence of anti-CCP 
and RF, high ESR, and initial monotherapy were observed to be independent predictors 
for joint damage progression in the individual joint. In addition, the clinical presence of 
swelling and tenderness multiplies the absolute risk for progression by its OR. 
Previous data suggested a disconnect between inflammation and joint damage in patients 
treated with TNF blockers at patient level, that is, even when there is little clinical response, 
treatment with TNF inhibitors can inhibit the progression of joint damage11,12,14,22. This dis-
sociation was present at the individual joint level in patients treated with an initial com-
bination of methotrexate and infliximab as well. The exact pathogenic mechanism of the 
sion, with the exception of swelling versus erosion progression and JSN progression in 
group 2 and tenderness versus erosion progression in group 3. In patients treated with 
the initial combination methotrexate and infliximab (group 4) neither swelling nor ten-
derness were significantly associated with progression of erosions, JSN and SHS in the 
individual joint, with the exception of tenderness and SHS progression, indicating a dis-
connect between clinical signs of synovitis and radiological damage progression. 
d i s Cus si O n  
We found that clinical signs of synovitis in hands and feet are associated with the devel-
opment of joint damage progression at the individual joint level. The association is as 
strong for swelling as for tenderness and similarly strong for the outcomes erosion pro-
gression, JSN progression and SHS progression. 
We showed a dose-response relationship, indicating that a persistent synovitis, that is, 
the presence of clinical synovitis during two or more out of five clinical assessments, 
was associated with a higher risk for progression compared with clinical synovitis at 
only one assessment. The association is probably even stronger for joints that show 
signs of inflammation during three to five visits, however, due to a dynamic treatment 
strategy aiming at low disease activity in the BeSt study, the number of joints with syno-
vitis during more than two visits is limited, and therefore we had insufficient power to 
assess a stronger dose-response effect. Furthermore, our results suggest that a joint with 
clinical signs of synovitis despite treatment has a worse prognosis than a joint with clin-
ical synovitis before the start of treatment. 
The relationship between clinical signs of synovitis and joint damage progression is 
stronger in hands than in feet. Although there was a significant association between 
tABle 4 GEE results (OR (95% CI)) for the outcomes erosion progression, joint space narrowing progression 
and Sharp-van der Heijde progression yes/no, showing the association between swelling, tenderness and joint 
damage progression split for baseline and follow-up clinical assessments
Erosion progression JSN progression   SHS progression
Swollen never Reference Reference Reference
Only swollen at baseline 1.2 (0.77 – 1.9) 1.6 (1.1 – 2.4) 1.3 (0.98 – 1.8)
Only swollen during follow-up, 1x 2.0 (1.1 – 3.4) 1.5 (0.91 – 2.7) 1.8 (1.2 – 2.8)
Only swollen during follow-up, ≥2x 2.7 (1.5 – 4.6) 2.4 (1.1 – 5.4) 2.0 (1.2 – 3.3)
Swollen at baseline and during follow-up 3.2 (2.1 – 4.9) 3.3 (2.2 – 4.9) 3.0 (2.2 – 4.0)
Tender never Reference Reference Reference
Only tender at baseline 1.2 (0.77 – 2.0) 1.3 (0.83 – 2.1) 1.4 (0.99 – 2.0)
Only tender during follow-up, 1x 2.0 (1.1 – 3.4) 1.4 (0.86 – 2.3) 1.7 (1.1 – 2.5)
Only tender during follow-up, ≥2x 3.8 (2.3 – 6.3) 3.3 (1.9 – 5.7) 3.4 (2.2 – 5.2)
Tender at baseline and during follow-up 3.6 (2.5 – 5.4) 3.2 (2.1 – 4.8) 3.3 (2.4 – 4.5)
All corrected for: total SHS baseline, erosions at baseline yes/no per joint (for outcome erosion progression), JSN at baseline yes/
no per joint (for outcome JSN progression), SHS at baseline yes/no per joint (for outcome SHS progression), age, gender, body mass 
index, rheumatoid factor (RF)/anti-CCP2 status (double positive, RF-positive or CCP2-positive, double negative), treatment group and 
erythrocyte sedimentation rate.
CCP, cyclic citrullinated peptide; GEE, generalised estimating equations; JSN, joint space narrowing; SHS, Sharp-van der Heijde score.
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dissociation between synovitis and joint damage in patients treated with TNF inhibitors is 
unclear. Altering of the receptor activator for nuclear factor κβ ligand (RANKL)/osteopro-
tegerin (OPG) ratio by TNF blockade and thereby inhibiting osteoclast activation proba-
bly plays a role. 14,23-25 The disconnect again emphasises the important role of TNFα in the 
development and progression of joint damage. 
A limitation of this study might be that there were no ultrasound or MRI data available, 
which might have given insight in subclinical synovitis. However, the clinical associations 
we observed are accurate. With ultrasound or MRI a stronger association between syno-
vitis and progression might be observed. Another drawback might be that the percentage 
of joints with progression was limited, as a result of the effective treatment approach.
In conclusion, swelling and tenderness are independently associated with erosion and 
JSN progression, but not in patients treated initially with MTX and infliximab combina-
tion treatment.
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The Sharp-van der Heijde method (SHS; range 0-448)1 is an often used and well- 
validated method to assess joint damage on x-rays in rheumatoid arthritis (RA). It is a 
comprehensive method that requires training, making it less feasible for clinical practice. 
The simplified erosion and narrowing score (SENS, range 0-86)2 scores the same joints 
as SHS, but without grading of damage per joint, making it quicker and easier to learn. 
Using SENS takes 7 minutes for seven sets of radiographs, compared with 25 minutes 
for seven sets using SHS.2 
In earlier studies, SENS showed good reliability and responsiveness, but these studies either 
had no restrictions in disease duration or limited patient numbers.2-4 We aimed to compare 
the properties of SENS and SHS in a large group of early, intensively treated RA patients 
with limited joint damage during 5 years of follow-up in the BeSt (Behandel Strategieën 
[Treatment Strategies]) study. Details of the study have been described earlier5. 
Annual radiographs of hands and feet in years 0-5 were scored in one session per patient 
in random time sequence using SHS by two independent readers blinded for patient 
identity. Per reader, the SENS was derived from the SHS.
In total, 2595 sets of radiographs were present from 498 patients (mean 5.2 sets per 
patient). Median (IQR)/mean(SD) SHS and SENS at baseline were 3.0 (0.5-9.5)/7.1 (10.2) 
and 2.0 (0.5-5.5)/3.8 (4.7), respectively. Mean SHS progression in year 1-5, respectively, 
was 3.4, 1.5, 1.1, 1.5, 1.6; mean SENS progression was 1.7, 0.6, 0.4, 0.5, 0.6.
The reliability of SENS was comparable to SHS with moderate to high between-reader 
intra-class correlation coefficients (ICCs). Between-reader ICCs for total SHS and 
SENS varied between 0.74 and 0.93 for both methods. For progression from baseline, 
between-reader ICCs varied between 0.90 and 0.95 without differences between the 
methods and was stable over time. 
SENS had lower absolute progression scores than SHS, as expected inherent to the scale 
(figure 1). In most patients, positive SHS change scores were accompanied with positive 
SENS change scores. However, the figures illustrate that in patients with large SHS pro-
gression the amount of SENS progression is highly variable.
Percentages with progression ≥1 unit were higher for SHS than for SENS (tables 1 and 2). 
Sensitivity varied between 69 and 89%, and specificity was high (94-99%). Comparable 
results were observed for progression ≥ the smallest detectable change. In year 1 (delta 
0-1) and 5 (delta 4-5), 11% and 27%, respectively, of patients with SHS progression ≥1 
units had no progression with SENS. This implies that in these patients damage progres-
sion occurs in already damaged joints but does not coincide with the development of 
damage in previously unaffected joints, in line with Bruynestein, et al.6 By disregarding 
grading of damage, the discriminative capacity of SENS is lower. Since differentiation in 
clinical trials and for example genetics studies, is often based on a minority of patients 
with joint damage progression, we believe that for research the benefit of time effi-
ciency does not compensate the lower discriminative power of SENS. In daily practice, 
it may be an acceptable alternative to the SHS. 
A limitation might be that we derived SENS from SHS. For comparing reproducibility 
of SENS and SHS this study design is not ideal. However, this design is appropriate for 
FiGure 1 Cumulative probability plots showing Sharp-van der Heijde score (SHS) progression with 
corresponding simplified erosion and narrowing score (SENS) progression of reader 1 in year 1 (delta 0-1) (A) 
and year 5 (delta 4-5) (B). Reader 2 showed comparable results (data not shown).
tABle 1 Responsiveness. Progression percentages at different time intervals for progression ≥1 unit using SENS 
and SHS, percentages of discordant observations and sensitivity and specificity using SHS as gold standard. 
% progression ≥ 1 units % discordance:
progression ≥1 units





Delta 1-0 42% (185/439) 39% (169/439) 11% (20/185) 2% (4/169) 89% 98%
Delta 2-1 34% (139/414) 30% (125/414) 17% (24/139) 8% (10/125) 83% 94%
Delta 3-2 30% (118/398) 22% (88/398) 31% (37/118) 8% (7/88) 69% 98%
Delta 4-3 35% (136/394) 28% (110/394) 22% (30/136) 4% (4/110) 78% 98%
Delta 5-4 32% (113/357) 24% (86/357) 27% (30/113) 4% (3/86) 73% 99%
SENS, simplified erosion and narrowing score; SHS, Sharp-van der Heijde score.
Values are percentages (n/n).
B
SHS progression SENS progression
























0,2       0,4                   0,6                 0,8   1

















tABle 2 Responsiveness: progression percentages at different time intervals for progression ≥ the smallest 
detectable change using SENS and SHS, percentages of discordant observations and sensitivity and specificity 
using SHS as gold standard.
SDC 
(% of maximum score)* 
% progression ≥ SDC % discordance: 
progression ≥SDC
SHS SENS SHS SENS SHS + SENS - SHS - SENS + Sensitivity Specificity
delta 1-0 5.9 (2.5) 2.8 (4.4) 20% (86/439) 20% (86/439) 14% (12/86) 14% (12/86) 86% 97%
delta 2-1 5.5 (2.3) 2.4 (3.8) 9% (37/414) 10% (40/414) 16% (6/37) 23% (9/40) 84% 98%
delta 3-2 4.4 (1.8) 2.1 (3.2) 11% (44/398) 7% (29/398) 39% (17/44) 7% (2/29) 61% 99%
delta 4-3 5.4 (2.3) 2.5 (3.9) 10% (40/394) 8% (32/394) 30% (12/40) 13% (4/32) 70% 99%
delta 5-4 6.3 (2.7) 2.5 (4.0) 9% (31/357) 8% (29/357) 19% (6/31) 14% (4/29) 81% 99%
SDC, smallest detectable change; SENS, simplified erosion and narrowing score; SHS, Sharp-van der Heijde score. 
Values are percentages (n/n), except for SDC.
*SDC (values in parentheses are percentage of maximum score of SHS and SENS in the study, that is 236 and 64 for SHS 
and SENS, respectively)  
comparing responsiveness of SENS and SHS, which was the main focus of our analysis. 
Furthermore, earlier research showed that the concordance between SENS scored sepa-
rately versus SENS derived from SHS was high (93.8% complete agreement)2. 
In summary, SENS is a valuable tool in clinical practice due to its time efficiency. How-
ever, we do not recommend SENS for research, because it is less sensitive, and by disre-
garding grading of damage per joint the discriminative power will be lower.
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i nt rO d uC t i O n
Rheumatoid arthritis (RA) is a systemic inflammatory disease which is associated with 
a higher prevalence of cardiovascular morbidity and mortality, possibly through effects 
on blood vessels that resemble the pathophysiology of atherosclerosis.1;2 Antirheumatic 
treatment aims at diminishing disease activity and thereby probably decreases cardio-
vascular risk.3 Various antirheumatic drugs may have other favourable and/or unfavour-
able effects on cardiovascular risk.4-13 
Because cardiovascular diseases account for a considerable burden of morbidity and 
mortality in patients with RA, the effect on cardiovascular risk should be considered 
when choosing a treatment strategy. Hypertension, a risk factor for developing cardio-
vascular disease, is highly prevalent in patients with RA.14 We analysed the relationship 
between disease activity and blood pressure (BP) and the effect of four different RA 
treatment strategies on BP during the first two years of treatment. 
PAt i ents An d me t h O d s
The BeSt study is a multicenter randomised clinical trial in disease-modifying antirheu-
matic drug (DMARD)-naïve patients with active RA (disease duration ≤2 years) com-
paring four different treatment strategies: sequential monotherapy (group 1, n=126), 
step-up combination therapy (group 2, n=121), initial combination therapy with pred-
nisone (group 3, n=133) and initial combination therapy with methotrexate and the 
tumour necrosis factor α (TNFα) inhibitor infliximab (group 4, n=128). Details of the 
study, including data about antirheumatic treatment in the four treatment arms, have 
been published previously.15;16
Treatment was adjusted based on 3-monthly disease activity score measurements 
(DAS44).17 If a patient had a DAS >2.4, treatment was adjusted according to the pre-de-
fined protocol for each group. If the DAS was ≤2.4 (low disease activity (LDA)) for at 
least 6 months, medication was tapered to a maintenance dose. Every 3 months, as part 
of a vital signs check, single measurements of systolic and diastolic blood pressure (SBP 
and DBP, respectively) were performed by trained nurses, blind to the treatment alloca-
tion. BP was measured according to local clinical standards: in 16 centers a sphygmoma-
nometer plus stethoscope was used and in four centers electronic devices were used. 
For each patient, the measurement method was the same during the study period. BP 
readings were performed at least one hour before or 4 weeks after, administration of 
infliximab (infliximab infusions every 8 weeks). Patients were classified into four DAS 
categories at each 3-monthly visit: remission (DAS <1.6), LDA (DAS ≥1.6 but ≤2.4), 
moderate disease activity (MDA, DAS >2.4 but ≤3.7) and high disease activity (HDA, 
DAS >3.7). Patients with a DAS <1.6 from 6 to 24 months (one DAS ≥1.6 allowed) were 
classified as ‘continuous remission’. Patients with a DAS >2.4 from 6 to 24 months, (one 
DAS £2.4 allowed) were classified as ‘continuous clinical failure’. 
ABs t r AC t
Objective: To evaluate the effect of disease activity and antirheumatic treatment on 
blood pressure (BP) in patient with recent-onset rheumatoid arthritis (RA). 
Methods: 508 patients with RA were randomised to receive (1) sequential 
monotherapy, (2) step-up combination therapy, (3) initial combination with 
prednisone or (4) with infliximab. Systolic and diastolic blood pressure (SBP, DBP), 
disease activity score (DAS) and body mass index (BMI) were evaluated every 3 
months. A linear mixed model was used to model SBP and DBP in each treatment 
group during year 1, adjusting for baseline BP, changes in BMI, DAS and cardiovascular 
medication. 
Results: In all groups, mean SBP and DBP were lower for patients with DAS ≤2.4 
than for patients with DAS >2.4. In addition, patients initially treated with infliximab 
(group 4) had a larger decrease in SBP and DBP over time than patients in groups 1-3. 
The decrease in BP was also observed in patients treated with infliximab after failure 
on conventional disease-modifying antirheumatic drugs in groups 1-3. The decrease 
in BP associated with treatment with infliximab occurred irrespective of the DAS 
response.  
Conclusion: A lower DAS is associated with lower BP. An additional BP decrease was 
observed in patients treated with infliximab. Further research is needed to confirm 
the effect of infliximab on BP.   
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n=126 n=121 n=133 n=128
Age, years 54 (13) 54 (13) 55 (14) 54 (14)
Women, n (%) 86 (68) 86 (71) 86 (65) 85 (66)
DAS score 4.5 (0.9) 4.5 (0.8) 4.4 (0.9) 4.3 (0.9)
HAQ score 0-3 1.4 (0.7) 1.4 (0.6) 1.4 (0.7) 1.4 (0.7)
SHS 0-448, mean (SD) 7.3 (9.5) 6.3 (6.9) 5.9 (6.5) 7.0 (10.0)
SHS 0-448, median  (IQR) 3.5 (1.5-9.5) 5.0 (1.5-8.1) 3.5 (1.5-8.5) 4.0 (1.5-8.5)
Systolic blood pressure, mmHg 137.6 (19.8) 139.8 (20.8) 136.1 (21.4) 135.7 (19.8)
Diastolic blood pressure, mmHg 84.1 (10.3) 84.6 (11.8) 84.7 (11.8) 83.6 (11.1)
Smoking yes, n (%) 45 (36) 44 (38) 44 (34) 40 (32)
BMI 26 (5) 26 (4) 26 (4) 26 (4)
Glucose 5.5 (1.3) 5.6 (1.4) 5.7 (1.5) 5.6 (1.4)
Creatinine 77 (15) 76 (14) 75 (18) 77 (13)
Cardiovascular history yes, n (%) 30 (24) 32 (26) 26 (20) 24 (19)
         Hypertension 10 (8) 14 (12) 10 (8) 9 (7)
         Peripheral vascular disease 9 (7) 9 (7) 4 (3) 10 (8)
         Coronary heart disease 5 (4) 4 (3) 9 (7) 6 (5)
         Other 10 (8) 12 (10) 5 (4) 4 (3)
History of renal disease, n (%) 0 (0) 0 (0) 1 (1) 0 (0)
Cardiovascular medication yes, n (%) 22 (18) 28 (23) 26 (20) 14 (11)
          Diuretics 6 (5) 7 (6) 7 (5) 3 (2)
          Betablockers 8 (6) 7 (6) 12 (9) 2 (2)
          ACE / AT-2 inhibitors 6 (5) 13 (11) 4 (3) 4 (3)
          Calcium channel blockers 3 (2) 3 (3) 6 (5) 3 (2)
          Statines 6 (5) 6 (5) 9 (7) 5 (4)
          Other 5 (4) 9 (7) 6 (5) 2 (2)
NSAID or COXIB use yes, n (%) 110 (87) 97 (80) 118 (89) 111 (87)
Data are presented as mean (standard deviation [SD]) unless otherwise noted.
ACE, angiotensin converting enzyme; AT-2, angiotensin-2 receptor; BMI, body mass index; COXIB, COX-2 inhibitors; 
DAS, disease activity score; HAQ, health assessment questionnaire; IQR, interquartile range; NSAID, non-steroidal anti-
inflammatory drugs; SHS, Sharp-van der Heijde score
with prednisone (p=0.002). Patients in group 4 also had lower DBP than patients in the 
other groups, although this was less pronounced and partly non-significant (table 2). 
No statistically significant differences were found between the other treatment groups, 
with the exception of a decrease in DBP of 2.0 in group 3 compared to group 1 (table 2). 
Study center and the use of leflunomide or ciclosporin did not influence the association 
between treatment and BP and were therefore omitted from the analysis.
In group 4, 22 patients (17%) were classified as ‘continuous clinical remission’ and 11 (9%) 
as ‘continuous clinical failure’ on infliximab. A comparable decrease in BP was observed 
statistical analysis     
The SPSS 16.0 software package was used. Baseline characteristics were analysed using 
one-way analysis of variance, the Kruskal-Wallis test and the chi-square test. Two dif-
ferent linear mixed model (LMM) analyses were performed for SBP and DBP, all with 
the unstructured covariance matrix. The first LMM was performed to compare SBP 
and DBP among the different DAS-categories based on all nine BP measurements per 
patient, corrected for age, gender, body mass index (BMI), the use of antihypertensive 
medication at baseline and the use of non-steroidal anti-inflammatory drugs (NSAIDs)/
cyclo-oxygenase-2 inhibitors (COXIBs) at baseline and during follow-up. Then LMM 
was used to model SBP and DBP during the first year of follow-up because from the 
protocol it follows that patients who were initially treated with infliximab or prednisone 
used it for at least 7.5 to 9 months. SBP and DBP at the four follow-up visits of year 1 
were used as outcomes, with time (as factor) and baseline SBP or DBP, randomisation, 
age, gender, NSAID/COXIB use at baseline and during each follow-up visit, antihyper-
tensive drug use at baseline, delta DAS and delta BMI (both for each visit compared 
with baseline) as fixed effects and a random patient effect. 
r e sults
The baseline characteristics between the four treatment groups were comparable.15 Mean 
(SD) BP (mmHg) at baseline was high to normal in all groups: 138 (20) /84 (10), 140 (21) 
/85 (12), 136 (21) /85 (12) and 136 (20) /84 (11) for groups 1-4 respectively. At baseline, mean 
(SD) DAS was 4.4 (0.9), 34% smoked and mean (SD) BMI was 26 (5) kg/m2. Of all patients, 
22% had a medical history of cardiovascular disease, comprising mainly hypertension 
(31%), peripheral vascular disease (26%) and acute coronary syndrome (19%). In groups 
1-4, 14%, 17%, 14% and 7% of patients were on anti-hypertensive medication at baseline, 
whereas 87%, 80%, 89% and 87% used NSAIDs or COXIBs. Detailed baseline characteris-
tics and cardiovascular comedication at baseline are shown in table 1. During the 2 years 
of the study, 27 patients were lost to follow-up. 
Mean DAS improved earlier in patients in treatment group 3-4 than in group 1-2. From 
year 1 onwards, disease activity was comparable and stable in all groups.16  Patients with 
LDA (DAS ≤2.4) had, on average, lower SBP and DBP than patients with MDA/HDA (DAS 
>2.4) (LMM, figure 1) also after correction for age, gender, BMI and the use of antihyper-
tensive medication and NSAIDs/COXIBs at baseline and during follow-up.  A similar effect 
was observed for the mean DBP values.
Figure 2 shows the progression of SBP and DBP in the four treatment groups over time. 
After correction for the change in DAS from baseline, baseline SBP, age, gender, NSAID/
COXIB at baseline and during follow-up, antihypertensive drug use at baseline and delta 
BMI, longitudinal data analysis of the first year (LMM) showed that initial combination 
treatment with infliximab was associated with a reduction in SBP of 4.8 mmHg com-
pared to sequential monotherapy (p=0.001), 3.0 mmHg compared to step-up combi-
nation therapy (p=0.04) and 4.5 mmHg compared to initial combination treatment 
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FiGure 1 Mean values of systolic and diastolic blood pressure in relation to various levels of disease activity 
in patients with recent-onset rheumatoid arthritis (linear mixed model results (LMM)). At all 9 visits, patients 
were classified according to their disease activity level. In the LMM the relationship between the level of 
disease activity and systolic and diastolic blood pressure was analysed, using all 9 visits.  
Remission: DAS <1.6; Low: DAS ≥ 1.6 but ≤ 2.4; Moderate: DAS >2.4 but ≤ 3.7; High: DAS >3.7. DAS, disease 
activity score. Error bars represent standard errors; *p < 0.01: Remission and Low versus Moderate and High; 
**p<0.01 Remission versus Moderate and High; #p=0.03: Low versus High 
FiGure 2 Systolic and diastolic blood pressure in the four different treatment groups during 2 years of follow-up 
with LMM results to account for missing values, with time (as factor), randomisation and time*randomisation 
as predictors
after correction for the improvement in disease activity. Decreases in SBP and DBP 
were observed in patients who received infliximab as initial therapy and in those who 
received infliximab after failing on previous treatments, although the latter had a less 
pronounced reduction in disease activity. Lower BP was seen in patients who failed on 
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in these patients (SBP -6.8 mmHg, DBP -1.7 mmHg for patients classified as ‘continuous 
clinical remission’ and SBP-4.9 mmHg, DBP -1.0 mmHg for those classified as ‘continu-
ous clinical failure’). In accordance with the protocol, patients who had a continuous 
good response on infliximab and those who failed on the highest dose discontinued 
infliximab. At the end of the 2-year observation period when the average blood pres-
sure appeared to return to the original value, only 18% of patients were still receiving 
infliximab. 
In total, 70 patients in groups 1-3 switched to treatment with methotreaxaat and 
infliximab because of DAS >2.4 on prior treatment steps. In these ‘delayed infliximab 
patients’, SBP decreased on average 2.2 and 4.7 mmHg after 6 and 12 months, and DBP 
decreased 1.3 and 3.9 mmHg after 6 and 12 months. These changes are not statistically 
different from the changes observed in patients initially treated with methotrexate and 
infliximab. 
d i s Cus si O n
This study shows that, in patients with RA, lower disease activity is associated with 
lower BP. This may represent part of the mechanism by which antirheumatic treatment 
can reduce the increased cardiovascular morbidity and mortality in RA. It is thought 
that systemic inflammation in RA leads to vasoconstriction and hypertension through 
up-regulation of the angiotensin II type 1 receptor and of endothelin and downregula-
tion of NO2.14  Effective suppression of inflammation may inhibit this process, and, as a 
consequence, may lower BP. 
Intriguingly, we found an additional reduction in SBP (up to almost 5 mmHg) and to a 
lesser extent (up to almost 3 mmHg) in DBP in patients treated with infliximab. Given 
that patients with RA are at increased risk for developing cardiovascular disease, such 
decreases in BP could be beneficial.1;14;18 In the LMM, initial treatment with infliximab 
was associated with a reduction in SBP compared with the other strategies and also 
tABle 2 Linear mixed model results with systolic and diastolic blood pressure from 3, 6, 9, and 12 months 
as outcome, corrected for baseline SBP, time (as factor), age, gender, use of NSAIDS/COXIBs at baseline, use 
of NSAIDs/COXIBs during follow-up, use of antihypertensive drugs at baseline, delta DAS, delta BMI, and a 
random patient effect. 
Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg)
Beta 95% CI Beta 95% CI
Group 1 – 2 1.82 -1.11 – 4.75 1.28 -0.43 – 2.99
Group 1 – 3 0.32 -2.57 – 3.21 2.04 0.35 – 3.73
Group 1 – 4 4.83 1.98 – 7.68 2.81 1.15 – 4.48
Group 2 – 3 -1.51 -4.47 – 1.46 0.76 -0.97 – 2.49
Group 2 – 4 3.01 0.08 – 5.93 1.54 -0.17 – 3.24
Group 3 – 4 4.51 1.67 – 7.36 0.77 -0.89 – 2.44
Beta represents differences in blood pressure between the groups; > 0: first treatment group mentioned has higher blood 
pressure; < 0: first treatment group mentioned has lower blood pressure.   
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suggest that treatment with infliximab has a drug-specific effect on BP which is inde-
pendent of the level of inflammation measured by the DAS. After 2 years the benefit of 
infliximab on SBP seems to disappear, probably due to discontinuation of infliximab in 
the most patients in accordance with the protocol.
To our knowledge, the effect of TNFa inhibitors on BP has not yet been described. There 
are, however, observations that anti-TNFa treatment is able to reverse endothelial dys-
function,13 decrease arterial stiffness19 and decrease plasminogen activator inhibitor-1 in 
patients with RA.20 
The BeSt study was not designed to analyse BP changes associated with antirheumatic 
treatment. The single BP measurements, done without a standardised measurement 
protocol, may have led to inconsistent BP measurements. Although the possibility of 
bias cannot be excluded, we think it is unlikely since the data collection occurred before 
the hypothesis was formulated, the nurses who measured BP were blind for treatment 
allocation and we found that adding the variable study center to the analyses did not 
change the results. The use of cardiovascular concomitant medication and of NSAIDs 
and COXIBs could have interfered with the observed differences between the groups, 
although we tried to correct for this in the analyses. Ideally, our BP data should be com-
bined with observations on the occurrence of cardiovascular adverse events. However, 
the BeSt study was not designed or powered to detect possible differences in such 
events and few have occurred within the first 2 years of the trial. 
Being aware of these limitations, the decrease in BP in patients treated with methotrex-
ate and infliximab remains an interesting and probably clinically relevant observation 
that needs further investigation.
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to a maintenance dose after 6 months. If the DAS was above 2.4 the next step of the 
protocol was taken. In total, 20 hospitals in the south-western part of The Netherlands 
have participated in the BeSt study.5
Primary outcomes were functional ability, 3 monthly measured with the health assess-
ment questionnaire (HAQ) and annual joint damage progression assessed on X-rays of 
hands, wrists and feet. Secondary outcomes were patient-reported outcomes (quality 
of life) and clinical remission percentages. Analysis of the first two years of follow-up 
showed an earlier improvement in disease activity, functional ability and quality of life, 
earlier clinical remission and less radiological damage progression in the initial combina-
tion therapy groups compared to the initial monotherapy groups.7 Due to continuous 
measurement of disease activity and changes in treatment if disease activity was too 
high, from one year onwards, clinical parameters were comparable across all groups and 
stable during 5 years of follow-up (chapter 4). After 5 years the initial combination ther-
apy groups showed less joint damage than the initial monotherapy groups. A detailed 
analysis of joint damage progression showed that after 5 years of follow-up the lower 
total joint damage progression in the combination therapy arms compared with the 
monotherapy groups is based on less progression during the first year of treatment, 
reflecting earlier clinical improvement. In later years annual progression rates were 
comparable between the monotherapy and combination therapy arms. There were no 
major differences in toxicity between the four treatment arms. 
setting a treatment goal and its association with clinical and   
radiological outcome
Abundant evidence showed the association between disease activity measures, func-
tional ability and joint damage progression, providing a rationale for early reduction 
of disease activity in rheumatoid arthritis with effective treatment strategies. Early in 
the disease course functional limitations are mainly determined by active inflammation 
(largely reversible), whereas with increasing disease duration, joint damage adds to func-
tional limitations (largely irreversible).8,9
In the BeSt study treatment was aimed at low disease activity (DAS ≤2.4), which was 
associated with a mean HAQ of 0.58 after 5 years of follow-up irrespective of initial treat-
ment. To analyse the association between disease activity and functional ability in more 
detail, in chapter 5 a longitudinal analysis of disease activity and functional ability was 
performed. By using interaction terms we analysed whether the association between 
a change in DAS and a change in HAQ was dependent on follow-up duration and 
absolute DAS-value. We found that a larger decrease in DAS is associated with a larger 
decrease in HAQ. This association was dependent on the absolute DAS-level but did 
not change with follow-up duration. According to the model, a DAS decrease from 2.5 
to 1.5 will improve HAQ more than a decrease from 3.5 to 2.5, probably because of more 
residual disease activity. A matrix was constructed to visualise the findings. These data 
suggest that striving for the lowest possible disease activity is valuable, in early and in 
longstanding disease. 
This thesis focuses on treatment strategies and outcome measures in rheumatoid arthri-
tis. In chapter 1 a general introduction for this thesis is given. Rheumatoid arthritis (RA) 
is an inflammatory autoimmune disease characterised by synovitis, particularly of small 
joints of hands and feet, although larger joints can be involved as well. Patients with 
RA often suffer general complaints like fatique and morning stiffness and may suffer 
extra-articular manifestations. RA is associated with severe morbidity and even mortal-
ity if not treated properly. The last decades RA has been evolved from a disease were 
treatment was aimed at symptom relief towards a disease were treatment is aimed 
at disease control. Hereby, the outlook of patients diagnosed with RA improved dra-
matically.1 The early institution of disease-modifying antirheumatic drugs (DMARDs), 
combination therapy, the availability of drugs specifically targeting the immune system 
(biologicals) and tight-controlled treatment, aiming at minimal disease activity have 
contributed to this improvement and led to a shift in treatment paradigm.2-4 Chapter 
2 reviews clinical presentation, diagnosis and treatment options of RA patients with an 
emphasis on the importance of early referral and early effective treatment. 
strategy trials
Randomised double-blind clinical trials to investigate the efficacy of treatment usu-
ally have a static design with a head-to-head comparison of different (combination of) 
drug(s) during a mostly limited duration of follow-up. Although this a valuable and 
indispensable ‘gold standard’ design to compare the efficacy of drugs, the translation to 
clinical practice can hamper. Treating a chronic disease in clinical practice is a dynamic 
process, with therapy changes in case of insufficient response (treat to target), adverse 
events or other patient- or drugs related factors. Strategy trials have a dynamic design, 
which more resembles daily practice. Instead of the emphasis on the static compari-
son of individual drugs, the emphasis lies on the application of the different treatment 
options in a continuous, dynamic, more individualized and ‘real life’ approach. These 
dynamic trials play a pivotal role in translating the available evidence from RCTs to clini-
cal practice. Chapter 3 summarizes recent strategy trials in the treatment of rheumatoid 
arthritis. The BeSt study (acronym for ‘Behandel Strategieën’; Dutch for ‘treatment strat-
egies’), which is the base of this thesis, is an example of a strategy trial.5,6
the Best study
In the BeSt study, 508 patients with recent-onset rheumatoid arthritis (less than two 
years) according to the 1987 American College for Rheumatology (ACR) criteria were 
randomised into four treatment strategies: 1. sequential monotherapy (n=126), 2. step-up 
combination therapy (n=121), both starting with methotrexate monotherapy, 3.initial 
combination therapy with a tapered dose of prednisone (n=133), and 4. initial combi-
nation therapy with the tumour necrosis factor (TNF) α inhibitor infliximab (n=128). In 
each strategy, patients were treated according to a stepwise protocol, all aiming at low 
disease activity. Every 3 months the disease activity score (DAS) was calculated. If the 
DAS was 2.4 or lower (i.e. low disease activity) treatment was continued and tapered 
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comparing remission versus low disease activity as treatment goal with the outcomes 
functional capacity, progression of joint damage and quality of life is lacking until now. 
Such a trial would provide direct evidence for the (possible) gain of using clinical remis-
sion as treatment goal compared with the treatment goal low disease activity.  
remission
In chapter 7, 13 remission definitions have been compared, including four variants of 
the 2011 ACR/EULAR remission criteria: clinical practice and clinical trial, with 28/28 as 
well as 68/66 joint counts.20 The most stringent remission definition was ACR/EULAR 
clinical trial remission with 68/66 joint counts classifying the least patients in remission, 
followed by the other variants of the 2011 ACR/EULAR remission criteria set. From the 
composite scores the strictest definitions were SDAI remission and CDAI remission, fol-
lowed by remission defined with the original DAS and his variants. The DAS28 with BSE 
or CRP classified most patients in remission. The main question is whether the differ-
ence in classification, what might be based on relevant residual disease activity in the 
less stringent definitions, is associated with worse outcome in daily functioning and the 
occurrence of joint damage progression. With generalised estimating equation (GEE) 
analyses we analysed the association between all remission definitions, functional ability 
(measured with HAQ) and joint damage progression (measured with the Sharp-van der 
Heijde method) on a continuous and on a dichotomous scale. As expected, remission 
was associated with better functional ability and less joint damage progression accord-
ing to all definitions. Although the proportions of patients classified as having clinical 
remission vary considerably between the different definitions, the absolute predicted 
HAQ and Sharp-van der Heijde progression showed high accordance, as did the esti-
mated probabilities of HAQ >0.5 and SHS progression ≥3.0 in all indices. Although a 
direct statistical comparison is lacking, the clinical relevance of the differences in HAQ 
and SHS progression between the different definitions seems limited. This raises ques-
tions about the validity of remission definitions, especially the strict definitions. It sug-
gests that the difference between strict and less strict definitions might not be based 
on clinical relevant residual disease activity, at least not leading to a significant change in 
daily functioning and joint damage progression. 
Which remission definition should be preferred? Since all definitions perform compa-
rable despite considerable differences in classification, there is no clear answer to this 
question and the answer will largely be based on personal preferences. The 2011 ACR/
EULAR remission criteria have to prove value in future research. 
How can existing remission definitions be improved? Clinical remission is associated 
with radiological remission on the group level; however, on individual patient level all 
available clinical remission criteria allow some residual disease activity associated with 
joint damage progression (chapter 7). Therefore, parallel to clinical remission, radiologi-
cal remission should be part of a remission definition, but finding a proper definition is 
a challenge. Besides a radiological outcome, an ideal remission definition should include 
a timeline. Real remission is durable and stable over time.
The original DAS have been criticised for its complicated tender joint count: the Ritchie 
articular index.10 With the RAI 53 joints are scored for tenderness on a graded scale of 0-3 
per joint, it uses joint groups of which only the highest tender score per group counts and 
the joints differ from the 44 joints assessed for swelling. In chapter 6 we validated three 
simplified versions of the DAS with simplified tender joint counts to replace the RAI: a 
variant omitting the grading (DAS 0-1), a variant omitting the grading and the grouping 
(DAS-TJC53) and a variant omitting the grading and grouping and using only the 44 joints 
which are assessed with the swollen joint count (DAS-TJC44). We compared these three 
variants with the original DAS. The correlations between the alternatives and the origi-
nal DAS is high, and the classification into clinical remission, low disease activity (LDA), 
moderate disease activity (MDA) and high disease activity (HDA) using the cut-offs of 
the original DAS was highly comparable. In addition, the percentages of patients with 
rapid radiological progression (>5 SHS points in 1 year) in the different disease activity 
levels showed high agreement across the DAS variants. These results indicate that a sim-
plified DAS variant seems a valid alternative to the original DAS. The DAS-TJC44 may be 
the most practical because it assesses the same joints for swelling and tenderness.
In addition to changing the tender joint counts, in chapter 6 we also evaluated the 
original DAS and its variants using either a patients’ global assessment of disease activ-
ity (PGA) or of general health (GH), both assessed on a visual analogue scale of 0-100 
mm. In literature both versions are used, but it was unknown whether these were inter-
changeable. Although both VAS scores in individual patients could differ considerably, 
used as part of a composite score the difference is negligible, probably because of the 
limited weight of this component in the total score. These results suggests that both 
can be used, confirming the study by Khan, et al.11 
After the development of the original DAS, a variety of composite indices to measure 
disease activity have been published, all with proposed cut-offs for remission, LDA, 
MDA and HDA. All these composite indices have shown to be related to function-
ality and joint destruction. No direct of comparison of the indices was made so far 
and no consensus exists on which index should be used. In chapter 7 we compared 
the classification in disease activity levels of 9 often used composite indices and found 
considerable variation in the proportion of patients in the subsequent levels across the 
different indices.12-15 CDAI and SDAI classified more patients in low disease activity and 
less in remission; DAS28 and DAS28 with CRP had a smaller proportion in LDA and 
more in remission and MDA. However, all indices showed a ‘dose relationship’ with the 
outcomes functional ability and joint damage progression in a remarkably similar way, 
raising the question of the clinical relevance of the differences in classification. 
In addition to the longitudinal association between DAS and HAQ as analysed in chap-
ter 5, these data suggest the importance of setting a strict treatment goal, ie remission, 
because remission is associated with the fewest functional limitations and joint damage 
progression. This is in line with the EULAR recommendations for the treatment of RA 
and the recommendations of the international ‘Treat to target’ initiative in which clin-
ical remission is recommended as treatment goal.16,17 Unfortunately, a large clinical trial 
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ment arms (chapter 4). Because of the high remission percentages, the BeSt study 
incorporated discontinuation of treatment in patients in prolonged clinical remission 
(>6 months) from the third year onwards. The last effective drug was immediately 
reintroduced in case of losing remission. After 5 years 10-19% of patients were in drug-
free remission (completers analysis), for a median duration of 23 months (chapter 4). 
In chapter 9 drug-free remission is studied in more detail. In total, 23% of all patients 
achieved drug-free remission during 5 years of follow-up, of whom 51% were still drug 
free after 5 years follow-up (median 23 months), 46% had to restart treatment because 
they lost remission, and 3% were lost to follow-up. Predictors for a relapse were the 
presence of anti-cyclic citrullinated peptide antibodies (anti-CCP), sulfasalazine as last 
DMARD, low baseline health assessment questionnaire (HAQ) score and high mean 
DAS until remission. The DAS and its components immediately before discontinuation 
were not predictive for the occurrence of a flare. After restarting treatment, the major-
ity of patients again achieved clinical remission after 3-6 months. Joint damage progres-
sion was slightly higher in the patients who restarted treatment compared to the sus-
tained drug-free remission group. The patients who restarted treatment had an unfa-
vourable risk pattern for joint damage progression: positive anti-CCP and more joint 
damage at the time of discontinuation.26 A controlled discontinuation study would be 
necessary to assess whether the relapses and the small amount of joint damage would 
have occurred when medication was continued. Such a randomised-controlled stop 
trial is currently performed in the Netherlands (POEET study), in which TNF inhibitors 
are discontinued in patients in prolonged clinical remission, while continuing conven-
tional DMARDs like methotrexate. Before the arrival of biologicals, Ten Wolde, et al. 
performed a double blind placebo-controlled discontinuation study in patients with 
longstanding disease who were in clinical remission in which all antirheumatic medica-
tion was discontinued. There, discontinuation of treatment led to more disease flares.27 
Despite large differences in patient populations, these data suggest that the relapse rate 
is probably higher than it would have been if medication was continued. On the other 
hand, the data also suggest that a considerable part of patients would have relapsed 
irrespective of continuing or discontinuing medication. Taking these factors into con-
sideration, discontinuation of medication can be considered in patients in prolonged 
remission. Discontinuation should be performed under strict control of disease activity 
and as a shared decision between patient and the rheumatologist, carefully weighing 
benefits and risks.
Clinical synovitis versus progression of joint damage
The interrelationship between disease activity, functional ability and progression of joint 
damage is well-established and forms the basis of current treatment approaches.8,9,18 
Although generally accepted, limited studies assessed the association between clinical 
signs of synovitis (tenderness, swelling) and progression of joint damage on the individ-
ual joint level in a methodological correct manner.28,29 In chapter 10, clinical assessments 
of tender and swollen joints during year 1 in in patients of the BeSt study were related 
discontinuing medication
Targeted treatment with a predefined goal with treatment adjustments until the goal is 
reached is recommended in RA treatment.17 However, no recommendations are pub-
lished on what to do if a treatment target is reached. Should medication be continued 
or is it possible to taper or even complete discontinue treatment? Discontinuation can 
be beneficial regarding adverse events and costs but, on the downside, may stimulate a 
relapse of disease with potential harmful consequences. Is it possible to predict which 
patients have a high risk for a flare of disease? In the chapters 8 and 9 the discontinuation 
of infliximab in patients with persistent low disease activity and discontinuation of all 
drugs in patient in persistent remission has been assessed, respectively.   
Discontinuing infliximab in persistent low disease activity
Treatment with a TNF inhibitor combined with methotrexate is effective in the early 
effective suppression of disease activity and the prevention of joint damage, but is 
expensive and has a possible risk for adverse events. Therefore, the early discontinu-
ation of TNF blockers might be beneficial. In the BeSt study infliximab was discon-
tinued if patients had low disease activity for at least six months. In chapter 8 the 
discontinuation of infliximab is studied in more detail, in patients who initially started 
infliximab (group 4) as well as in patients starting infliximab after failing at least three 
conventional DMARDs (groups 1 to 3). In total, 45% of patients treated with infliximab 
were able to discontinue infliximab. Of those 80% were able to stop for at least one 
year and 48% had to restart infliximab because of a flare of disease during a median 
follow-up period of 7.2 years. The amount of joint damage in the year after stopping 
infliximab was limited, irrespective of the occurrence of a flare. Retreatment of inflix-
imab was successful in 84%. Predictors for a flare of disease were smoking, the presence 
of shared epitope and long infliximab treatment (≥18 months). These results are largely 
in line with the limited number of studies on discontinuing TNF inhibitors, although 
differences in patient characteristics, study designs and requirements for the discontin-
uation of TNF blockers differed, harming a direct comparison.21-24 Since even tempo-
rarily discontinuing TNF inhibitors can be beneficial with regards to costs and adverse 
events, the cessation of TNF inhibitors should be considered in individual patients with 
persistent low disease activity with little risk factors for a flare under strict control of 
disease activity.      
Drug-free remission
With the growing percentages of remission with new effective and early treatment, the 
question whether treatment should be continued or can be discontinued in patients in 
long term remission becomes more important. Discontinuation of treatment in clinical 
remission has rarely been studied in modern treatment approaches.25 From the begin-
ning of the BeSt study remission percentages were higher than expected beforehand 
in this population with recently diagnosed active RA. After 5 years, 48% of patients 
were in clinical remission, defined as DAS <1.6, without differences between the treat-
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SENS ignores grading of damage per joint, is around three times faster than the Sharp-
van der Heijde method and is quicker and easier to learn. The results showed that SENS 
is a valuable and structured method for assessing joint damage in clinical practice due to 
its time efficacy. However, SENS is not recommended in research because the method 
is less sensitive and because grading of damage is disregarded, the discriminative power 
will be lower.
Cardiovascular disease
The (patho)physiological phenomenon inflammation is thought to play a role in a 
variety of diseases of which atherosclerosis is an example.31 Rheumatoid arthritis carries 
a higher risk for cardiovascular diseases, which is suggested to be comparable to the 
effect of having diabetes mellitus.32 Besides a higher prevalence of traditional risk factor 
in RA, shared inflammatory pathways between RA and atherosclerosis probably con-
tributes to the increased risk. Because of this increased risk, attendance should be paid 
to traditional risk factors including life style changes and optimal treatment of hyper-
tension, hypercholesterolemia and diabetes mellitus. Additionally, attention should be 
paid to the role of treatment of RA in relation to cardiovascular disease and its risk fac-
tors. Chapter 12 shows an association between disease activity level and blood pressure. 
Although small, the association was present for systolic and diastolic blood pressure 
suggesting that a lower level of inflammatory activity is associated with a more favour-
able cardiovascular risk pattern. Furthermore, we observed a decrease in systolic and 
diastolic blood pressure in patients treated with the combination methotrexate and 
the TNFα inhibitor infliximab; in the other groups no decrease was observed. These 
results should be interpreted with caution because the BeSt study was not developed 
to compare blood pressure and observations were based on single blood pressure 
measurements without a measurement protocol. Nevertheless, in the light of the high 
burden of cardiovascular disease in rheumatoid arthritis patients this might be a clini-
cal relevant observation.  
early start?
The BeSt study illustrates that with effective treatment early in the disease course, a 
significant improvement in clinical parameters and limited joint damage progression is 
realistic in a group of patients with active rheumatoid arthritis. At baseline, all patients 
fulfilled the 1987 classification criteria for rheumatoid arthritis. The process of devel-
oping rheumatoid arthritis can be seen on a timeline from an unknown pathophysi-
ological event at the beginning, auto-antibody responses, towards subclinical inflam-
mation and signs and symptoms of what is called ‘RA’, to which patients with a genetic 
predisposition are more susceptible. The 1987 classification criteria incorporated rela-
tively late manifestations of the disease process such as damage and rheumatoid nod-
ules; this means that there is a strong possibility that early RA is not classified as such. 
Not identifying and treating early RA could result in progression to severe destructive 
disease. The window-of-opportunity hypothesis suggests the presence of a period of 
to the progression of erosions and joint space narrowing as assessed on radiographs 
after year 1 in the same joint. Swelling and tenderness were independently associated 
with progression of joint damage. The associations were comparable strong for erosions, 
joint space narrowing and total joint damage progression. Although tenderness might 
be seen as a less specific marker for RA synovitis than a swollen joint, chapter 10 showed 
that both swelling and tenderness were independently associated with progression of 
joint damage with comparable OR, indicating that measuring tenderness has additional 
value upon measuring swelling alone.  
The longer swelling and tenderness is present, the higher the chance for progression. 
The dose-response relationship was found in the first follow-up year, underlining the 
importance of early effective targeted treatment. The association was found to be 
stronger in hands than in feet, probably because of more difficult joint assessments in 
the feet. Although there is a clear relationship, clinical signs of synovitis explain only a 
part of the total variability leading to the progression of joint damage. Several known 
and unknown factors determine the risk for joint progression in the individual joint: 
patient characteristics, local joint circumstances and treatment. Besides swelling and 
tenderness, known predictors for joint damage progression like auto-antibodies (anti-
CCP and rheumatoid factor), acute phase reactants, age, total baseline joint damage, 
baseline damage per joint, were also found to be related to progression of erosions 
and joint space narrowing in the individual joint. Beyond these factors, the presence of 
swelling and tenderness increases the risk for progression by its odds ratio.     
We found that the treatment strategy interacts with the association between clinical 
signs of synovitis and joint damage progression, both with tenderness and swelling. 
Analysis per treatment strategy showed that in patients treated with initial combination 
therapy including infliximab there was no statistically significant association between 
signs of synovitis and joint damage progression, this in contrast to the findings in the 
other three treatment arms. These results confirm at joint level a disconnect between 
clinical inflammation and joint damage progression that has been shown earlier on 
patient level30 and underline the importance of the pro-inflammatory cytokine tumour 
necrosis factor (TNF) alpha in the pathophysiology of joint damage. 
Assessing progression of joint damage in clinical practice
Regular assessments of joint damage progression should be part of clinical practice when 
treatment is evaluated. Irrespective of clinical parameters, treatment change should be 
considered if patients show joint damage progression on x-rays, which on the long term 
may lead to functional limitations. Joint damage progression without clinical symptoms 
might be the only hint of subclinical inflammation indicating that treatment is insuf-
ficient. Ideally, joint damage progression should be assessed using a structured scoring 
method. Used methods as the Sharp-van der Heijde method and Larssen score are 
comprehensive, time-consuming and require training which hamper the use in clinical 
practice. In chapter 11 a comparison between the comprehensive, well-validated Sharp 
van der Heijde method and the simplified erosion and narrowing score (SENS) is made.
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research will elucidate whether treatment initiation when these criteria are fulfilled is 
early enough or whether treatment should be initiated before this stage. Challenging is 
the development of effective therapeutic strategies in patients who cannot achieve or 
keep clinical remission with current therapies.     
The variety of clinical remission definitions all allow residual disease activity, potentially 
leading to joint damage progression, providing a rationale for aiming at radiological 
remission parallel to clinical remission in the future. However, first needs to be proven 
that radiological remission is treatable and that aiming at radiological remission has 
additional value in improving patients outcome above aiming at clinical remission.35 If 
that is the case, next challenges are the development of radiological remission criteria 
feasible for clinical practice, preferable combined with a clinical remission definition, 
to convince clinicians of the necessity of regular structured damage scoring and the 
implementation into clinical practice by arranging training in simple structured damage 
scoring systems like the simplified erosion and narrowing score world-wide. 
The clinician should continuously weigh the efficacy, side effects, risk for over- and 
undertreatment and costs of available treatment options in an evidence-based way, 
which is almost impossible with the massive and growing treatment possibilities. New 
trials with a dynamic design mimicking clinical practice like BeSt will add to the devel-
opment of evidence-based strategies that can be incorporated in daily practice and can 
help the clinician in choosing optimal treatment. The exact role of the newer biologicals 
in treatment strategies is unclear. Of large value would be a clinical trial with a direct 
comparison of available biologicals, including TNF inhibitors, in early as well as in more 
established disease, preferable in a dynamic treatment design. The growing number of 
eligible drugs would make the inclusion of all candidates into a trial challenging. 
In the BeSt study treatment is individualised by making treatment decisions based on 
disease activity levels of the individual patient. Although partly tailored, all patients fol-
lowed predefined treatment steps and the decision in all patients was based on the DAS 
with the cut-offs 2.4 and 1.6, ignoring the development of radiological joint damage pro-
gression. Tailor made treatment is necessary not only to prevent over- and undertreat-
ment, but also for keeping health costs manageable. Further development of predic-
tion models, probably by introducing genetic and biological risk factors instead of more 
clinical characteristics may contribute to more personalised treatment in the future. 
The difficulties lie in the identification of these important biological characteristics and 
feasibility for clinical practice. 
Conclusion
This thesis describes several clinical aspects of modern RA treatment from the per-
spective of a randomised controlled trial comparing four different treatment strategies. 
Starting with combination therapy led to an earlier improvement of clinical character-
istics with an advantage on joint damage progression until 5 years of follow-up com-
pared to starting with monotherapy. With the availability of new treatment options, 
including biologicals, the early aggressive start of treatment and target-steered treat-
time somewhere on this timeline in which a longstanding immunological benefit can 
be expected when the proper treatment is initiated.33 Withholding treatment until 
patients fulfil the 1987 criteria for RA, and keeping in mind the growing evidence for 
the benefit of early effective treatment, the window of opportunity might be (partly) 
missed. The BeSt study aimed at early treatment, including patients who had less than 
2 years of arthritic symptoms, however, since patients were also required to fulfil the 
1987 classification criteria, one may argue that many patients did not have ‘early RA’. 
Although in some patients remarkable results were observed, in many disease activ-
ity remained smouldering or flared and radiological damage progression continued 
to increase over time, possibly the result of a relatively late start of treatment. When 
exactly treatment has to start in patients with (undifferentiated) arthritis in order to 
achieve a long-lasting benefit and to prevent joint damage progression remains unclear. 
The PROMPT study shows that anti-CCP positive patients with inflammatory arthritis, 
not yet fulfilling the 1987 classification criteria, benefit from early treatment with meth-
otrexate with suppression of disease activity and radiological damage progression.34 
However, in most patients the symptoms progressed to ‘1987 classified RA’ after MTX 
was discontinued showing that early treatment with MTX was insufficient to change 
the disease course. The most effective early treatment has yet to be determined. To 
classify RA in an earlier phase of the disease, the 2010 classification criteria for RA were 
developed with the consequence of encouraging earlier initiation of treatment. Ideally, 
treatment should start immediately after the occurrence of the first immunological 
event that in time will lead to the progression of RA, or even better, treatment should 
prevent that event to happen. To do so, the challenge is to identify and understand 
pivotal events in the development of inflammatory arthritis. Once identified, the next 
step is to develop specific targeted treatment in order to prevent these master switches 
to occur. 
Future challenges
To continue the followed road of improving treatment options and thereby improving 
the outlook and prognosis of recently diagnosed RA patients further unravelling of the 
pathophysiology, and as mentioned above, identification of the major pivotal events 
leading to RA is essential. Then we could enter a new era of targeted treatment leading 
towards cure and/or prevention of the disease. 
Until then, the available treatment options should be used in an optimal manner, which 
is challenging with the growing armamentarium of available therapies. Further imple-
mentation of early, aggressive targeted treatment aiming at remission is the first step 
towards optimising treatment. With the development of treatment recommendations 
an important start has been made, but still a large gain can be made here. Regular 
disease activity measurements should be the base of treatment decisions. The devel-
opment of the 2010 ACR/EULAR criteria for RA made it possible to assess the efficacy 
of DMARDs and biologicals, alone or in combination, earlier in the disease course in a 
well-defined group, what will be translated to clinical practice the next decades. Future 
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ment the outlook for recently diagnosed RA patients improved considerably the past 
few decades. Where treatment has changed from symptom control to more and more 
disease control over the past few decades, RA itself appears to have changed, leaving 
the traditional clinical picture of a chronically progressive, destructive disease. For a 
majority of patients, suppression of disease activity and radiological damage progres-
sion can effectively be achieved and clinical remission has become a realistic treatment 
goal. Clinical remission without DMARDs, which was found in up to 20% of patients, 
has become real now, coming close to cure. Further exploration of the biological and 
immunological background of RA and earlier start of more individualised aggressive 
treatment may change rheumatoid arthritis into a curable or even preventable disease 
in the future.  
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de Best studie
In de BeSt studie zijn 508 patiënten met recent gediagnosticeerde reumatoïde artri-
tis (korter dan 2 jaar), welke voldeden aan de 1987 classificatie criteria van de Ame-
rican College of Rheumatology (ACR), gerandomiseerd in vier behandelstrategieën: 
1. sequentiële monotherapie (n=126), 2. step-up combinatie therapie (n=121), beide star-
tend met methotrexaat monotherapie, 3. initiële combinatietherapie met prednison en 
4. initiële combinatietherapie met de tumor necrosis factor (TNF) alpha remmer inflixi-
mab (n=128). In alle behandelarmen werden patiënten behandeld volgens een stapsge-
wijs protocol strevend naar lage ziekte activiteit. Elke 3 maanden werd de disease activity 
Score (DAS) bepaald. Bij een DAS van 2,4 of kleiner (lage ziekteactiviteit) werd de behan-
deling voortgezet en na 6 maanden afgebouwd tot een onderhoudsdosering. Bij een 
DAS groter dan 2,4 werd overgestapt op de volgende behandelstap van het protocol. 
Twintig ziekenhuizen in zuidwest Nederland namen deel aan de BeSt studie. 
Primaire uitkomstmaten waren dagelijks functioneren, driemaandelijks gemeten met 
de health assessment questionnaire (HAQ), en progressie van gewrichtsschade, jaarlijks 
gemeten op röntgenfoto’s van handen, polsen en voeten met de Sharp-van der Heijde 
methode (SHS). Secundaire uitkomstmaten waren remissiepercentages en kwaliteit van 
leven. De resultaten van de eerste twee jaar lieten een snellere verbetering in ziekteactivi-
teit, dagelijks functioneren en kwaliteit van leven zien en minder progressie van gewrichts-
schade in de initiële combinatietherapiegroepen (groep 3 en 4) ten opzichte van de initi-
ele monotherapiegroepen (groep 1 en 2). Als gevolg van de continue metingen van ziek-
teactiviteit en zo nodig aanpassing van de behandeling waren de klinische uitkomsten 
na een jaar vergelijkbaar in alle behandelgroepen en bleven stabiel gedurende 5 jaar fol-
low-up (hoofdstuk 4). Na 5 jaar behandeling hadden de initiële combinatietherapie groe-
pen minder gewrichtsschade dan de initiële monotherapiegroepen. Een gedetailleerde 
analyse van de schadeprogressie per jaar liet zien dat het verschil in schadeprogressie van 
de initiële combinatietherapieën t.o.v. de initiële monotherapieën gebaseerd is op een 
verschil in schadeprogressie in het eerste jaar, waar de combinatietherapie groepen een 
snellere afname van ziekteactiviteit lieten zien. In de daaropvolgende jaren is de jaarlijkse 
radiologische progressiesnelheid gemeten met de SHS vergelijkbaar in alle groepen. Er 
waren geen duidelijke verschillen in toxiciteit gevonden tussen de behandelgroepen.
het vaststellen van een behandeldoel en de associatie van ziekteactiviteit 
met klinische en radiologische uitkomsten
Veel wetenschappelijke studies hebben de associatie tussen ziekteactiviteit, functionele 
capaciteit en het optreden van gewrichtsschade aangetoond. Dit vormt de achtergrond 
van het vroeg inzetten van effectieve behandelstrategieën om ziekteactiviteit vroeg en 
adequaat te onderdrukken, zodat functionele beperkingen en gewrichtsschade zoveel 
mogelijk voorkomen kunnen worden. Vroeg in het ziektebeloop worden functionele 
beperkingen vooral verklaard door actieve inflammatie (grotendeels reversibel), terwijl 
later in het ziektebeloop gewrichtsschade meer gaat bijdragen aan beperkingen in func-
tioneren (grotendeels irreversibel). 
Dit proefschrift behandelt klinische aspecten van behandelstrategieën en uitkomstma-
ten in patiënten met reumatoïde artritis. Reumatoïde artritis (RA) is een inflammatoire 
auto-immuunziekte welke gekenmerkt wordt door synovitis van met name de kleine 
gewrichten van handen en voeten. Grotere gewrichten kunnen echter ook aangedaan 
zijn. RA patiënten hebben vaak algemene symptomen, zoals moeheid en ochtendstijf-
heid, en kunnen last krijgen van extra-articulaire manifestaties. RA is geassocieerd met 
ernstige morbiditeit en mortaliteit, vooral als de ziekte niet goed behandeld wordt. De 
laatste decennia is de behandeling van RA sterk veranderd: waar behandeling eerder 
gericht was op symptoombestrijding, is de behandeling tegenwoordig gericht op het 
zoveel mogelijk onderdrukken van inflammatie om beperkingen in het dagelijks func-
tioneren, gewrichtsschade en extra-articulaire manifestaties te voorkomen en kwaliteit 
van leven te behouden. De prognose voor patiënten met recent gediagnosticeerde RA 
is hiermee aanzienlijk verbeterd.   
Het vroeg starten met zogenaamde disease-modifying antirheumatic drugs (DMARDs), 
combinatietherapie, de introductie van geneesmiddelen die specifiek gericht zijn op het 
immuunsysteem (biologicals) en strikte en regelmatige meting van ziekteactiviteit met 
aanpassing van medicatie totdat een behandeldoel gehaald is (‘tight control’ en ‘treat 
to target’) hebben bijgedragen aan deze verbetering in prognose en hebben geleid tot 
een verschuiving in behandelparadigma’s. In hoofdstuk 1 wordt een algemene inleiding 
op het proefschrift gegeven. Hoofdstuk 2 geeft een overzicht van klinische presentatie, 
diagnose en behandelmogelijkheden voor RA patiënten waarin het belang van vroege 
verwijzing naar een reumatoloog benadrukt wordt om het vroeg starten van effectieve 
behandeling mogelijk te maken.
strategie studies
De effectiviteit van behandelingen wordt vaak onderzocht in gerandomiseerde, dub-
belblinde placebo-gecontroleerde trials (RCTs). Deze studies hebben veelal een statisch 
design waarin een directe vergelijking van verschillende (combinaties) van geneesmid-
delen tijdens een meestal beperkte, vaste follow-up periode wordt verricht. Alhoewel 
dit het waardevolle en onmisbare ‘gouden standaard’ design is voor effectiviteitsverge-
lijkingen, is de vertaalslag naar de klinische praktijk vaak moeilijk. De behandeling van 
een chronische ziekte is een dynamisch proces waarbij behandeling aangepast wordt bij 
onvoldoende respons (treat to target), bijwerkingen of door andere patiënt- of medica-
tie-gerelateerde factoren. In strategie studies wordt met een dynamisch design de klini-
sche praktijk zoveel mogelijk nagebootst. In plaats van een vaststaande statische verge-
lijking van individuele geneesmiddelen, wordt de nadruk gelegd op de toepassing van 
verschillende behandelmogelijkheden in een dynamische, individuele ‘real life’ aanpak. 
Deze dynamische studies spelen een belangrijke rol in de vertaling van data uit RCTs 
naar de klinische praktijk. In hoofdstuk 3 worden de belangrijkste resultaten van recente 
strategie studies in de behandeling  van RA samengevat. De BeSt studie (acroniem voor 
Behandel Strategieën) waarop dit proefschrift is gebaseerd is een voorbeeld van een 
strategie studie.
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HDA. Al deze indices zijn gerelateerd aan functioneren en gewrichtsschade, maar er is 
geen uitgebreide directe vergelijking van de indices verricht. Er bestaat geen consensus 
over welke score de voorkeur heeft. In hoofdstuk 7 hebben we 9 verschillende ziekte- 
activiteits-scores met elkaar vergeleken en zagen dat de classificatie in remissie, LDA, 
MDA en HDA aanzienlijk kon verschillen. De belangrijkste verschillen waren dat met 
CDAI en SDAI minder patiënten in remissie werden geclassificeerd en meer in LDA ten 
opzichte van de andere indices. Bovendien classificeerden DAS28 en DAS28 met CRP 
een kleiner percentage in LDA en meer in remissie en MDA. Ondanks de verschillen in 
classificatie was de associatie van de verschillende indices met dagelijks functioneren 
en progressie van gewrichtsschade opvallend vergelijkbaar, wat de vraag oproept of de 
verschillen in classificatie klinische relevantie hebben.              
Deze resultaten vormen, naast de longitudinale associatie tussen DAS en HAQ (hoofd-
stuk 5) een extra argument om naar een strikt behandeldoel te streven, d.w.z. klinische 
remissie in plaats van LDA, omdat remissie geassocieerd is met minder functionele 
beperkingen en minder progressie van gewrichtsschade. Dit komt overeen met de 
internationale aanbevelingen van het ‘Treat to target’ initiatief van de European League 
Against Rheumatism (EULAR) waarin klinische remissie als behandeldoel wordt aan-
bevolen. Een grote clinical trial waarin de behandeldoelen remissie en lage ziekteactivi-
teit rechtstreeks worden vergeleken met als primaire uitkomsten dagelijks functioneren, 
progressie van gewrichtsschade en kwaliteit van leven ontbreekt helaas tot op heden. 
Hiermee zou op een directe wijze aangetoond kunnen worden wat de winst van streven 
naar remissie boven streven naar lage ziekte activiteit zou zijn.
Eerdere studies hebben laten zien dat er, na een vroege afname van HAQ door het star-
ten van behandeling, gemiddeld na 3-6 jaar een toename in HAQ optreed, Waarschijnlijk 
wordt dit verklaard door irreversibele HAQ achteruitgang door progressie van gewrichts-
schade. Met aanhoudende targeted treatment en het beperken van gewrichtsschade kan 
irreversibele toename van functionele beperkingen uitgesteld worden en in een subgroep 
van patiënten misschien zelfs voorkomen worden. Het is veelbelovend dat na 8 jaar fol-
low-up in  de BeSt studie de HAQ stabiel blijft met een gemiddelde (SD) van 0,59 (0,59).  
remissie     
In hoofdstuk 7 zijn 13 remissiedefinities met elkaar vergeleken, waaronder vier varianten 
van de 2011 ACR/EULAR remissie criteria: de criteria voor de klinische praktijk en klini-
sche trials, zowel met 28/28 als met 68/66 gewrichtsscores. De ACR/EULAR klinische 
trial definitie met 68/66 gewrichten bleek van alle definities de meest strikte met de 
laagste remissiepercentages, gevolgd door de andere varianten van de 2011 ACR/EULAR 
remissie criteria. De DAS28 met bezinking en CRP classificeerde de meeste patiënten in 
remissie. De belangrijkste vraag was of de verschillen in classificatie, wat mogelijk geba-
seerd is op relevante resterende ziekteactiviteit in de minder strenge definities, geassoci-
eerd is met slechtere uitkomsten in dagelijks functioneren en het meer gewrichtsschade. 
Met generalised estimating equation (GEE) analyses hebben we de associatie tussen 
de remissiedefinities, dagelijks functioneren (gemeten met HAQ) en schadeprogressie 
In de BeSt studie werd gestreefd naar lage ziekteactiviteit (DAS ≤2,4). Dit heeft geleid 
tot een gemiddelde HAQ score van 0,58 na 5 jaar behandeling. Om de associatie tus-
sen ziekteactiviteit en functioneren in meer detail te bestuderen, is in hoofdstuk 5 een 
longitudinale analyse van ziekteactiviteit en functioneren verricht. Met interactieter-
men is gekeken of de associatie tussen een verandering in DAS en een verandering in 
HAQ afhankelijk is van de follow-up duur en het absolute DAS niveau. We toonden aan 
dat een grotere afname in DAS geassocieerd is met een grotere afname in HAQ. Deze 
associatie is afhankelijk van het absolute DAS niveau, maar niet van de follow-up duur. 
Volgens het model is een afname in DAS van 2,5 naar 1,5 geassocieerd met een grotere 
verbetering in HAQ dan een daling van 3,5 naar 2,5, mogelijk door meer resterende ziek-
teactiviteit. Deze data suggereren dat het zinvol is om te streven naar maximale onder-
drukking van ziekteactiviteit, zowel vroeg als later in het ziektebeloop.
De originele DAS wordt wel bekritiseerd om de ingewikkelde gewrichtsscore voor pijn: 
de Ritchie articular index (RAI). Voor de berekening van de RAI moeten 53 gewrichten 
gescoord worden op pijn, gegradeerd van 0 tot 3 per gewricht. Een aantal gewrichten 
wordt gegroepeerd waarbij alleen de hoogste score per groep telt. Bovendien worden er 
andere gewrichten gescoord dan de 44 gewrichten die op zwelling worden onderzocht 
met de DAS. In hoofdstuk 6 hebben we drie vereenvoudigde versies van de DAS gevali-
deerd met een eenvoudiger gewrichtsscore voor pijn ter vervanging van de RAI: 1. een 
variant waarbij de gradering achterwege wordt gelaten (DAS 0-1), 2. een variant zonder 
gradering en groepering (DAS TJC53), en 3. een variant zonder gradering en groepering 
waarbij dezelfde 44 gewrichten worden onderzocht op pijn die ook op zwelling worden 
gescoord (DAS-TJC44). Deze drie varianten zijn vergeleken met de originele DAS. De 
correlaties tussen de alternatieve versies en de originele DAS waren hoog en de classi-
ficatie in klinische remissie, lage (LDA), matige (MDA) en hoge ziekteactiviteit (HDA) 
kwam grotendeels overeen. Ook de percentages van patiënten met snelle radiologische 
progressie (5 SHS punten in één jaar) in de verschillende ziekteactiviteitsniveaus waren 
vergelijkbaar met de verschillende DAS varianten. Deze resultaten suggereren dat een 
gesimplificeerde versie van de DAS een valide alternatief voor de originele DAS is. De 
DAS-TJC44 lijkt de meest praktische optie, omdat in deze versie dezelfde gewrichten 
voor pijn en zwelling gescoord worden. 
Naast de verandering in de pijnlijke gewrichtsscore hebben we in hoofdstuk 6 de origi-
nele DAS en zijn varianten vergeleken met de algemene indruk van de patiënt zelf van 
enerzijds ziekteactiviteit (PGA) en anderzijds algemene gezondheid (GH), beide op een 
visuele analoge schaal (VAS) van 0 tot 100 mm. Beide versies worden in de praktijk door 
elkaar gebruikt, maar het is onbekend hoe de vergelijkbaarheid is. Alhoewel in individu-
ele patiënten de VAS scores behoorlijk konden afwijken, waren de verschillen als onder-
deel van een ziekteactiviteitsscore klein, waarschijnlijk door het beperkte aandeel van de 
VAS in de totaalscore. Deze resultaten suggereren dat beiden gebruikt kunnen worden, 
zoals ook een recente studie van Khan, et al. (Ann Rheum Dis 2012) heeft laten zien. 
In navolging van de originele DAS zijn er verschillende samengestelde indices voor het 
meten van ziekte activiteit gepubliceerd met eigen cut-offs voor remissie, LDA, MDA en 
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ten die direct bij aanvang van de studie met infliximab zijn gestart (groep 4) als in pati-
enten waarbij infliximab werd gestart na falen van minimaal 3 conventionele DMARDs 
(groepen 1 t/m 3). Van alle patiënten die gestart waren met infliximab kon 45% stoppen, 
waarvan 80% minimaal een jaar; ongeveer de helft herstartte infliximab in verband met 
een DAS >2,4 tijdens een mediane follow-up duur van 7,2 jaar. In het jaar na het stop-
pen van infliximab was er weinig progressie van gewrichtsschade, zowel in de patiën-
ten met als zonder opvlamming. Herbehandeling met infliximab was succesvol in 84%. 
Voorspellers voor het optreden van een flare waren roken, de aanwezigheid van het 
zogenaamde ‘shared epitope’ en langdurige behandeling met infliximab (≥18 maanden). 
Deze resultaten komen in grote lijnen overeen met het beperkt aantal studies dat naar 
het stoppen van anti-TNF heeft gekeken. Er zijn echter grote verschillen in patiëntkarak-
teristieken, studieopzet en voorwaarden waarop anti-TNF gestopt mocht worden, waar-
door de studies niet goed vergelijkbaar zijn. Naar aanleiding van deze resultaten en de 
overweging dat ook het tijdelijk staken van TNF remmers voordelig is met het oog op 
kosten en bijwerkingen, werd geconcludeerd dat het staken van infliximab overwogen 
moet worden in patiënten met langdurige lage ziekteactiviteit en weinig risicofactoren. 
Voorwaarde is dat de ziekteactiviteit streng gecontroleerd dient te worden.  
Medicatie vrije remissie
Met de groeiende remissiepercentages door de inzet van vroege, effectieve behandelingen 
wordt de vraag of medicatie voortgezet moet worden in patiënten in langdurige remissie 
relevant. Het staken van medicatie is nauwelijks onderzocht in moderne behandelstrate-
gieën. In de BeSt studie zijn de remissiepercentages vanaf het begin van de studie hoger 
dan op voorhand verwacht in deze populatie van patiënten met recent gediagnosticeerde 
actieve RA (hoofdstuk 4). Na 5 jaar was in alle behandelgroepen 48% van de patiënten in 
klinische remissie, gedefinieerd als DAS <1,6. Vanaf het 3e jaar werd het mogelijk alle medi-
catie te staken bij patiënten die langdurig in remissie waren (>6 maanden). De laatste 
effectieve DMARD werd direct herstart als remissie verloren ging. Na 5 jaar was 10-19% 
in medicatievrije remissie (completers analyse) met een mediane duur van 23 maanden 
(hoofdstuk 4). In hoofdstuk 9 zijn de patiënten met medicatievrije remissie in detail bestu-
deerd. Van alle patiënten hebben 23% medicatievrije remissie bereikt gedurende 5 jaar 
follow-up, waarvan 51% nog medicatievrij was op t=5 jaar (mediaan 23 maanden), 46% 
medicatie heeft moeten herstarten i.v.m. een flare en 3% was ‘lost to follow-up’. Voorspel-
lers voor een opvlamming waren de aanwezigheid van antistoffen tegen gecitrullineerde 
eiwitten (anti-CCP), sulfasalazine als laatste DMARD, een lage baseline HAQ en een hoge 
gemiddelde DAS tot remissie werd bereikt. De DAS en de onderdelen van de DAS net voor 
het staken van de laatste DMARD hadden geen voorspellende waarde. Na het herstarten 
van de behandeling in verband met een flare bereikte de meerderheid binnen 3-6 maan-
den weer remissie. De herstarters hadden iets meer progressie van gewrichtsschade dan de 
patiënten die remissie behielden na het staken van de medicatie. Naast de tijdelijke toe-
name in ziekte activiteit heeft het ongunstiger risicoprofiel voor het optreden van schade 
(meer anti-CCP positief en meer schade op het moment van staken) hier waarschijnlijk 
(gemeten met de SHS) geanalyseerd, zowel op een continue als een dichotome schaal. 
Zoals verwacht was het hebben van remissie geassocieerd met beter functioneren en 
minder gewrichtsschade met alle definities. Alhoewel de aantallen patiënten die geclas-
sificeerd werden als remissie met de verschillende definities aanzienlijk verschilden, 
kwamen de absolute geschatte HAQ en SHS progressie scores in grote mate overeen, 
evenals de geschatte kansen op een HAQ >0.5 en SHS progressie ≥3.0. Een directe statis-
tische vergelijking was helaas niet mogelijk. De klinische relevantie van de verschillen in 
HAQ en schadeprogressie met de verschillende definities lijkt beperkt. Dit roept vragen 
op over de validiteit van de verschillende remissie definities, in het bijzonder de meest 
strenge. Het suggereert dat de verschillen tussen strengere en minder strenge defini-
ties niet gebaseerd is op klinisch relevante residuele ziekteactiviteit, in ieder geval niet 
leidend tot een significante verandering in dagelijks functioneren en schadeprogressie. 
Welke remissiedefinitie heeft dan de voorkeur? Omdat alle definities tot zeer vergelijk-
bare uitkomsten leiden ondanks verschillen in classificatie is er geen eenduidig antwoord 
op deze vraag te geven. De keuze zal vooral afhangen van persoonlijke voorkeuren. De 
2011 ACR/EULAR remissie definities moeten in de toekomst hun waarde nog bewijzen.
Hoe kunnen remissiedefinities verbeterd worden? Klinische remissie hangt op groeps-
niveau (deels) samen met radiologisch remissie. Op individueel patiëntniveau laten alle 
klinische remissiedefinities echter residuele ziekteactiviteit toe die geassocieerd is met 
schadeprogressie (hoofdstuk 7). Daarom zou radiologische remissie onderdeel van een 
remissie definitie moeten zijn parallel aan klinische remissie, alhoewel het vaststellen 
van een definitie hiervoor moeilijk is. Naast een radiologische uitkomst zou een ideale 
remissiedefinitie een tijdscomponent moeten bevatten. Echte remissie is blijvend.
het stoppen van medicatie
Behandeling volgens het ‘treat to target’ principe, met een vast behandeldoel en aan-
passing van de behandeling tot dat het doel bereikt is, wordt geadviseerd in RA patiën-
ten. Er bestaan echter geen richtlijnen over wat te doen als het behandeldoel bereikt is. 
Moet medicatie voortgezet worden of kan medicatie afgebouwd worden of zelfs hele-
maal worden gestopt? Stoppen heeft als voordelen dat er geen bijwerkingen meer kun-
nen optreden, patiënten geen medicatie hoeven in te nemen en de kosten beperkt blij-
ven. Aan de andere kant kan het stoppen van medicatie bijdragen aan een opvlamming 
van de ziekte met potentieel schadelijke gevolgen. In de hoofdstukken 8 en 9 worden res-
pectievelijk het staken van infliximab bij patiënten met langdurig lage ziekteactiviteit en 
het staken van alle medicatie bij patiënten in langdurige klinische remissie bestudeerd.
Het stoppen van infliximab bij patiënten met langdurig lage ziekteactiviteit
Een TNF remmer gecombineerd met methotrexaat kan ziekteactiviteit snel en effectief 
onderdrukken en gewrichtsschade voorkomen, maar is duur en kan bijwerkingen geven. 
Daarom zou het snel stoppen van een TNF remmer voordelig kunnen zijn. In de BeSt 
studie werd infliximab gestopt als patiënten gedurende 6 maanden lage ziekteactiviteit 
hadden. In hoofdstuk 8 is het staken van infliximab nader geanalyseerd, zowel in patiën-
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stoffen (anti-CCP en reumafactor), acute fase eiwitten, leeftijd, de totale hoeveelheid 
gewrichtsschade en de SHS score per gewricht bij aanvang van de studie, naast zwelling 
en pijn ook gerelateerd zijn aan progressie van erosies en gewrichtsspleetvernauwing op 
individueel gewrichtsniveau. Naast deze factoren vergroot de aanwezigheid van zwel-
ling en pijn het absolute risico op progressie met de bijbehorende odds ratios.  
In hoofstuk 10 laten we tevens zien dat behandeling de associatie tussen klinische 
symptomen van synovitis  en de progressie van gewrichtsschade beïnvloedt, zowel bij 
zwelling als bij pijn. In patiënten die initieel behandeld werden met de combinatie 
metho- trexaat en infliximab (groep 4) werd geen significante associatie tussen synovitis 
symptomen en schadeprogressie gevonden, in tegenstelling tot de andere 3 behandel-
groepen. Deze resultaten bevestigen de dissociatie tussen klinische symptomen van 
inflammatie en progressie van gewrichtsschade op gewrichtsniveau, welke op patiënt- 
niveau reeds beschreven was en onderstrepen het belang van het pro-inflammatoire 
cytokine TNF alfa in de pathofysiologie van gewrichtsschade. 
het vaststellen van progressie van gewrichtsschade in de klinische praktijk
Het regelmatig bepalen van gewrichtsschadeprogressie zou een standaard onderdeel 
moeten zijn bij het evalueren van een behandeling in de klinische praktijk. Een toe-
name in gewrichtsschade gemeten op röntgenfoto’s kan, onafhankelijk van de klinische 
respons, een verandering van medicatie rechtvaardigen, aangezien dit op termijn kan 
leiden tot functionele beperkingen. Toename van gewrichtsschade zonder objecti-
veerbare klinische symptomen zou de enige hint kunnen zijn voor de aanwezigheid 
van subklinische inflammatie bij onvoldoende effectieve behandeling. Idealiter wordt 
progressie van gewrichtsschade vastgesteld met een gestructureerde scoringsmethode. 
Veel gebruikte methodes, zoals de Sharp-van der Heijde methode en de Larssen score, 
zijn uitgebreid, kosten relatief veel tijd en vereisen training, wat het gebruik in de klini-
sche praktijk belemmert. In hoofdstuk 11 wordt een vergelijking gemaakt tussen de uit-
gebreide, goed gevalideerde Sharp-van der Heijde score (SHS) en de ‘simplified erosion 
and narrowing score' (SENS). SENS laat de gradering per gewricht achterwege, is onge-
veer 3 keer sneller dan de SHS en is makkelijker te leren. De resultaten laten zien dat SENS 
een waardevolle gestructureerde methode is om gewrichtsschade vast te stellen in de 
klinische praktijk doordat de methode sneller is. Voor het gebruik in onderzoek is SENS 
minder geschikt omdat de methode minder sensitief is en het onderscheidend vermo-
gen kleiner zal zijn door het weglaten van de gradering per gewricht.
Cardiovasculaire ziekte
Er wordt gedacht dat het (patho)fysiologische fenomeen inflammatie een rol speelt in 
diverse ziekten, waaronder atherosclerose. RA is geassocieerd met een verhoogd risico 
op cardiovasculaire ziekten, vergelijkbaar met patiënten met diabetes mellitus. Naast 
een hogere prevalentie van traditionele cardiovasculaire risicofactoren, dragen overlap-
pende inflammatoire pathways waarschijnlijk mee aan het verhoogde risico op cardio-
vasculaire aandoeningen in RA. Door dit verhoogde risico is het belangrijk extra aan-
aan bijgedragen. Een gecontroleerde stop studie zou nodig zijn om te onderzoeken of de 
flares en de kleine hoeveelheid gewrichtsschade ook waren opgetreden als de medicatie 
voortgezet zou zijn. Een dergelijke gerandomiseerde studie loopt momenteel in Neder-
land, op initiatief van de NVR (POEET-studie), waarbij anti-TNF gecontroleerd gestaakt 
wordt in patiënten in langdurige klinische remissie. De conventionele DMARDs worden in 
deze studie gecontinueerd. Destijds, toen biologicals nog niet beschikbaar waren, hebben 
Ten Wolde, et al. (Lancet, 1996) een dergelijke placebo-gecontroleerde stop-studie verricht 
waarbij alle medicatie werd gestaakt in patiënten in klinische remissie met een lange ziek-
teduur, waarin stoppen met medicatie geassocieerd was met meer flares. Alhoewel de BeSt 
populatie duidelijk verschilt van deze populatie, suggereren de resultaten van Ten Wolde, 
et al. dat door het stoppen van de medicatie de hoeveelheid flares waarschijnlijk is toe-
genomen in de BeSt studie. Aan de andere kant laat deze studie zien dat een groot deel 
van de opvlammingen ook zou zijn opgetreden als de medicatie gecontinueerd zou zijn. 
Met deze overwegingen in het achterhoofd kan het stoppen van medicatie in patiënten 
in langdurige remissie overwogen worden. Dit moet wel gebeuren onder strikte controle 
van ziekteactiviteit en als een gezamenlijke beslissing van reumatoloog en patiënt na een 
zorgvuldige afweging van voor- en nadelen. 
Klinische synovitis versus progressie van gewrichtsschade
De relatie tussen ziekteactiviteit, dagelijks functioneren en progressie van gewrichtsschade 
is uitgebreid onderzocht en vormt de basis van huidige behandelstrategieën. Alhoewel 
het een algemeen aanvaard concept is, hebben slechts weinig studies de associatie tussen 
klinische symptomen van synovitis (pijn, zwelling) en progressie van gewrichtsschade op 
individueel gewrichtsniveau met een goede methodologie onderzocht. In hoofdstuk 10 
zijn bevindingen van lichamelijk onderzoek van zwelling en pijn uit het eerste jaar gere-
lateerd aan progressie scores van erosies en gewrichtsspleetvernauwingen binnen het-
zelfde gewricht, vastgesteld op röntgenfoto’s van baseline en na 1 jaar follow-up. Zwelling 
en pijn waren beiden onafhankelijk geassocieerd met progressie van gewrichtsschade op 
gewrichtsniveau met vergelijkbare odds ratios. De associaties waren ongeveer even sterk 
voor erosies, gewrichtsspleetvernauwing en totale SHS progressie per gewricht. Ondanks 
dat een pijnlijk gewricht soms wordt beschouwd als een minder specifieke marker voor 
synovitis dan een gezwollen gewricht, laat hoofdstuk 10 zien dat het vaststellen van pijn 
toegevoegde waarde heeft naast het vaststellen van zwelling alleen. Hoe langer zwelling 
en pijn aanwezig is, hoe groter de kans op progressie. Deze dosis-response relatie werd 
vastgesteld in het eerste jaar, wat het belang van vroege effectieve doelgerichte behande-
ling onderstreept. De associatie is sterker in de handen dan in de voeten, waarschijnlijk 
doordat het onderzoeken van gewrichten in de voeten moeilijker is. 
Alhoewel er een duidelijke relatie tussen klinische symptomen van synovitis en schade-
progressie bestaat, verklaart dit slechts een deel van de totale variabiliteit in gewrichts-
schade. Vele bekende en onbekende factoren bepalen het risico op het optreden van 
gewrichtsschade: patiëntkenmerken, lokale factoren in het gewricht en behandeling. 
In hoofdstuk 10 werd gezien dat bekende voorspellers voor gewrichtsschade, zoals anti-
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worden. De meeste patiënten ontwikkelden echter alsnog RA volgens de 1987 criteria 
na het staken van methotrexaat, wat laat zien dat methotrexaat onvoldoende in staat 
is het ziektebeloop te beïnvloeden. De meest effectieve therapie in dit ziektestadium 
moet nog worden vastgesteld. Om RA eerder te kunnen classificeren zijn de 2010 clas-
sificatie criteria ontwikkeld, mede om vroegere behandeling te stimuleren. Idealiter zou 
behandeling gestart moeten worden direct na het optreden van de eerste immuno-
logische verandering welke op den duur leidt tot de progressie naar RA, of nog beter, 
behandeling zou deze verandering moeten voorkomen. Voordat dit bereikt is, ligt de 
uitdaging in het identificeren en begrijpen van de essentiële stappen in de pathofysio-
logie van RA. De volgende stap is dan de ontwikkeling van gerichte therapie die het 
optreden van deze masterswitches kan voorkomen.   
toekomstperspectieven
Om de ingezette weg van het verbeteren van behandelmogelijkheden en daarmee de 
prognose van recent gediagnosticeerde RA te verbeteren voort te zetten is het essenti-
eel meer inzichten in de pathofysiologie te krijgen, en zoals reeds genoemd, de nood-
zakelijke stappen die tot RA leiden te identificeren. Dan kan een fase betreden worden 
waarbij gerichte therapie kan leiden tot de genezing en/of preventie van de ziekte.
Tot dan moeten de bestaande therapieën zo efficiënt mogelijk toegepast worden, wat 
niet makkelijk is met het steeds groter aantal therapieën in het arsenaal van de reuma-
toloog. Verdere implementatie van vroege doelgerichte therapie strevend naar klinische 
remissie is de eerste stap in de optimalisatie van behandeling. Met de ontwikkeling van 
behandelrichtlijnen is een goede stap voorwaarts gezet, maar er is op dit terrein nog veel 
winst te behalen. Het frequent meten van ziekteactiviteit zou de basis van behandelbe-
slissingen moeten vormen. De 2010 ACR/EULAR classificatie criteria voor RA hebben 
de weg vrijgemaakt voor studies naar het vroeger inzetten van DMARDs en biologicals, 
alleen of in combinatie, in een duidelijk gedefinieerde groep, wat vertaald kan worden 
naar de klinische praktijk in de komende decennia. Toekomstig onderzoek zal moeten 
uitwijzen of het starten van de behandeling als aan deze criteria voldaan wordt vroeg 
genoeg is of dat behandeling nog eerder gestart zou moeten worden. Een andere uitda-
ging is om effectieve strategieën te ontwikkelen in de patiënten bij wie het nog niet lukt 
klinische remissie te behalen of behouden. 
Alle bestaande klinische remissiedefinities laten residuele ziekteactiviteit toe, potenti-
eel leidend tot gewrichtsschade, een argument om in de toekomst naar radiologische 
remissie te streven parallel aan klinische remissie. Eerst moet worden vastgesteld dat 
radiologische remissie te realiseren is met behandeling en dat het streven naar radiologi-
sche remissie leidt tot betere uitkomsten voor patiënten dan het streven naar klinische 
remissie alleen. Als dat zo blijkt te zijn, zijn de volgende uitdagingen het opstellen van 
een radiologische remissie definitie, bij voorkeur gecombineerd met een klinische defi-
nitie, het overtuigen van clinici van het nut van regelmatig en gestructureerd meten van 
gewrichtsschade en het implementeren in de klinische praktijk door wereldwijde trai-
ning in relatief eenvoudige gestructureerde meetmethoden zoals de SENS.
dacht te besteden aan traditionele risicofactoren, waaronder veranderingen in lifestyle 
en de optimale behandeling van hypertensie, hypercholesterolemie en diabetes melli-
tus. Bovendien is het belangrijk om de rol van RA behandeling in relatie tot cardiovascu-
laire risicofactoren en –ziekten in ogenschouw te nemen. Hoofdstuk 12 laat een associatie 
tussen ziekteactiviteit en bloeddruk zien. Alhoewel het effect weliswaar klein is, werd de 
associatie gevonden voor zowel systolische als diastolische bloeddruk, suggererend dat 
een lager niveau van inflammatie samengaat met een gunstiger cardiovasculair risico-
profiel. Er werd tevens een afname in systolische en diastolische bloeddruk gevonden 
in patiënten die behandeld zijn met de initiële combinatie methotrexaat en de TNF 
remmer infliximab. In de andere behandelgroepen werd geen bloeddrukdaling gezien. 
Deze resultaten moeten voorzichtig geïnterpreteerd worden omdat de BeSt studie niet 
opgezet is om bloeddrukverschillen te meten en de observaties zijn gebaseerd op enkel-
voudige bloeddrukmetingen zonder meetprotocol. Desondanks kan dit, ‘dankzij’ het 
hoge risico op cardiovasculaire ziekten in RA, een klinisch relevante observatie zijn.
Vroeg starten?
De BeSt studie illustreert dat met effectieve behandeling vroeg in het ziektebeloop een 
significante verbetering in klinische parameters en het beperken van progressie van 
gewrichtsschade haalbaar is in een groep patiënten met actieve RA. Bij aanvang van de 
studie voldeden alle patiënten aan de 1987 classificatie criteria voor RA. De ontwikkeling 
van RA kan gezien worden op een tijdslijn, beginnend met een onbekend pathofysio-
logisch event, via de vorming van auto-antistoffen, via subklinische inflammatie tot een 
combinatie van symptomen en eigenschappen dat ‘RA’ wordt genoemd, waarbij deze 
ontwikkeling vaker voorkomt bij diegenen met een genetische predispositie voor RA. 
Onderdeel van de 1987 classificatie criteria zijn relatief late manifestaties van de ziekte, 
zoals gewrichtsschade en reumanoduli, waardoor de diagnose in een vroeg stadium 
gemist kan worden. Het niet identificeren en daardoor niet behandelen van vroege RA 
kan leiden tot progressie naar een ernstige destructieve ziekte. De window-of-opportu-
nity hypothese suggereert het bestaan van een periode ergens op deze tijdslijn waar-
bij met de juiste behandeling een blijvend immunologisch voordeel bewerkstelligd kan 
worden. Met het wachten met behandelen tot patiënten aan de 1987 classificatiecriteria 
voldoen wordt de window-of-opportunity mogelijk (deels) gemist. In de BeSt studie 
werd gestreefd naar vroege behandeling in patiënten die minder dan 2 jaar klachten 
van artritis hebben, maar doordat ze aan de 1987 classificatie criteria moesten voldoen 
was een deel van de patiënten het stadium van vroege RA al gepasseerd. Ondanks dat 
er bij een aantal patiënten opvallende behandelresultaten werd gezien, bleef bij veel 
patiënten de ziekte sluimeren en bleef radiologische schade ontstaan. Wanneer behan-
deling gestart moet worden in patiënten met (ongedifferentieerde) artritis om een lang- 
durig voordeel te bewerkstelligen en gewrichtsschade te voorkomen blijft onduidelijk. 
De PROMPT studie heeft laten zien dat in anti-CCP positieve patiënten met artritis 
die nog niet aan de 1987 criteria voldeden baat hebben bij vroege behandeling met 
methotrexaat waarmee ziekteactiviteit en radiologische progressie onderdrukt kunnen 
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van de biologische en immunologische achtergrond van RA en het vroeger inzetten van 
agressieve therapie meer gericht op het individu kan RA veranderen in een te genezen 
of zelfs te voorkomen ziekte in de toekomst.
De reumatoloog heeft de taak een continue afweging te maken tussen effectiviteit, 
bijwerkingen, risico op over- en onderbehandeling en kosten - een bijna onmogelijke 
opgave met de steeds verder toenemende behandelopties. Nieuwe strategie studies 
met een dynamische opzet die de klinische praktijk zoveel mogelijk benaderen zoals 
de BeSt studie, zullen leiden tot nieuwe evidence-based strategieën voor de klinische 
praktijk die de reumatoloog kan ondersteunen in het kiezen van de optimale behan-
deling. Het is onduidelijk wat de precieze rol van de nieuwere biologicals in behandel-
strategieën zou moeten zijn. Een klinische studie waarin een directe vergelijking wordt 
gemaakt tussen de beschikbare biologicals, inclusief anti-TNF, bij voorkeur in een dyna-
misch design zou van grote waarde zijn, zowel in vroege als in meer gevorderde ziekte. 
Het groeiende aantal beschikbare middelen maakt de inclusie van alle potentiele kandi-
daten in één studie moeilijk.
In de BeSt studie is er deels sprake van behandeling toegespitst op de individuele pati-
ent, omdat behandelbeslissingen genomen werden op basis van individuele metingen 
van ziekteactiviteit. Ondanks dat de behandeling deels aangepast werd op het individu, 
volgden alle patiënten een protocol met vooraf vastgestelde behandelstappen en de 
veranderingen in medicatie werden in alle patiënten gebaseerd op DAS cut-offs van 2,4 
en 1,6, waarbij het optreden van radiologische schade buiten beschouwing werd gelaten. 
Gepersonaliseerde behandeling is nodig om onder- en overbehandeling te voorkomen 
en om de kosten van de gezondheidszorg beheersbaar te houden. Verdere ontwikke-
ling van voorspelmodellen, mogelijk met name door het introduceren van genetische 
en biologische risicofactoren in plaats van het uitbreiden van predictiemodellen met 
klinische parameters, kan bijdragen aan behandeling die meer gericht is op het individu 
in de toekomst. De moeilijkheid ligt in de identificatie van deze belangrijke biologische 
kenmerken en de toepasbaarheid hiervan in de klinische praktijk.
Conclusie
Dit proefschrift beschrijft diverse aspecten van de moderne behandeling van RA vanuit 
het perspectief van een gerandomiseerde gecontroleerde studie waarin vier verschil-
lende behandelstrategieën worden vergeleken. Starten met combinatietherapie leidt tot 
een vroegere verbetering van klinische uitkomsten met een gunstig effect op de progres-
sie van gewrichtsschade na 5 jaar follow-up ten opzichte van starten met monotherapie. 
Met de beschikbaarheid van nieuwe behandelmogelijkheden, waaronder biologicals, de 
vroege agressieve start van behandeling en doelgerichte behandeling zijn de vooruit-
zichten voor patiënten met recent gediagnosticeerde RA aanzienlijk verbeterd de laat-
ste decennia. Het doel van behandeling is veranderd van symptoombestrijding naar 
het steeds beter controleren van de ziekte; RA zelf lijkt hierdoor veranderd en neemt 
steeds meer afstand van het traditionele klinische beeld van een chronisch progressieve, 
destructieve ziekte. Onderdrukking van ziekteactiviteit en schadeprogressie kan in de 
meerderheid van de patiënten worden bereikt en klinische remissie is een realistisch 
behandeldoel geworden. Medicatievrije remissie, wat werd gezien in bijna 20% van de 
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